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1 Introduction
6
1. In search of 
building blocks 
o f mental 
disorders
The rise o f neuroscience and genetics has im proved our knowledge of the 
neurobiological underpinnings o f m ental disorders. Still, psychiatric di­
agnoses are derived from  clinical descriptions and not from  m easures of 
the underlying pathophysiology. Over the past decades efforts o f numerous 
experts have contributed to an international classification system, with 
valid diagnostic criteria for every m ental disorder: the Diagnostic and Sta­
tistical M anual o f M ental Disorders ( d s m ) . '  Nevertheless, due to various 
reasons the clinical heterogeneity of psychiatric disorders is very broad, 
one reason being that the classification system allows for different sets of 
symptoms to m eet the diagnostic algorithm, com orbidity with other dis­
orders, and differences in course and prognosis.
A good example to illustrate the heterogeneity of psychiatric diagnoses 
according to d s m - i v  is the diagnosis o f ‘Borderline Personality Disorder’. 
W ith a polythetic form at o f at least five out of nine diagnostic criteria 
(Table 1), there are 151 ways o f m eeting the diagnostic criteria for this dis­
order (i.e. satisfying 5, 6 ,7, 8, or 9 criteria in all different com binations).2
Ever since the advent of psychiatry researchers have been trying to iden­
tify core m anifestations of psychiatric diseases, for no particular symptom 
is perfectly sensitive or specific to a particular psychiatric disorder. Nancy 
Andreasen, a prom inent contem porary psychiatrist, draws a parallel with 
how we think in cancer research: cancer is a disease with diverse clinical 
m anifestations that are due to more fundam ental m echanism s (i.e. dys­
regulation of cell proliferation). In her view, hallucinations and other psy­
chiatric sym ptom s are m erely m anifestations o f an underlying, yet 
unknown fundam ental process.3 In otherwords: we should be lookingfor 
the building blocks of m ental disorders.
Previous research has revealed that many psychiatric syndromes have a 
high genetic load. Analogous to hypertension, type II diabetes and other 
prevalent m edical conditions, the genetic background of m ost m ental dis­
orders are thought to be related to various different genes o f sm all effect 
size interacting w ith each other and to gene-environm ent interactions,4 
in contrast to singular M endelian dom inant disorders such as H unting­
ton ’s disease. Recent publications further indicate that rare copy num ber 
variations (c n v s ) at num erous genetic loci may substantially increase the 
risk of disorders such as schizophrenia, autism, m ental retardation and 
a d h d .5-7 These weakly-to-moderately recurrent c n v s  are assum ed to have 
either been transm itted or occurred de novo, and seem ed to be causative 
or contributory factors.
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Affective criteria
—  nappropriate intense anger or difficulty controlling anger-e.g. 
frequent displays of temper, constant anger, recurrent physical fights
—  Chronic feelings of emptiness
—  Affective instability due to a marked reactivity of mood-e.g. 
intense episodic dysphoria, irritability, or anxiety usually lasting 
a few hours and only rarely more than a few days
Cognitive criteria
—  Transient stress-related paranoid ideation or severe dissociative 
symptoms
—  Identity disturbance: striking and persistent unstable self-image 
or sense of self Behavioural criteria (forms of impulsivity)
—  Recurrent suicidal behaviour, gestures, or threats, or self mutilating 
behaviour
—  Impulsivity in at least two areas that are potentially self-damaging 
that do not include suicidal or self-mutilating behaviour
Interpersonal criteria
—  Frantic efforts to avoid real or imagined abandonment that do not 
include suicidal or self-mutilating behaviour
—  A pattern of unstable and intense interpersonal relationships 
characterised by alternating between extremes of idealisation and 
devaluation
Table 1: DSM-IV Diagnostic Criteria for Borderline Personality Disorder (arranged according to Lieb 
et al., 2004).1;8 Five of nine criteria needed to diagnose borderline personality disorder.
Endophenotypesa, m easurable com ponents betw een the phenotype 
and the distal genotype, have em erged as an im portant concept in the 
study o f com plex psychiatric disorders (Figure 1). An endophenotype may 
be neurophysiological, cognitive, endocrinological, biochem ical, neu- 
roanatom ical or psychological in nature. In essence, endophenotypes 
“identify the downstream  traits o f the clinical phenotype as well as the up­
stream consequences of genes”.9 Endophenotypes m aybe optim ally used 
in refining psychiatric diagnoses. According to the criteria listed in Table
2, endophenotypes are primarily state-independent trait markers of pre­
sum ed inherited vulnerability to a disease.10 However, treatm ent effects 
on endophenotypic deficits have been reported as well.
A lthough m any researchers have em braced the endophenotype con­
cept, several critical issues need to be addressed. Some o f the cognitive 
deficits were present only in a proportion o f the patients investigated, 
show ing low specificity and sensitivity and high variability.11 In a critical 
meta-analysis, Flint and M unafo argued that the effect sizes reported so 
far for endophenotypes are not larger than for clinical phenotypes.12 The 
results o f recent meta-analyses, however, did show strong effects o f genetic 
variation in catechol-O-methyltransferase (effect size d = 0.73) on prefrontal 
activation13 and in the serotonin transporter gene (d = 0.57) on the activation 
o f  the am ygdala,7 in deed  m uch stronger than typical gene-phenotype 
associations.
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Figure 1: Schem atic overview of the endophenotype approach in schizophrenia research 
(Gottesman & Gould, 2003).9 Several gene regions and putative endophenotypes are implicated 
in the pathophysiology of schizophrenia. The reaction surface shows the dynamic developmental 
interplay among genetic, environmental, and epigenetic factors that produce cumulative liability 
to developing schizophrenia. The figure is not to scale.
A deeper understanding o f the aetiology o f psychiatric disorders may 
improve treatm ent and foster prevention.14 The overall goal o f the present 
thesis is to contribute to the growing insight into the pathophysiology and 
treatm ent o f two serious m ental disorders, schizophrenia and borderline 
personality disorder, by focusing on cognitive dysfunctions (i.e. cognitive 
endophenotype), and on the effects o f antipsychotics on the clinical phe­
notype and cognitive endophenotype. The sim ilarities and differences 
between these two com plex disorders in clinical symptoms and cognitive 
im pairm ent will be addressed later in this chapter.
In our search for candidate endophenotypes, my fellow-researchers 
and I have conducted several exploratory studies exploiting various out­
com e m easures. The studies reported in this thesis were specifically 
designed to look for biological correlates in patients and the thesis hence 
does not com prise any studies describing fam ily m em bers or outcom es of 
genetic analyses. We did additionally explore the effects o f treatm ent with 
novel antipsychotics on both cognitive and clinical outcom e measures. 
Following a concise account of schizophrenia and borderline personality 
disorder and their known neurobiological underpinnings and available 
treatm ents, the outline of the thesis is explained in more detail.
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2.
Schizophrenia
1 The endophenotype is associated with illness in the population.
2 The endophenotype is heritable.
3  The endophenotype is primarily state-independent (which is present in an 
indvidual whether or not the illness is active).
4 Within families, endophenotype and illness co-segregate.
5  The endophenotype found in affected family members is seen more in 
non-affected family members than in the general population.
Table 2: Criteria for endophenotypes (Gottesman et al.,2003)9
2.1 Clinical symptoms
Schizophrenia is a severe, chronic m ental disorder characterized by recur­
rent psychotic episodes affecting 1% of the general population.15 Its clini­
cal symptomatology is usually subdivided into three sym ptom  categories, 
with ‘positive sym ptom s’ including delusions and intrusive hallucinations, 
often o f a bizarre, paranoid nature, and ‘negative sym ptom s’ referring to 
the loss of basic em otional and motivational behaviour. ‘Cognitive im pair­
m ent’, the third symptom cluster, concerns deficits in attention, working 
m emory and planning, to name but a few affected processes, although this 
cluster is not included in the present d s m - i v  classification (Table 3).
The illness can have a devastating effect on the lives o f patients and their 
relatives. However, it has a very heterogeneous prognosis that ranges from 
total recovery to a typical pattern o f social decline w ith difficulty m ain­
taining interpersonal relations. Especially cognitive im pairm ent and ne­
gative sym ptom s are associated to a poorer prognosis.16 O nset typically 
occurs in early adolescence, and the lifetim e prevalence is about 1%.17 Men 
and w om en are equally affected, but w om en have a later age of onset and 
a better prognosis.18
Schizophrenia has a high mortality rate, with suicide being the leading 
cause of premature death.19 Up to 30% of patients attem pt suicide, and four 
tot ten percent die from  suicide.20;21 The increased mortality is also attri­
butable to other causes, such as the higher frequency o f sm oking and drug 
abuse am ong patients, the higher prevalence of cardiovascular disease and 
the dim inished access to health care.19
2.2 History
From the nineteenth century onwards psychotic disorders were no longer 
view ed as a form  o f insanity or som ethin g to be blam ed for but increa­
singly considered regrettable m edical conditions. A major step forward in 
the differentiation of psychotic disorders was the identification of syphilis, 
a venereal disease that ultim ately leads to paralysis and psychosis. It was 
Kraepelin w ho was the first to provide a conceptual fram ework by distin­
gu ish in g ‘dem entia praecox’ from  ‘dem entia paralytica’. He described de­
m entia praecox as a progressively deteriorating condition with “a loss of 
unity in the activities o f em otions, intellect and volition in them selves and 
am ong one another” .22 Recognizing that dem entia was not typical to all 
patients, Bleuler put forward the term  ‘schizophrenia’. In his view schizo­
phrenia was prim arily a dissociative process with a variety o f m anifesta­
tions.23 In the 1950s, the first drug therapies such as chlorprom azine and 
haloperidol were registered. During the 1960s and 70s the anti-psychiatry 
m ovem ent declared schizophrenia a ‘m yth’. Major advances in the under­
standing of biological, psychological and social risk factors were m ade at
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the end o f the twentieth century. Today, there is a huge body o f evidence 
supporting a neurodevelopm ental basis for schizophrenia.24;25 More re­
cent discussion concerns the am biguousness and nosological validity of 
the term ‘schizophrenia’ and suggestions have been put forward to rename 
the syndrome in the next d s m  edition, am ong w hich were ‘integration dis­
order’ or ‘salience dysregulation syndrom e’.26;27
A Characteristic symptoms: Two (or more) of the following, each present for 
a significant portion of time during a 1-month period (or less if sucessfully 
treated):
1 Delusions
2 Hallucinations
3 Disorganized speech (e.g., frequent derailment or incoherence)
4 Grossly disorganized or catatonic behaviour
5 Negative symptoms, i.e., affective flattening, alogia, or avolition
B Social/occupational dysfunction: For a significant portion of the time since 
the onset of the disturbance, one or more major areas of functioning (such 
as work, interpersonal relations, or self-care) are markedly below the level 
achieved prior to the onset (or failure to achieve expected level of achievement).
C Duration: Continuous signs of the disturbance persist for at least 6 months. 
This 6-month period must include at least 1 month of symptoms that meet 
Criterion A.
D Schizoaffective Disorder and Mood Disorder With Psychotic Features have 
been ruled out.
E Substance/general medical condition exclusion: the disturbance is not due 
to the direct physiological effects of a substance (e.g., a drug of abuse, a 
medication) or a general medical condition.
F No relationship to a Pervasive Developmental Disorder.
Table 3 : DSM-IV Diagnostic Criteria for Schizoprenia (shortened).1
2.3 Pathophysiology 
Even today it is unclear w hether schizophrenia is a unitary disease process 
with a wide range of m anifestations or a constellation o f distinct diseases. 
Genetic vulnerability is a m ajor com ponent, considering the concordance 
o f approxim ately 50% in m onozygotic twins, and 9 to 17%  in dizygotic 
twins.21 In fact, experts estim ate that the heritability o f schizophrenia is as 
high as 80%.28 Several chrom osom e locations have already been linked to 
the syndrome, m ost notably 22q and 8p (Figure 1).29-31 Initially, it was sug­
gested that a m ultitude of different genes all converge functionally upon 
schizophrenia risk via an influence upon synaptic connectivity.32 More re­
cently, with high rates of structural variations (e.g. c n v s  caused by small-sized 
deletions or duplications) having been demonstrated in schizophrenia pa­
tients, genom ic alterations have been proposed to play an im portant role 
in the pathophysiology as w ell.33-37
Various environm ental risks have been linked to schizophrenia inclu­
ding prenatal and perinatal events, sociodem ographic factors and drug
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abuse (Table 4). At present, hypotheses on the aetiology of schizophrenia 
try to integrate the genetic and environmental findings (Figure 2) as it is 
assum ed that com plex interactions between these factors may be the key 
to its developm ent and course.38;39
Prenatal and perinatal events:
Maternal infections (influenza, Rubella, Toxoplasmosis, veneral infections) 40-44
Smoking during pregnancy45
Diabetes mellitus during pregnancy45
Obstetric complications 46
Malnutrition 47
Sociodemographic factors:
Lower social class 48 
Ethnic migration 49-5 
Living in rural areas 5
Cannabis abuse 52 53
Table 4: Environmental risk factors for schizophrenia. (R eferences added in superscript).
Figure 2: A developmental model of schizophrenia (Di Forte et a l .) '
2.4 Neurobiological findings 
Structural and functional brain im aging studies have helped enhance our 
knowledge of the brain regions that are involved in schizophrenia. An over­
all reduction in brain volum e, the loss o f cortical grey m atter and ventri­
cular enlargem ent are the m ost frequently reported findings.55-57 Positron 
em ission tom ography ( p e t ) revealed hypofunction of the frontal lobes, 
thalamus and cerebellum. W ith the aid of Functional Magnetic Resonance 
Im aging (fMRi) more sophisticated dysfunctional networks encom passing 
more brain regions have becom e detectable.58
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In the last decade, the study o f cognitive im pairm ent has becom e one of 
the central issues in schizophrenia research. The syndrome has been as­
sociated with a broad array of neuropsychological im pairm ents, including 
information processing, working memory, attention, problem solving, social 
cognition, processing speed, verbal and visual mem ory and learning.59;60 
Psychom otor slow ing has also been suggested as an additional primary 
cognitive feature, but this still needs further study.61
In general, patients studied during their first episode present clear evi­
dence o f neuropsychological im pairm ent, with overall perform ance levels 
o f one standard deviation below  that o f healthy controls.60 The course of 
the cognitive im pairm ent is also heterogeneous; while some patients (tem­
porarily) show m odest deficits, others suffer from  a dram atic intellectual 
decline rem iniscent of the term ‘dem entia praecox’.
Patients with schizophrenia exhibit deficits in several laboratory-assessed 
neurophysiological abilities that have been proposed as endophenotypes.11;62 
These deficits extend from the earliest pre-attentive stages of information 
processing to higher-order cortical functions. Successful inform ation pro­
cessing requires the ability to inhibit intrinsic responses to irrelevant or re­
dundant responses, and reciprocally, to facilitate responses to novel or 
deviant responses and there is sufficient evidence to suggest that in schizo­
phrenia patients suffer deficits in both processes.62 Impaired deviance de­
tection is measuredfrequently using the P300 Event-Related Potential (e r p ), 
a brain response to new or infrequent stimuli with peak latency at 300 msec. 
The P300 reflects a variety of cognitive functions, such as attention and wor­
king memory, that are involved in the processing of new stimuli.63
Frequently studied paradigms of inhibitory failure are P50 sensory gating, 
prepulse inhibition o f the startle response (ppi), and antisaccadic eye 
movements. Inhibition is a m echanism  that is thought to keep our beha­
viour goal-directed. Although conceptually linked, there are many different 
types of experim ental inhibition tasks, each with different biological sub­
strates.64 Below, I will discuss the three inhibitory paradigm s separately.
In the P50 sensory gating paradigm  auditory e r p s  are m easured in a 
double-click paradigm , w ith a 500 m sec interstim ulus interval. Sensory 
gating occurs w hen the e r p  am plitude elicited by the second click is sup­
pressed relative to the e r p  waveform  elicited by the first click. Sensory ga­
ting is considered to be a norm al pre-attentive inhibitory m echanism  that 
prevents the brain from  bein g overtaxed by sensory input; it is already 
dem onstrable after 50 msec, suggesting it does not depend on any effort­
ful control. P50 gating deficits have been found in 70% of schizophrenia 
patients tested and in 58% o f their unaffected relatives (and in 16% of un­
related healthy controls),i0 and have been associated with several gene lo­
cations.62 In addition, the sensory gating deficit is dim inished by clozapine 
treatment, a second-generation antipsychotic.65
ppi refers to the normal reduction of a m otor startle reflex elicited by a 
loud noise w hen this is preceded by a w eaker non-startling stim ulus, the 
prepulse. Anim al and hum an studies suggest that the startle response is 
m ediated by a neuronal circuit in the low er brainstem  and that the re­
sponse can be attenuated by several structures am ong which the prefrontal 
cortex.66;67 Since a reduction of ppi has been dem onstrated in 38% o f the 
schizophrenia patients tested, in 47% o f their siblings, and only in 22% of 
unrelated controls,i0  it is considered a potential endophenotype.68-70 In 
addition, effects o f second-generation antipsychotics on the ppi deficit 
have been found.71;72
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3. Borderline
Personality
Disorder
A third  cand idate en dophen otype w ith  an in h ibitory paradigm  is the 
antisaccade task. In this eye m ovem ent task, participants are seated with 
their heads secured in a stable position and asked to fixate on a central 
point. They are instructed to inhibit reflexive eye m om ents to unexpected 
stim uli at either side o f the fixation point and to m ake an eye m ovem ent to 
the opposite direction, hence ‘antisaccade’.73 Inhibition abnorm alities in 
this task have consistently been found in the schizophrenia spectrum , es­
pecially in patients with negative symptoms, and have been related to spe­
cific gene locations.62 It is estim ated that 48% o f schizophrenia patients 
show inhibition deficits, while this is 23% for relatives and 8% for healthy 
controls.10
2.5 Treatm ent
The m anagem ent o f schizophrenia involves a broad array of treatm ent in­
terventions such as education, assertive com m unity treatm ent, social 
skills training, supported em ploym ent, cognitive behaviour therapy and 
sim ultaneous treatm ent of substance abuse.74-79 Even so, the cornerstone 
o f the treatm ent of schizophrenia is the prescription o f antipsychotic m e­
dication, w ithout w hich m ost psychosocial interventions w ould be im- 
possib le.45;80 Antipsychotic treatm ent often results in a substantial 
im provem ent or rem ission of the positive symptoms, although m any pa­
tients will still suffer from negative symptoms and cognitive deficits.21;81
There is ongoing debate about w hich antipsychotic w ould be the drug 
o f choice for patients with schizophrenia. Current evidence suggests that, 
in general, both second-generation and conventional antipsychotics have 
com parable clinical efficacy, whereas only clozapine has proven superio­
rity.82;83 The second-generation antipsychotics, also referred to as ‘atypical’, 
have gained a prom inent role in the treatm ent of schizophrenia relative to 
the conventional agents because o f better treatm ent adherence and a 
low er risk of extra-pyramidal side effects.84 However, the relatively high 
doses of typical antipsychotics used in comparative studies may have con­
tributed to the higher incidence of extrapyramidal side effects.85 Benefi­
cial effects on cognitive sym ptom s have been claim ed in prelim inary 
studies.72;86;87 Nevertheless, also the second-generation antipsychotics have 
serious side effects, am ong w hich are sedation, weight gain, anticholiner­
gic effects, sexual dysfunction and m etabolic side effects. These adverse 
effects evidently have a major im pact on the patients’ treatm ent adherence 
and their well-being.
So far, m ost comparative studies included chronic, severely ill patients; 
few trials have addressed the question w hether deterioration can be re­
duced at an early stage of the disease.88;89 Studies with head-to-head com ­
parisons o f different antipsychotics in patients w ith recent-onset 
schizophrenia are imperative to ultim ately establish w hich antipsychotic 
agent has the best risk-benefit ratio with regard to m edical, cognitive and 
social outcome.
3.1. Clinical symptoms 
Borderline personality disorder ( b p d ) is a com plex psychiatric disorder 
characterized by a pervasive pattern o f instability in interpersonal rela­
tionships, self-image, affects and im pulse control (Table 1). Self-destruc­
tive behaviour is a prim ary feature of b p d ; two-thirds o f b p d  patients 
attem pt suicide, resulting in suicide rates of 8 -io% .90;91 The onset o f b p d  
typically occurs in early adulthood and the syndrome is estim ated to occur
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in 1-5%  of the general population92, with a three tim es higher prevalence 
in w om en.91 In contrast to w hat was previously assum ed, b p d  is not a sta­
ble, untreatable personality trait: Zanarini and colleagues found that 88% 
of their b p d  sam ple no longer m et the diagnostic criteria after ten years.93
3.2 History
It is remarkable that one o f the m ost widely and com monly used diagnoses 
in m odern clinical practice has a relatively young history. It was not until 
1980 that the ‘borderline’ diagnosis was included in the d s m - i i i . Knight 
first proposed the term  to describe patients “on the border between neu­
rosis and psychosis” .94 Kernberg postulated the broader concept o f the 
‘Borderline Personality O rganization’ for cases characterized by a weak 
identity form ation, prim itive defences (e.g. splitting, denial, projective 
identification), whose reality testingw as, in general, intact, but who were 
vulnerable to transient failures.95 The d s m - i i i  definition of Borderline Per­
sonality Disorder arose from  Gunderson’s and Singer’s widely cited review 
that identified descriptors in several areas of interest, such as impulsive 
actions, interpersonal relationships and social m aladaptation.96 The new 
diagnosis ‘Schizotypal Personality Disorder’ was introduced at the same 
time, resulting in a clearer dem arcation o f the b p d  and schizophrenia con­
cepts.97 The introduction of the b p d  diagnosis in the d s m - i i i  prom pted 
w ide recognition o f the disorder am ong clinicians and induced re­
searchers to question the validity of the diagnosis. Several authors found 
these psychotic-like symptoms to occur in about 75% of b p d  patients while 
the phenom ena were rare in other patient groups.98-101 In line with these 
findings, the m ost prom inent revision in the d s m - i v  was the addition of a 
ninth criterion: “transient, stress-related severe dissociative sym ptom s or 
paranoid ideation” .
3.3 Pathophysiology
The exact pathophysiology of b p d  is unknown. Genetic factors and child­
hood experiences are thought to interact and cause em otional dysregula­
tion and im pulsivity (Figure 3).102 Family aggregation, adoption and twin 
studies all suggest an underlying genetic risk, albeit that the num ber of 
large-scale studies is still lim ited. In one such larger scale twin studies, 
there was a concordance o f 35% in monozygotic twin pairs and 7% in dizy­
gotic twin pairs.103
Many b p d  patients report instances o f one or m ore childhood adverse 
life events,104 w ith 40 to 71%  of inpatients m entioning childhood sexual 
abuse.8 In their recent meta-analysis and in contrast to clinical expecta­
tions, Fossati et al. found only a moderate association (pooled r= .28) be­
tween childhood sexual abuse and b p d .105 Zanarini and colleagues 
concluded that childhood sexual abuse is “neither necessary nor sufficient 
for the developm ent o f the disorder,” while other childhood experiences 
constitute significant risk factors as well.104 Insecure attachment and neglect 
by one of the caregivers are considered to be m ajor predictors.106;107
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Figure 3: Neurobehavioural model of borderline personality disorder
3.4 Neurobiological findings 
Evidence from  various neuroscientific directions converges on prefrontal 
(inhibitory) dysfunction in com bination with amygdala hyperactivity.8;102;108 
Structural and functional m r i  has revealed a dysfunctional network with 
several brain regions being involved in b p d , including the anterior cingu- 
late cortex, the orbitofrontal prefrontal cortex and the dorsolateral pre­
frontal cortex, the amygdala and the hippocam pus.8;109
Several electrophysiological studies found a link between b p d  and com ­
plex-partial epileptic seizures and various e e g  aberrations such as reduced 
p300 am plitudes and shortened r e m  latencies were uncovered.110 N eu­
roendocrine research revealed a hyperresponsiveness of the hypothalamic- 
pituitary-adrenal axis in patients w ith b p d  and a history o f childhood
abuse.111
Neuropsychological b p d  studies report conflicting results. W hile some 
authors observed severe executive dysfunctions sim ilar to those seen in 
brain injury patients,112-114 others did not find any differences with healthy 
subjects.115;116 A recent m eta-analysis concluded that b p d  patients per­
form ed more poorly than healthy controls across all neuropsychological 
dom ains with m ean effect sizes (Cohen’s d) ranging from  -0.29 for cogni­
tive flexibility to -1.43 for planning.117 The broad heterogeneity o f the phe­
notype is often viewed as the primary cause of the inconsistent outcom es, 
but the low specificity o f som e cognitive tests may also have contributed.
There is a reasonable body of literature describing neuropsychological 
im pairm ent in b p d , but few studies have investigated more specific dys­
functions in inhibition or deviance detection, such as have been described 
for schizophrenia, despite the recom m endations o f several theorists.118- 
120 In the present thesis, the topic o f disinhibition in b p d  is addressed in 
several chapters.
The search for endophenotypes has only ju st begun. Siever and col­
leagues conclude that the heritability may be stronger for discrete dim en­
sions than for the b p d  diagnosis per se and suggest supplem enting the 
categorical classifications with personality trait dim ensions.102 Especially 
im pulsivity is studied extensively, while endophenotypes o f other sym p­
tom  dom ains such as affective instability, anxiety or psychotic-like symp­
tom s are researched less often.102 The psychotic-like sym ptom s are 
addressed in Friedel’s recently postulated dopam ine hypothesis that sug­
gests adding dysfunctional dopam inergic responses to the already known
16
4 .
Schizophrenia 
and Borderline 
Personality 
Disorder
5. Aim s and 
outline o f the 
thesis
serotonergic deficit as a key sym ptom  in patients w ith b p d .121 Although 
warranting further research, the hypothesis is supported by the transient 
w orsening seen in b p d  patients in dopam inergic challenge studies122 and 
the positive effects o f antipsychotic agents.123
3.5 Treatm ent
There are few controlled trials on BpD-specific therapeutic interventions. 
A long-term therapeutic alliance is considered crucial in the treatm ent of 
the disorder,91 and patients can benefit from  both psychosocial and phar­
macological regimens. In the 1990s and the first decade of this m illennium  
several psychotherapeutic treatm ent program m es were launched. So far, 
L in ehan’s d ialectical behaviour therapy has gained the m ost em pirical 
support,124 while the effect o f partial hospital treatm ent on psychodynamic 
principles has also been established.125 Recently, a Dutch com parative 
study reported schem a-focused psychotherapy to be more effective than 
psychodynam ic-oriented therapy.126
In the treatm ent o f b p d  adjunctive benefit can be achieved by com bin­
ing symptom-targeted pharm acotherapy with psychotherapy.127 Although 
hardly evidence-based, the use of m edication is widespread for specific in­
dications: antidepressants and m ood stabilizers for m ood shifts and de­
pressive sym ptom s, for instance,128 and antipsychotics for cognitive 
distortions and ideas o f reference.123;129
Having presented the clinical and neurobiological findings to date, I will 
next discuss differences and sim ilarities betw een the two disorders. As 
m entioned above, the borderline diagnosis has h istorical roots in the 
schizophrenia spectrum. In the past it was even suggested that b p d  was a 
fo rm e  fru s te  (an atypical, m ild or incom plete form) o f schizophrenia.130 At 
present, rather than b p d , the schizoid and schizotypal personality disor­
ders are considered to fall within the schizophrenia spectrum.
The heterogeneity of both disorders has been underlined in the previ­
ous paragraphs. Although the ‘classical’ phenotypes are distinct from each 
other, in both syndromes patients share a predisposition to psychotic fea­
tures. W hile subgroups o f b p d  patients report transient psychotic-like 
symptoms, the psychotic features in schizophrenia are more severe and 
occur more often in episodes lastin g weeks to m onths. In contrast, the 
BpD-specific symptoms of affective instability and affective impulsivity are 
generally absent in schizophrenia. It may som etim es be difficult for clini­
cians to differentiate between the two disorders. W hile neurobiological re­
search findings indicate that psychotic-like sym ptom s may be specific for 
b p d , in daily clinical practice it only takes a secondary position; the m a­
jority of b p d  patients and their relatives are rather faced with interpersonal 
conflicts, affective instability, or with reckless, suicidal behaviour.
So far, the pathophysiology o f the two disorders is unknown, but pre- 
frontal circuits are involved in both. To date, neurobiological research 
studies addressing differences and com m unalities o f the two disease types 
are lacking.
The above overview clearly shows that we are only just beginning to gain a 
deeper understanding o f com plex psychiatric disorders in general and 
schizophrenia and borderline personality disorder in particular. Cognitive 
neuroscience has provided us with tools to search for the building blocks 
o f these syndromes. This thesis focuses on two m ain issues: cognitive dys­
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functions in schizophrenia and b p d  and the effects o f antipsychotics on 
the clinical phenotype and cognitive dysfunction. For reasons o f legibility, 
the thesis is divided into two parts, each being dedicated to one disorder.
In Part I o f the thesis our exploratory studies on pathophysiological as­
pects and psychopharm acological treatm ents of schizophrenia are pre­
sented. The research questions that are addressed read as follows:
—  Do patients with recent-onset schizophrenia show aberrant psychom o­
tor functioning? If so, are the psychom otor deficits part o f the cognitive 
deficit? (Chapter 2)
—  Is there a difference in clinical efficacy and effectiveness between the 
two second-generation antipsychotics ziprasidone and olanzapine? 
(Chapter 3)
—  Does treatm ent with second-generation antipsychotics ameliorate the 
cognitive deficit in patients with schizophrenia? (Chapter 4)
—  Is there a difference between olanzapine and ziprasidone in their abil­
ity to alter the cognitive deficit in patients with schizophrenia? (Chap­
ters 4 and 5)
—  Part II com prises our studies on borderline personality disorder, in 
w hich we posed the follow ing research questions:
—  Do patients with b p d  show aberrant cognitive perform ance on the anti­
saccades paradigm  (Chapter 6), sensorim otor gating (Chapter 7), and 
error-related negativity? (Chapter 8)
—  If so, does the cognitive perform ance of b p d  patients resem ble that o f 
patients with schizophrenia?
— Are patients with psychotic-like sym ptom s more susceptible to cogni­
tive deficits? (Chapters 7 and 8)
—  How effective are various second-generation antipsychotics for patients 
with b p d ? (Chapter 9)
—  Finally, in Chapter 10 the results and conclusions o f the studies re­
ported in this thesis will be put into a broader perspective.
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Abstract
Introduction
Methods
Results
Discussion
Psychomotor slowing is regarded as an important clinical phenomenon in 
schizophrenia and simple graphic tasks consistently revealed deficits in the 
(implicit) planning and execution of motor actions in patients with chronic 
schizophrenia. The aim of the present study is to test the hypothesis that 
such deficits are already present in patients with recent-onset schizophrenia.
Psychomotor performance and several aspects of movement planning were 
analyzed in 36 patients with recent-onset schizophrenia and a group of 33 
matched healthy controls. Participants were required to draw patterns 
varying in complexity in three different figure-copying tasks, match and draw 
simple symbols in the Digit Symbol Substitution Test (DSST) and connect 
target circles with varying orientations in a newly developed Line Sequencing 
Task.
Relative to the controls, the patients showed significantly longer initiation 
times when the patterns in the copying tasks became more complex, 
suggesting increased difficulty in movement planning. Overall, they were not 
slowed in the execution stages. in the cognitively more demanding DSST, 
the patients were significantly slowed in both the initiation and movement 
phases. Moreover, they selected less optimal movement directions in the 
Line Sequencing Task.
Psychomotor planning deficits are already present in the early stages of 
schizophrenia and involve deficient planning but intact motor action.
Planning difficulties can be detected in motor sequences as well. The results 
indicate that the cognitive deficit in schizophrenia also affects the implicit 
planning of very simple movements.
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1. Introduction Psychom otor slowing is considered an im portant clinical phenom enon 
in schizophrenia but its exact nature rem ains unclear as it involves m ulti­
ple aspects such as goal selection, inhibition, planning, sequencing and 
execution. Psychom otor slowing is a prognostic factor for poor social, 
functional and clinical outcom e1 while the m a t r i c s  neurocognition com ­
mittee identified ‘speed of processing’ as a separable cognitive dim ension 
in schizophrenia.2 In a recent meta-analysis Dickinson et al. concluded 
that the deficit in ‘processing speed’, as m easured by digit-symbol coding, 
is both substantial (mean effect size 1.57) and significantly larger than the 
effects o f other often-studied m easures such as verbal memory, executive 
dysfunction, and w orking memory.3
Frequently used tests m easuring processing speed like the Digit Sym­
bol Substitution Task ( d s s t )  and the Trail M aking Test have strong 
psychom otor com ponents.214 It rem ains to be shown to what extent the di­
m ension o f speed of processing proves itself a truly separable cognitive 
factor independent of other fundam ental com ponents o f processing.5 In 
addition, it is not yet clear to what extent psychom otor processes should 
be categorized under the general heading of processing speed. Particu­
larly the more com plex psychom otor planning tasks not only require 
efficient sensorim otor processing, but sufficient executive functioning, 
w orking mem ory and sustained attention as well.
W ith the aid o f a digitizing tablet it is possible to analyze the subjects’ 
psychom otor behavior in the d s s t  accurately. By distinguishing the initi­
ation and execution phases o f m ovem ents one can gain a better 
understanding of the specific deficits that affect psychom otor perfor­
m ance.6 Previous kinem atic research o f processing speed u sing the d s s t  
showed a m arked slowing in a group of schizophrenia outpatients that, in 
the absence of a prolongation o f m ovem ent time, was predom inantly 
caused by increases in initiation tim e.7 However, in a group o f chronic in­
patients both m ovem ent and initiation tim es were prolonged w ithout the 
two processes showing any correlations.8
H ence, in order to exam ine subtle m otor d eficits in schizophrenia, 
traditional neuropsychological tests that assess processin g  speed 
alone do not suffice and should  be com plem en ted  w ith  additional 
k in em atic analyses or w ith  sim pler m otor tests (e.g. fin ger tap p in g  or 
draw ing tasksi;8 ). Finally, the d istin ction  betw een processin g  and 
m otor speed is supported  by two recent factor analyses u nd erscorin g 
that m otor speed can indeed be delineated  from  processin g  speed in 
sch izop h ren ia.9110
Graphic tasks are w ell suited for the assessm ent o f psychom otor slo­
w ing since they allow the cognitive load o f the tasks to be m anipulated, 
and both the cognitive and m otor processes im plicated in psychom otor 
activity to be evaluated. In two copying experiments involving com plex 
figures with a high cognitive load on planning, attention and w orking 
memory, chronic schizophrenia patients were observed to exhibit m otor 
slowing, especially those with more pronounced negative sym ptom s.11112
Two characteristics o f the patient sam ples com plicate the interpreta­
tion of these earlier findings. First, the schizophrenia populations all 
consisted of chronic patients in the advanced stages of the disease. Since 
cognitive perform ance is associated with social outcom e,13 the results 
were possibly confounded by a selection bias (i.e., only patients w ith ne­
gative symptoms or a continuous need for care were examined). Although 
there is a vast am ount o f data suggesting a broad im pairm ent in several
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2. M ethods
cognitive dom ains at an early stage o f schizophrenia,14-17 data on psy­
chom otor slowing obtained in recent-onset patients are still limited. 
Cross-sectional studies have shown deficient processing speed in com ­
parison to normal controls or norm  groups,i8  but the few available 
longitudinal studies showed mixed results.19-22
Also the use of atypical antipsychotics could have confounded earlier 
research by enhancing cognitive functioning.23 Recent meta-analyses in­
dicated that second-generation antipsychotics have a positive effect on 
both the motor-skill dom ain and processing speed, whereas the typical 
agent haloperidol showed negative effects.24125 So far, none of the studies 
using graphic tasks adequately addressed the potential effects o f concur­
rent psychopharm acological treatment.
W ith the present study we sought to resolve these issues and prevented 
effects due to selection bias and long-term  m edication use by using a 
heterogeneous sam ple of patients with recent-onset schizophrenia and a 
group o f carefully m atched healthy controls, both medication-free at the 
tim e of testing. The m ain objective of the present study was to gain a bet­
ter understanding of psychom otor slow ing in recent-onset schizophrenia 
by studying the initiation and execution o f m otor actions through graphic 
tasks, including the d s s t .
The literature on cognitive im pairm ent in schizophrenia largely refers 
to ‘higher dysfunction’, as m easured by clinical tasks like the w c s t  or 
Tower of London.26 In the present study we researched if the elem ents 
studied (am ong w hich goal selection, m otor planning, initiation, inhibi­
tion, and sequencing) are also distorted in the m ost sim ple of motor 
tasks. Note that for reasons of readability and succinctness we use the 
term ‘p lanning’ throughout this paper but m ean this to refer to the nu­
merous processing activities that for the m ost part evolve in the initiation 
stages of a m ovem ent sequence.
A subsidiary aim  o f our investigations was to broaden our knowledge of 
m otor perform ance by studying directional sw itching effects in a newly 
developed switch task, i.e. the Line-Sequencing Task, in w hich subjects 
have to decide if and w hen to ‘sw itch’ their m ovem ent direction to secure 
an optim al performance.
We hypothesized that the initiation and execution of m otor actions 
w ould both be affected in recent-onset schizophrenia. Secondly, we ex­
pected that in planning m otor sequences and in contrast to the controls, 
the patients w ould prefer a constant m ovem ent strategy and accordingly 
hypothesized that they w ould have difficulty sw itching m ovem ent direc­
tions, delaying switches until a later shift in line orientation, thus 
showing prolonged perseveration).
2.1. Participants
The 36 schizophrenia patients that we exam ined in the current study had 
all been recently diagnosed with a schizophrenia-spectrum  disorder and 
were recruited to participate in a m ulti-center research project on the cog­
nitive effects o f antipsychotics (NCT00145444). The patients for the present 
study were recruited in only two centers o f the m ulti-center project 
(Utrecht and Nijmegen). The tests reported here were adm inistered at the 
patients’ baseline visit. Patients were aged betw een 18 and 40 years and 
had a diagnosis o f schizophrenia, schizoaffective disorder or schizo­
phreniform  disorder, based on the structured clinical interview for d s m - i v  
( s c i d - i ) . 27
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Inclusion criteria were a C linical G lobal Im pression Severity score ex­
ceeding 4 (‘moderately ill’) and a m axim um  lifetim e exposure to antipsy­
chotics o f 16 weeks. Only patients with a duration of illness o f less than 5 
years were included in this study. A lthough the inclusion criteria for 
“recent-onset schizophrenia” of other recent studies were stricter,28 in the 
present study we focused prim arily on m edication status, as it is hard to 
pinpoint the exact onset o f schizophrenia. We only included patients not 
taking psychopharm acological agents at the tim e o f testing and required 
the follow ing washout periods: antidepressants: 7 days or more; MAO-in­
hibitors: 2 weeks or more; fluoxetine: 5 w eeks or more; antipsychotics: 12 
h or more; and depot agents: 2 weeks or m ore. The washout periods were 
based on the pharm acological half-life o f the agents, except for the an­
tipsychotics where the washout period was shorter due to ethical consid­
erations. Exclusion criteria were substance dependence (incidental 
substance abuse was not an exclusion criterion), a positive drug screen for 
am phetam ines, cocaine or opioids at baseline, m ental retardation or or­
ganic m ental disease, a history o f epilepsy, and physical illnesses. The pa­
tien ts’ clinical condition was assessed by m eans o f the Positive and 
Negative Syndrome Scale.29
The control group consisted of 33 healthy students who were recruited 
from  a school for secondary vocational education. The students were care­
fully m atched for age, sex, handedness and estim ated intelligence (IQ as 
based on the National Adult Reading Test30).
The study was approved by the local ethics com m ittee and all partici­
pants had given their written inform ed consent for the entire study project 
(including both the m edication trial and this particular study) prior to their 
participation.
2.2. General task procedure
Participants were always asked to draw as fast and as accurately as possi­
ble using a regularly shaped electronic pen on sheets of normal paper that 
were placed on a digitizing tablet ( w a c o m ® ) .  The x and y coordinates of 
the pen were recorded with a frequency o f 200 Hz and a spatial accuracy of
0.2 mm. Data acquisition and analysis were perform ed w ith Oasis® soft­
ware.31 The stimuli o f the three copying tasks were displayed on a computer 
screen.
2.3. Experimental tasks
2.3.1. DSST
In the Digit Symbol Substitution Task, a subtest o f the W echsler Adult In­
telligence Scale 3rd ed.32, participants were asked to make as many correct 
substitutions (symbols) as possible w ithin 120 sec.
2.3.2. Copying tasks 
We u sed a serieso fv ery  sim ple copying tasks that, although incorporating 
specific m anipulations, did not overly tax w orking memory. First, the com ­
plexity o f the stim ulus figures was m anipulated by varying the num ber of 
elem ents or the fam iliarity o f the figures. The second com plexity variable 
was based on a stim ulus-preference conflict: drawing follows several im ­
plicit plan nin g rules or so-called graphic production rules that entail se­
veral starting and progression principles.33 For instance, people tend to 
begin drawing at the top and left and have the tendency to connect strokes 
instead o f lifting the pen between successive strokes. W hen a drawing ac­
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tion involves ‘conflicting rules’, e.g. w hen one is instructed to start drawing 
at the bottom  left-hand side, this requires additional planning, resulting 
in longer latency tim es.34
2 .3 2 .1. Conflicting Figures Task 
In the Conflicting Figures Task, subjects were asked to copy sim ple pat­
terns that are either consistent or in conflict w ith the above m entioned 
graphic production rules.11 The patterns consist o f three and four seg­
ments. The task com prises ten pairs o f ‘conflicting’ and ‘non-conflicting’ 
mirror im ages (Figure 1).
2.3.22. Imposed Starting-Point Task 
In the Im posed Starting-Point Task subjects were asked to copy L-shaped 
patterns with the instruction to start drawing at the position indicated by 
a black dot (Figure 1).12 The im posed starting point either corresponds to 
or conflicts with the preference predicted by the graphic production rules 
(L-shape vs. inverted L-shape, respectively). We m anipulated the factor 
starting preference (‘Start left’ vs. ‘Start right’) and accordingly presented 
four different figures 12 tim es in a random  order.
2.32.3. Complex Figures Task 
In the Com plex Figures Task subjects were asked to reproduce figures pre­
sented on a com puter screen, w ith their com plexity and fam iliarity being 
m anipulated experimentally.7 The stim ulus figures are divided into three 
categories according to their degree of (qualitative) familiarity: capital let­
ters, fam iliar and unfam iliar patterns. Each category is subdivided into two 
com plexity groups, i.e., four- and eight-segm ent patterns (Figure 1). The 
patterns are presented in a pseudo-random  order and do not rem ain visi­
ble during drawing although participants are given the possibility to recall 
and reinspect the stimulus.
' vq p ,
B
Figure 1. Examples of stimuli patterns used in the copying tasks. Panel A: Conflicting figures. The right- 
hand pattern is ‘in conflict w ith the graphic production rules’ as it does not allow the participant to start 
drawing at the preferred top left. Panel B: L-shaped patterns w ith an imposed starting point. The two 
right-hand stimuli are not congruent w ith normal preferences. Panel C: Complex figures. Examples of 8- 
segment capital letters and familiar and unfamiliar figures.
29
2.3.3. Line-Sequencing Task 
For the present study we developed a new drawing task, an adaptation o f a 
two-segm ent figure-sequencing task ,35 requiring subjects to connect pairs 
o f sm all open circles (diameter 0.5 cm, distance 2 cm) with straight lines 
in sequences of ten pairs (Figure 2). The m ain goal o f the task is to assess 
planning processes and perseveration during fast m otor actions. The task 
consists o f five trials in w hich the sequence o f line orientation ‘rises’ from 
horizontal to vertical (Sequence 1), five trials in w hich the line orientation 
‘drops’ form  vertical to horizontal (Sequence 2), and ten control trials with 
a random  sequence o f line orientations. The trials were perform ed in a 
random ized order. Perseveration in this task was operationalized by the 
percentage o f trials executed w ithout switches.
Vertical lines are m ost frequently drawn from  top to bottom  and hori­
zontal lines from  left to right. If, in a sequence of lines, the line orienta­
tion changes progressively in sm all steps, then at some line tilt the subject 
has to resolve the conflict between these two preferences and m ust ‘switch’ 
from  one to the other. It is im portant to note that the participants were ig­
norant as to the im posed switches: they did not receive any ‘sw itching’ in­
structions and were hence free to choose if and w hen they switched.
Figure 2 . The two stim ulus sequences used in  the Line Sequencing Task. The presented circles 
(real size: circle diameter 0.5 cm, between-circle distance 2 cm) are to be connected w ith  pen 
strokes as fast and as accurately as possible starting in  the leftm ost box. Somewhere in  the 
sequence the two graphic production rules ‘clash’. In  Sequence 1 (top row), for instance, people 
w ill tend to start drawing from  le ft to the righ t (consistent w ith  the graphic production rule ‘start 
le ft’) and w ill m aintain this movement orientation u n til box 5 or 6 where most people w ill sh ift 
the ir orientation and start at the top (consistent w ith  the graphic production rule ‘start at the top ’).
2.4. Statistical analysis 
For the d s s t  we first conducted a m ultivariate analysis o f variance 
( m a n o v a )  on all dependent variables, followed by Student t-tests. The de­
pendent variables were the num ber of correct substitutions, w riting time 
(mean tim e per sym bol in s), m atching tim e (the accum ulated pen-up pe­
riods between two successive symbols; in sec), velocity (cm/sec), symbol 
size (in cm), the num ber of errors and the num ber o f corrections. In the 
calculation o f the w riting tim e, the first sym bol o f each new line was ex­
cluded because o f the large distance that had to be covered by the pen.
In the analyses of the three copying tasks we started with a m a n o v a  with 
initiation tim e (the period between stim ulus appearance and onset o f the 
first pen-down movement) and m ovem ent tim e (the tim e spent drawing) 
of all the tasks as the dependent variables and Group (patients vs. controls) 
as the between-subjects factor. Next, we analyzed the results for each task 
by three separate a n o v a s  with initiation time, m ovem ent tim e and draw­
ing velocity (cm/sec) as the dependent variables, and Group as the be- 
tween-subjects factor. In the Com plex Figures Task, ‘stop tim e’ (intervals 
spent stationary during trial performance) and ‘reinspection tim e’ (time 
used to reinspect the figure) were additional dependent variables, with the
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3. Results
latter bein g analyzed with M ann-W hitney U test, because the data were 
not normally distributed.
For each copyingtask cognitive load was analyzed using within-subject 
variables, which for the Conflicting Figures Task were Conflict (conflicting, 
non-conflicting figures) and Size (3,4 line elements) and for the Imposed 
Starting Point Task Conflict (2 levels: in accordance vs. in conflict with 
graphic production rules) and Preference (start left, start right). For the 
Com plex Figures Task the within-subject factors were Familiarity (figures, 
patterns and letters) and Com plexity (4, 8 line elements).
In the Line-Sequencing Task, a n o v a s  were used w ith total m ovem ent 
time, line length, drawing velocity and ‘the percentage o f trials w ithout di­
rectional sw itches’ as the dependent variables. In order to test w hether pa­
tients displayed the ‘inconvenient’ upward drawing direction, the three 
(nearly) vertical directions (20°, 10° and 0°) were pooled for analysis and an 
a n o v a  was used with the percentage of upward strokes as dependent vari­
able, Sequence (Sequences 1, 2 and random) as within-subject factor and 
Group as the between-subjects factor.
All a-priori statistical analyses (2-sided, a  = 0.05) were perform ed with 
spss 11.0. For the calculation o f effect sizes C ohen’s d and partial squared 
eta (h 2) were used.
The participants’ dem ographics are presented in Table 1. There were no 
significant group differences with respect to age, handedness, sex, or in­
telligence. 14 o f the 36 patients had no lifetim e use of antipsychotics.
3.1. d s s t
The results o f the d s s t  are shown in Table 2. The om nibus m a n o v a  o f all 
seven d s s t  variables revealed a significant group difference (F (7,59) = 6.02; 
p < 0.001, h 2 = 0.40). The patients had a significantly lower num ber o f cor­
rect substitutions and both the patients’ m atching and w riting tim es were 
prolonged relative to those of the controls, with correspondingly low ve­
locities. The differences were not caused by a difference in sym bol size 
(t= 0.98; p = 0.49). The patients and controls also did not differ in the number 
o f errors (t = 1.85; p = 0.07) or corrections (t = 0.924; p = 0.36).
In the m a n o v a  we found a significant group effect (F (6,62) = 3.24; p < 0.01, 
h 2 = 0.267). Below, the results o f the three tasks are discussed separately.
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Recent-onset 
schizophrenia patients 
(N = 36)
Healthy 
controls 
(N = 33)
Statistic
Age (years) (mean, SD) 24.9 (5.1) 23.5 (6.9) 0. 
0 
 ^
a
Estimated duration of illness 
(days) (mean, SD, median)
389 (460; 180)
Gender (M /F ) 30/8 26/7
o 
^
 
.0
.9 
0. 
0 
V 
II
Handedness (R /L) 35/3 32/1 .7
.3
0. 
0 
II 
II
Estimated premorbid IQa 
(mean, SD)
97.6 (9.0) 97.7(11.0) t = 0.12 
(p = 0.90)
Education level" 3.9 (1.4) 4.2 (1.3) t = 0.77 
(p = 0.44)
Prior lifetime antipsychotics 
use (days)
13.1 (17.4) - -
PANSS positive symptoms 
(mean, SD)
22.21 (4.2) - -
PANSS negative symptoms 
(mean, SD)
18.66(5.8) - -
PANSS general 
psychopathology (mean, SD)
38.61 (7.8) - -
PANSS total score (mean, 
SD)
79.47 (13.6) - -
DSM-IV classification (N)
Schizophrenia, paranoid type 14
Schizophrenia, disorganized 
type
5
Schizophrenia, 
undifferentiated type
2 - -
Schizophrenia, residual type 1
Schizoaffective disorder 3
Schizophreniform disorder 11
Table 1. Demographics
p a n s s  = the Positive and Negative Symptom Scale in schizophrenia;
SD = standard deviation.
a Intelligence quotient based on N ational Adult Reading Test. 
b Dutch scale for education level (1 = primary education, 7 = university level).
Schizophrenia
patients
Controls Difference (CI) t d
Mean number of correct 
substitutions
59.3(14.5) 78.5(11.16) .8)12.o.55.219. 6 .05* -  1.43
Mean matching time (s) 1.55 (0.47) 1.11 (0.21) 0.44 (0.290.60) 5.73* 1.21
Mean writing time (s) 0.52 (0.16) 0.41 (0.07) 0.10 (0.050.15) 3.92* 0.89
Mean writing velocity (cm /s) 3.04 (0.56) 3.56 (0.67) -  0.53 ( -  0.83 to -  0.22) 3.45* -  0.84
Table 2. Digit Symbol Substitution Task. Means (SD) of the number of correct substitutions, 
writing time, matching time and writing velocity per dig it for the schizophrenia patients (n = 36) 
and the matched controls (n = 33). D ifference w ith  Confidence Intervals (C l). T-statistic and 
e ffec t size Cohen’s d are reported as well. S ignificant group differences are indicated.
*  p< 0.001.
3.2. Copying tasks
3.2.1. Conflicting Figures Task 
Results are shown in Table 3. The m ain Group effect for initiation time was 
not significant, but on trend level (p = 0.057). The factor Conflict had no 
m ain effect on the initiation tim es, whereas the effect for Size was signifi­
cant. The significant Group x Size interaction indicated a decreased task
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performance in the patients when complexity increased. Contrast analysis 
revealed that this was due to the increase from  3 to 4 line segm ents (F (1,65) 
= 10.52, p< 0 .0 i; Figure 3).
The m ain Group effect for m ovem ent time was not significant (p = 0.18), 
nor were there any significant group interactions. Additional analysis of 
the velocity data showed that the patients and the controls used sim ilar 
drawing velocities (F (1,65) = 1.81; p = 0.18).
Factor Conflict (C) Size (S) Group (G) C x S G x C G x S G x C x S
Initiation time 2.60 33.11*** 3.76A 5.18 1.20 3.24* 1.75
Movement time 10.03** 440 .4 *** 1.81 5.35** 0.13 2.32 1.98
Table 3 . Conflicting Figures Task
Differences between schizophrenia patients and controls: F-values and in­
teraction effects o f Conflict, Size and Group on m ovem ent variables.
***p < 0.001; **p < 0.01; *p < 0.05; ^p < 0.10.
0.9 -
0 .8 ---------------------------------------------------------------------------
2 lines 3 lines 4  lines
-Q -SZ - NC
-■ -Sz- C
- 0 -  HC -NC
-•-H C -C
Figure 3 . The mean initiation times (s) in the Conflicting Figures copying task fo r the 
figures consisting of 2, 3 or 4 line segments. sz  = schizophrenia; hc = healthy controls; 
NC = non-conflicting figures; C = conflicting figures.
3.2.2. Im posed Starting-Point Task 
Results are shown in Table 4. Analysis o f the initiation tim es yielded no 
significant main group effect (p = 0.09). The significant Group x Preference 
interaction showed that initiation tim es were prolonged in the schizo­
phrenia group w hen the starting points were in conflict w ith the graphic 
production rules (F (1,65) = 5.08, p = 0.03).
The com parison o f m ovem ent tim es failed  to show a group effect 
(F (1,65) = 0.20; p = 0.65) or an effect for the factor Conflict. The Group x Conflict 
interaction w as also not significant, in d icatin g  that irrespective o f the 
im posed starting points, the two groups were equally fast. M ean drawing 
velocity also failed to show group differences (F (1,65) = 0.27; p = 0.61).
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Factor Conflict
(C)
Preference
(P)
Group
(G)
C x P G x C G x P G x C x P
Initiation time 4 9 .75*** 0.05 2.94* 11.76*** 1.00 5.08* 1.75
Movement time 0.06 3.50* 0.27 46.15*** 0.08 1.43 1.54
Table 4. Imposed s ta rting  Point Task
Differences between schizophrenia patients and controls: F-values and in­
teraction effects o f Conflict, Preference and Group on m ovem ent variables. 
***p< 0.001; *p<0.05; ^p< o.io.
3.2.3. Com plex Figures Task 
Results are shown in Table 5. There were no group effects or group inter­
actions as regards initiation tim es. However, the patients needed signifi­
cantly longer reinspection tim es in the more com plex patterns (4-segment 
patterns: Z = -  2.362, p < 0 .0 i; 8-segm ent patterns Z = -  2.661, p< 0 .0 i). 
There was a significant m ain Group effect for m ovem ent tim e (F (1,64) = 
5.11; p<0.05), indicating that the patients were generally faster than the 
controls. The significant Group x Fam iliarityx Com plexity interaction 
(F (2,63) = 3.58; p = 0.03) showed that the patients were faster on the simple 
4-segment figures, but slower on the 8-segment ones. Additional interaction 
analyses revealed a difference in response styles in the m ore com plex fi­
gures: the patients reached a higher velocity (F (1,65) = 5.11; p < 0.05) but 
tended to m ake more stops (F (2,63) = 2.76; p = 0.07).
Factor Familiarity
(F)
Complexity
(C)
po
)
F x C G x F G xC G x F x C
Initiation time 52 .6 0*** 78 .59*** 1.04 18.79*** 1.98 2.10 0.82
Movement time 127.69*** 1146.82*** 5.11* 35 .3 2*** 2.25 0.16 3.58*
Table 5 . Complex Figures Task
Differences between schizophrenia patients and controls: F-values and in­
teraction effects o f Familiarity, Com plexity and Group on m ovem ent vari­
ables. ***p < 0.001; *p<0.05.
3.3. Line-Sequencing Task 
The total m ovem ent tim es o f the patients and controls in the Line-Se- 
quencingTask did not differ (F (1,65) = 0.60; p = 0.44) with drawing velocity 
being sim ilar as well (11.65 cm/sec and 11.52  cm/sec resp.; F (1,64) = 0.16; 
p = 0.90), although m ean line length in the patients was longer, i.e. they 
had generated more overshoots (F (1,64) = 4.14; p = 0.04).
Figure 4 displays the m ean percentage o f left-to-right/bottom-to-top di­
rections. Note that in Sequence 1 more than 90% o f the lines were drawn 
in the usual, preferred direction from  left to right, but that at the end of 
the sequence (at 20°, 10° and 0°) still a high percentage o f the lines were 
drawn in the less preferred, more inconvenient upward direction. In Se­
quence 2, many participants already opted for the bottom-up direction at 
the very start o f the sequence and did not switch along the way. The pa­
tients showed a significantly higher percentage of trials executed without 
directional switches (66% vs. 40.9%; F (1,64) = 8.30; p < 0.01). The drawing 
directions in the random  trials were quite sim ilar to those of Sequence 1. 
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In Sequence 1 the percentages of upward strokes were 65% for the patients 
and 41% for the controls; for Sequence 2 this was 48% and 36% and in the 
random  condition 55% and 29%, respectively. The a n o v a  with percentage 
o f upward strokes as dependent variable showed a significant Group ef­
fect (F (1,64) = 5.65; p = 0.02), a significant difference between the three Se­
quences (F (2,63) = 8.65; p< 0.001) and a significant Group by Sequence 
interaction (F (2,63) = 4.90; p = 0.01).
Sequence 1
100 
90 
80 
«  70 
“  60 
I  50 
g 40 
“ ■ 30 
20 
10
------- " / /  / I I
Figure 4 . Percentages of lines drawn starting from the bottom le ft in sequence 1 o f the Line 
sequencing Task (top  graph) and those drawn starting from the top right in sequence 2 
(bottom  graph).
3.4. Additional analyses 
Although we had been careful in m atching our groups for age, intelligence 
and educational level, we performed the above analyses again but this time 
corrected for all three variables, w hich yielded sim ilar difference scores 
and significance levels. We additionally com puted post-hoc correlations 
between the dependent variables and the follow ing clinical variables: ill­
ness duration, total PANSS-score, positive p a n s s  score and negative p a n s s  
score. None o f the analyses revealed a significant correlation.
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4. Discussion The present study dem onstrated that patients w ith recent-onset schizo­
phrenia were significantly slower than healthy, m atched controls in the 
initiation o f m otor actions as soon as they encountered a m inor increase 
in complexity, e.g. more line segm ents or unfam iliar figures, forced star­
ting points, digit-symbol m atching or the planning of a m otor sequence. In 
general, the slow ing occurred only in the initiation phase. In contrast to 
our hypothesis, slowingwas absent in the execution phase. Apparently, the 
cognitive processes that support m otor control, such as goal selection, 
planning, sequencing and response inhibition are already deficient in pa­
tients with recent-onset schizophrenia. We will first discuss the results of 
the various tasks separately.
The lower d s s t  scores in the patient group are in accordance with pre­
vious studies.2-4 Sim ilar to a recent report,8 our kinem atic analyses re­
vealed that both m atching and writing tim es were slowed in the patients, 
w hich contradicts previous findings of prolonged initiation tim es only.6;7 
However, it needs to be noted that in our study we used a more recent ver­
sion of the w a i s  in w hich the corresponding sym bols had to be drawn in­
stead o f the digits. Evidently, w riting down digits requires the retrieval of 
different inform ation and is a m uch more autom atic process, whereas 
drawing sym bols possibly requires ‘online’ m otor planning. Apparently, 
patients with schizophrenia are slower in m atching and drawing symbols 
than they are in m atching and w riting digits.
The results o f the Conflicting Figures copying task indicated that the 
patients had protracted initiation tim es but sim ilar m ovem ent tim es in 
com parison w ith the controls. The fact that they experienced planning 
problem s in copying figures w ith four line segm ents suggests that a di­
m inished working-m em ory capacity may have played a role. In contrast to 
previous findings in patients with chronic schizophrenia, we only found 
an effect o f conflict in initiation tim e and not in m ovem ent tim e.11
Forcing our subjects to start drawing L-shaped patterns at an im posed 
starting point significantly prolonged initiating tim es in our patients. Our 
results resem ble those found in chronic patients, although in our study 
the difference between patients and controls was less pronounced.12 The 
task required the inhibition of automatic motor responses, which are based 
on the graphic production rules. Apparently, even the planning of very simple 
motor behaviors is already impaired in recent-onset schizophrenia patients.
In the Com plex Figures Task, the patients had longer initiation times 
copying unfam iliar patterns relative to their healthy peers, w hich finding 
was in accordance w ith previous findings in chronic schizophrenia pa- 
tients.7 Further analyses revealed a difference in m ovem ent strategies: al­
though the patients’ velocity was higher, they made more stops and took 
more tim e reinspecting the stimuli. There are two possible explanations 
for this response strategy. Schizophrenia patients may have more problems 
setting a required m otor action in m otion. Their fast responses may thus 
reflect a disinhibited autom atic response m echanism  that subsequently 
requires m ore online feedback (reinspection). Alternatively, their fast 
response style may reflect a com pensating m echanism  for their underlying 
planning or imprinting defect. Supporting this assumption, Delevoye-Turrell 
et al. showed that allocation prior to m ovem ent onset is low  in schizo­
phrenia patients, suggesting low allocation o f attention for p lanning and 
high allocation of attention for m otor execution.36 In terms of the working- 
m em ory m odel proposed by Baddeley, in schizophrenia patients this may 
result in an im pairm ent in the visuospatial sketchpad.37
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As to the Line-Sequencing Task, we hypothesized that the schizophrenia 
group w ould stick to a direction that was progressively becom ing more un­
com fortable longer and w ould consequently choose to switch to the re­
versed, more preferred drawing direction at a later stage than the controls. 
However, the patients proved to apply a different drawing strategy: they 
more often opted for the uncom fortable bottom-up direction to draw the 
vertical lines and changed their orientation less often than the controls 
did. This seem s to suggest a stronger tendency to perseverate, a well- 
known cognitive deficit in schizophrenia.38 However, as in the random  se­
quences, the group difference in the percentage of bottom-to-top strokes 
was com parable, the follow ing explanation seem s more probable: if at the 
start o f each line one w ishes to avoid the effort o f m aking a decision as to 
drawing direction, then one is likely to adopt one single strategy and draw 
all lines from  left to right and from  bottom  to top. And although this would 
save decision tim e and m ental effort, this is achieved at the cost o f draw­
ing precision as was reflected by the larger num ber of overshoots in the 
schizophrenia group. Thus, the results o f the Line-Sequencing Task indi­
cate that recent-onset schizophrenia patients are already im paired in the 
coherent planning o f sim ple m otor sequences. The results are in line with 
a recent report showing a m otor-planning deficit (i.e. pointing to a target) 
w hen the planning involved an internal representation o f a stim ulus se­
quence.39
Taken together, our results indicate that psychom otor slowing already 
m anifests itself inpatients that have only recently been diagnosed with the 
clinical syndrome. The overall effects o f longer initiation tim es we found 
are in line w ith previous reports using sim ilar m ethods in m edicated, 
chronic patients with schizophrenia, although the effect sizes were less 
pronounced. It is possible that our data show an underestim ation of the 
deficits in schizophrenia as we also included patients with schizophreni­
form  disorder who may ultim ately not all develop the full-blown schizo­
phrenia syndrom e. However, w ith an effect size of d= 1.43 (indicating a 
68% non-overlap betw een the groups), the d s s t  shows to be a potent 
marker for recent-onset schizophrenia.
The finding that the schizophrenia group differed from  the controls 
more on the d s s t  than on the copying tasks is consistent with Dickinson 
e ta l.’s recently published meta-analysis on the d s s t .3 However, this result 
cannot be taken as evidence o f the existence o f a separable cognitive do­
m ain of ‘speed of processing’. As Carter and Barch clearly point out in their 
recent presentation of the c n t r i c s  initiative, the d s s t  taps many different 
processes and its heightened sensitivity may result from  its gauging a com ­
bination of these separate cognitive effects rather than from  m easuring a 
general and larger deficit in an extra cognitive dom ain (speed o f proces- 
sing).5 We agree with the authors that it remains unclear “how to assess the 
general properties o f the speed o f cognitive processing in aw ay that is suf­
ficiently independent of other fundam ental com ponents of processing”.5 
In addition, our interpretation of the results we obtained in the Line-Se­
quencing Task suggests an alternative explanation of the relatively high 
d s s t  group differences. In the Line-Sequencing Task our schizophrenia 
group may not have been able to plan how to draw each line in advance. 
Like the drawing o f a symbol in the d s s t  (or connecting targets in the Trail 
M aking Test), one can speed up the drawing o f a line by planning the next 
action w hile one is executing the present one. If patients with schizophre­
nia have great difficulty p lanning and executing actions simultaneously,
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they will carry out the two processes successively, resulting in lower scores 
on the d s s t .  Not a deficit in general processing speed but an inability in 
the cognitive control o f two different sim ultaneously required processes 
m ight then be at the basis o f the high sensitivity o f traditional neuropsy­
chological tests gauging psychom otor speed.
W hat m ost noticeably distinguishes our results from  those of previous 
reports in chronic patients is the absence of m otor slowing in the schizo­
phrenia group. We even observed the opposite: in some tasks the patients 
were faster than their healthy peers. We feel that the patients’ characteris­
tics, i.e. few negative symptoms and a recent onset of their disease, as well 
as the restrictions on m edication use may have contributed to this. Our 
finding is consistent with previous studies in recent-onset patients show­
ing im paired fine m otor dexterity with intact pure m otor speed.16;40;41 A se­
cond difference w ith previous reports is the absence of a correlation 
betw een negative sym ptom s and the cognitive defect. We think this is 
caused by the relatively low scores on the negative symptoms scale.42
Previous factor analytic studies suggested that psychom otor speed is a 
separable cognitive dim ension in schizophrenia.2 D ickinson et al. recently 
suggested that im paired processing speed is a central feature of the cog­
nitive deficit in schizophrenia and deserves systematic investigation.3 Still, 
it is difficult to assess speed o f cognitive processing com pletely inde­
pendently of other fundam ental com ponents of processing. Our study ex­
ploiting com puter-aided m onitoring o f graphom otor behavior was 
designed to gain a beginning insight into some of the cognitive processes 
that contribute to reduced processing speed in schizophrenia. The im ­
pairm ents we found are associated with several neurocognitive processes 
progressing in different anatom ical regions that together support motor 
control in terms of goal selection and inhibition (frontal cortex), selection 
o f targets (parietal cortex), sequencing (basal ganglia) and tim ing (cere­
bellum ).1 As fluent m otor action is crucial for everyday life, deficits may 
have serious consequences. The questions w hether the m otor-planning 
deficit in schizophrenia is related to other core cognitive deficits and 
whether it can be treated with antipsychotics need further research. By tes­
ting non-affected family members we may also resolve the issue of whether 
the observed psychom otor deficit is an endophenotype.3;43;44 The results of 
the present study suggest that psychom otor slowing results predominantly 
from  deficient planning and is indeed one of the syndrom e’s core deficits, 
consistent with w hat Kraeplin and Bleuler proposed in the early years of 
schizophrenia research.
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Abstract
introduction
Methods
Results
Discussion
Head-to-head comparisons of antipsychotics have predominantly included 
patients with chronic conditions. The aim of the present study was to 
compare the efficacy and tolerability of ziprasidone and olanzapine in 
patients with recent-onset schizophrenia.
The study was an 8-week, double-blind, parallel-group, randomized, 
controlled multicenter trial (NCT00145444 ClinicalTrials.gov).Seventy-six 
patients with schizophreniform disorder, schizophrenia or schizoaffective 
disorder (diagnosis < 5 years), and a maximum lifetime antipsychotic 
treatment <16 weeks participated in the study. Efficacy of ziprasidone (80­
160 mg/day) and olanzapine 10-20 mg/day was measured using the Positive 
and Negative Syndrome Scale (PANSS), the Clinical Global impression (CGi) 
Scale, the Calgary Depression Scale for Schizophrenia (CDSS),and the 
Heinrich Quality of Life Scale (HQLS); tolerability assessments included 
laboratory assessments, body weight, and electroencephalogram.
Olanzapine (n = 34) and ziprasidone (n = 39) showed equal efficacy as 
measured by the PANSS, CD SS,CGi, and HQLS. However, mean weight 
gain was significantly higher in the olanzapine group (6.8 vs 0.1 kg, p < .001). 
Ziprasidone was associated with decreasing levels of triglycerides, 
cholesterol, and transaminases, while these parameters increased in the 
olanzapine group (all p values <0.05). There were no significant differences in 
fasting glucose and prolactin levels or in cardiac or sexual side effects. 
Patients on ziprasidone used biperiden for extrapyramidal side effects more 
frequently (p < 0.05).
The results of this study indicate that ziprasidone and olanzapine have 
comparable therapeutic efficacy but differ in their side effect profile. 
However, there is a risk of a type ii error with this sample size. Clinically 
significant weight gain and laboratory abnormalities appear early after 
initiating treatment and are more prominent with olanzapine, while more 
patients on ziprasidone received anticholinergic drugs to treat extrapyramidal 
symptoms.
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1. Introduction The second-generation antipsychotics ( s g a s )  have established a prom i­
nent role in the treatm ent o f schizophrenia due to better treatm ent ad­
herence and a lower risk of extrapyramidal side effects.1 On the other hand, 
s g a s  also have side effects that have m ajor im pact on com pliance, such as 
sedation, w eight gain, anticholinergic effects, sexual dysfunction, and 
m etabolic syndrom e.2 The high attrition rates due to side effects in ran­
dom ized controlled trials ( r c t s )  and “practical trials” in chronic schizo­
phrenia patients indicate that there are lim itations to the use o f s g a s  in 
daily practice, despite their efficacy.3 Therefore, head-to-head comparisons 
betw een antipsychotics are necessary to answer the question w hich an­
tipsychotic drug has the best benefit/risk ratio.4
In the present study, we com pared the effects o f two s g a s :  olanzapine 
and ziprasidone. O lanzapine has a profile o f good efficacy but with a risk 
o f considerable w eight gain.5 In the Clinical Antipsychotic Trials o f Inter­
vention Effectiveness ( c a t i e )  trial, olanzapine and other s g a s  were com ­
pared w ith perphenazine in 1493 chronic schizophrenia patients. The 
results o f the c a t i e  trial suggest that olanzapine is superior to other an­
tipsychotics in term s o f treatm ent adherence and im provem ent o f psy­
chopathology.6 Ziprasidone is a relatively new antipsychotic drug that has 
shown to have com parable efficacy in com parison to conventional an- 
tipsychotics.7
So far, four head-to-head r c t s  com paring ziprasidone and olanzapine 
have been published. Breier et al found greater im provem ent in psy­
chopathology and a higher response and com pletion rate for olanzapine, 
whereas ziprasidone had a better profile for lipid profiles and weight gain.8 
In contrast, Sim pson et al did not detect differences in efficacy but did find 
a favorable m etabolic profile for ziprasidone, including less w eight gain 
and lower fasting insulin, triglycerides, and cholesterol.9110 In the c a t i e  
study, the tim e to discontinuingtreatm entw as lon gerfor olanzapine than 
for ziprasidone (p = 0.028 but not significant because o f correction for mul­
tiple com parisons), whereas the im provem ent in psychopathology was 
sim ilar for both antipsychotics. Ziprasidone had higher rates of insomnia, 
while olanzapine had more m etabolic effects and greater w eight gain.3 Re­
cently, the results o f the European First Episode Schizophrenia Trial ( e u ­
f e s t )  study, an open r c t  of s g a s  vs haloperidol in 498 patients with 
schizophrenia, were published. In the e u f e s t  study, ziprasidone and olan­
zapine showed a com parable treatm ent discontinuation, but there was 
more w eight gain in the olanzapine group and higher levels of akathisia in 
the ziprasidone group.11
In addition, two studies were published with a crossover design. A sig­
nificant im provem ent was found in an open-label study when stable pa­
tients on olanzapine were switched to ziprasidone.12 The follow-up results 
o f the c a t i e  study indicate, on the contrary, that am ong patients who had 
discontinued another atypical antipsychotic, sw itching to olanzapine was 
more effective than sw itchingto ziprasidone. M etabolic effects and weight 
gain favored ziprasidone, but ziprasidone had more serious adverse events 
and higher levels o f insom nia.13
It is im portant to underline that all these comparative studies, except 
for the e u f e s t  study, included mostly patients in the chronic stages o f the 
illness. Previous research suggests that first-episode patients respond bet­
ter to treatm ent and are more susceptible to side effects such as dystonia 
and prolactin increase.14 So far, it is unknow n whether this holds true for 
the drug-induced m etabolic syndrome as well. As schizophrenia is often a
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progressive disorder, it is im portant for clinicians to know w hich antipsy­
chotic can reduce the sym ptom s at an earlier stage. Few trials have ad­
dressed this question yet.15
Furthermore, there are two m ethodological com plications of studying 
patients with chronic schizophrenia. First, previous use o f antipsychotics, 
com orbidity, or ageing m ay confound outcom e variables such as m eta­
bolic effects. Second, there is potential study entry bias in chronic patients, 
favoring the inclusion o f more severe, hospitalized patients w ho are non­
responsive or noncom pliant. The higher response rates in first-episode pa­
tients are in accordance with this observation.16
The aim  o f the present study was to com pare the clinical efficacy and side 
effects o f ziprasidone and olanzapine in patients with recent-onset schiz­
ophrenia.
2.1 Patients: Inclusion and Exclusion Criteria 
Male or fem ale patients, 18-40 years of age, were recruited from  4 aca­
dem ic and nonacadem ic hospitals in The Netherlands and Belgium. The 
large m ajority o f the included subjects were acutely ill inpatients. All pa­
tients gave written inform ed consent before screening took place. A diag­
nosis o f schizophrenia, schizoaffective disorder, or schizophreniform  
disorder was confirm ed in Structured Clinical Interviews for d s m - i v ) .  Pa­
tients were included if the m axim um  lifetim e exposure to antipsychotics 
was < 16  weeks, duration of illness was < 5 years, and Clinical Global Im­
pression Severity ( c g i - s )  score was 4 (ie, at least “m oderately ill”).
Patients were excluded if they had a d s m - i v  diagnosis o f substance de­
pendency 3 m onths prior to screening or a positive drug screen for am ­
phetam ines, cocaine, or opioids at screening. Furthermore, patients were 
excluded if they had epilepsy, an organic mental disease (including mental 
retardation), a history of psychosurgery or any significant m edical illness, 
abnorm al laboratory values, electroencephalogram  ( e c g )  abnorm alities 
(includingheartrate-corrected QT-interval [QTc] 500 msec), or m edication 
that prolongs the QT interval. W om en who were pregnant, breast-feeding, 
or not using reliable contraceptive m ethods were excluded as w ell. C on­
current treatm ent w ith psychopharm acological agents was not allowed, 
whereas w ashout periods were perm itted depending on the type o f phar­
m acological agent (antidepressants: 7 days, m onoam ine oxidase in­
hibitors: 2 w eeks, fluoxetine: 5 w eeks, oral antipsychotics: 12 hours, 
depot agents: one cycle [at least 2 wk]). There were no further guidelines 
for tapering o ff the previous m edication. Patients w ho were deem ed u n ­
likely to follow  the study protocol and those at im m ediate risk of harm ing 
them selves or others were excluded as w ell. Previous treatm ent w ith 1 
o f the 2 study drugs (eg, nonresponding) did not serve as an exclusion 
criterion.
2.2.Study Design
The study was an 8-week, double-blind, parallel-group, random ized, con­
trolled m ulticenter trial (NCT00145444 ClinicalTrials.gov). Effects on cog­
nitive measures will be published elsewhere.17 Patients who com pleted the 
8-week study were offered to continue or to cross over to different medication. 
The results o f this second phase are beyond the scope o f the present article 
and will be described in another article. The study protocol was approved 
by the local ethical com m ittee and was carried out in accordance with the 
Declaration o f Helsinki.
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F ollow ing the screen in g period  of<  10 days, patien ts w ere tapered off 
their psychotropic treatment. Patients were random ized to 1 o f the 2 treat­
m ent groups in the ratio 1:1, receiving a fixed dose for the first 2 days of ei­
ther ziprasidone 40 m g twice a day or olanzapine 10 mg/day. From day 3 
onward, the dose regim en was flexible and consisted o f 3 doses (“low ,” 
“m edium ,” and “h igh”: ziprasidone 40, 60, or 80 m gtw ice a day or olanza­
pine 10 ,15 , or 20 mg/day respectively). The m edication was dispensed in 
a double dum m y design to keep the allocation double blinded.
Patients were assessed on day 1, day 3, week 1, w eek 2, week 4, and week 
8 and in between if necessary due to adverse events. In case of akathisia, 
propranolol was perm itted. In patients receiving stable doses o f anti­
cholinergic agents prior to randomization, the anticholinergic agents were 
w ithdrawn a w eek after random ization. If sedation was necessary, 
tem azepam  or oxazepam up to 20 mg/day was permitted. Any concom itant 
drug treatm ent rem ained constant during the study, and no such drug was 
started during the study unless considered m edically necessary (ie, anti­
depressants for com orbid depression).
The sam ple size was determ ined on the base o f the California Verbal 
Learning Test, the primary cognitive outcom e measure: Using a 2-sided 
test, a sample size of approximately 37 patients per treatm ent group would 
assure 80% power to detect a difference o f at least 1.6 points in change 
(p = 0.05) assum ing an SD of 2.4 (according to interim  results at wk 6 from 
studies R-0554 and R-0555, data on file).18
2.3.Efficacy Assessm ents
Clinical efficacy was assessed on the basis o f a reduction from  baseline to 
w eek 8 in the total score o f the Positive and Negative Syndrome Scale 
( p a n s s ) ,  the c g i - s  Scale, Clinical Global Im pression Im provem ent ( c g i - i )  
Scale, and the Calgary Depression Scale for Schizophrenia ( c d s s ) . 19 The 
p a n s s  was adm inistered at baseline, w eek 4, and w eek 8 (or end visit);20 
the c g i - s  and c g i - i  were adm inistered at every visit. The interpersonal re­
lations elem ent o f the H einrich Quality o f Life Scale ( h q l s )  was used to 
evaluate quality o f life at baseline and w eek 8.21
In addition to the continuous data, the percentages o f patients with 
clinical response were com pared, with response criteria set a priori at 20% 
reduction in the total p a n s s  scores. The results from  the p a n s s  were also 
considered in terms of proposed rem ission criteria (“m ild” or less on items 
P1, P2, P3, N1, N4, N6, G5, G9).The criterion “m aintenance over a 6-month 
period” could not be applied in the present study.22 The percentage o f pa­
tients who fulfilled these rem ission criteria was calculated as well.
2.4. Safety and Tolerability Measures
All adverse events, regardless o f the causal relationship, were m onitored 
and assessed on severity. Vital signs and body weight were checked at base­
line, w eek 4, and w eek 8. All patients underwent e c g  evaluation by a car­
diologist at baseline and at w eek 1. Laboratory safety assessm ents at 
baseline and week 8 included cholesterol, triglycerides, fasting glucose, 
prolactin, and the transam inases serum  glutam ic oxaloacetic transam i­
nase ( s g o t )  and serum glutam ic pyruvic transam inase ( s g p t ) .
Extrapyram idal side effects were m onitored with the St Hans Rating 
Scale ( s h r s ) , 2 3  Barnes Akathisia Scale ( b a s ) , 2 4  and Abnorm al Involuntary 
M ovem ent Scale ( a i m s ) .25 All participating researchers were trained in the 
adm inistration and scoring o f the instrum ents for efficacy and safety in
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consensus m eetings, with an independent expert and with high interrater 
reliability.
W here considered necessary by the investigator, biperidenw as adm in­
istered in case o f dyskinisia, parkinsonism , or dystonia, whereas propra­
nolol was adm inistered for akathisia. Tem azepam  and oxazepam  were 
allowed for insom nia or additional sedation.
2.5. Patients’ Opinion
The Drug Attitude Inventory ( d a i ) - 1 0  was used to assess patients’ opinion 
on the study treatm ent (baseline, w k 4, and w k 8).26
2.6. Discontinuation
Primary reasons for early discontinuation were recorded. The com pliance 
was checked every visit by counting the unused blisters. Patients unable 
to adequately com ply with m edication (com pliance <80% or >120% since 
the previous study visit) were withdraw n from  the study. Patients with 
m arked liver function abnorm alities were im m ediately withdrawn from 
the study ( s g o t / s g p t  3 x upper lim it o f the norms, alkaline phosphates 
1.5 x upper limit, total bilirubin 2 x upper limit). The difference between 
the two antipsychotics in treatm ent discontinuation was tested with a Ka­
plan-M eier analysis.
2.7. Statistical Analysis
The description of dem ographic data and the description and analyses of 
safety data were based on all subjects who were random ized and who were 
known to have taken at least one dose o f study m edication. The analyses of 
efficacy and effectiveness data were based on the intention-to-treat popu­
lation with the last observation carried forward.
For continuous data outcom e m easures, an analysis o f covariance ( a n -  
c o v a )  m odel was used to test the effect o f treatm ent at w eek 8 vs baseline. 
Dependent m easures in the a n c o v a  analyses were the p a n s s  total score 
(primary outcom e measure) and subscores, c d s s ,  c g i ,  and q l s .  The sub­
je c t ’s score at baseline included a covariate in order to control for the ini­
tial value. “Treatm ent center” was set as an extra independent variable. 
Analyses of c g i - i  scores did not include baseline terms because a baseline 
c g i - i  score could not be determined.
As with the efficacy analysis, a n c o v a  was used with treatm ent center 
as the factor and baseline levels as covariates. An additional baseline-to- 
m axim um  analysis was perform ed for the side effect scales b a s , a i m s ,  and 
s h r s .  In order to gain more insight into the clinical consequences of the 
study intervention, we perform ed additional analyses on proportions of 
patients with clinically significant abnorm alities based on international 
consensus (e.g., 7% weight increase). For dichotom ous data, Fisher exact 
tests were used. All statistical tests were 2 tailed (superiority design), with 
a 5% level o f significance. spss 14.0 was used for the statistical analysis.
3.1. Characteristics and Disposition o f Patients 
A total o f 81 patients were screened for eligibility, o f w hom  74 were ran­
dom ized to either the ziprasidone arm (n = 39) or the olanzapine arm 
(n = 35) (figure 1). There were no significant differences in the baseline cha­
racteristics between the 2 groups (tables 1 and 2). Seven of the patients in 
the ziprasidone group and 8 patients in the olanzapine group were exposed 
to olanzapine before. None of the patients were exposed to ziprasidone be­
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fore. The m ean study dose was 14 m g for olanzapine and 104 m g for 
ziprasidone. D uringthe first 8 weeks of treatm ent, 11  out of 39 patients in 
the ziprasidone arm and 6 out of 34 in the olanzapine arm discontinued 
the study; this difference was not statistically significant (Fisher exact test, 
p = 0.28). The Kaplan-Meier analysis for treatm ent discontinuation in time 
revealed no significant difference either (p = 0.22).
Figure i. Patient Disposition and Reasons fo r Discontinuation.
Olanzapine 
(n = 35), 
Mean (SD)
Ziprasidone 
(n = 39), 
Mean(SD)
Statistic 
(F, df, P)
Age (y) 23.1 (4.4) 24.3 (4.5) F1.72 = 1.52, P= .22
Days since onset of clinical 
symptoms
476 (544) 463 (524) F1.72 < 0.01, P= .96
Positive and Negative 
Symptoms Syndrome Scale: 
total score
80.8 (12.8) 80.5 (14.3) F1.72 = 0.16, P= .90
Calgary Depression Scale for 
Schizophrenia
4.2 (3.6) 5.3 (3.9) F1.72 = 1.64, P= .20
Clinical Global Impression 
Severity Scale
5.0 (0.8) 5.2 (0 .8) F1.72 = 0.45, P= .50
Global Assessment of 
Functioning Scale
32.0 (13.09) 33.6 (10.88) F1.72 = 0.31, P= .58
Body mass index 21.7 (2.6) 22.2 (2.2) F1.72 = 0.84, P= .36
Prior lifetime antipsychotics 
use (d)
19.1 (23.5) 22.1 (35.0) F1.72 = 0.17, P= .68
Table 2. Baseline Characteristics o f All Randomized Patients (n = 74).
Variable Olanzapine 
(n = 35), N (% )
Ziprasidone 
(n = 39), N (% )
Diagnosis
Schizophreniform disorder 13 (37) 14 (36)
Schizophrenia, paranoid type 15 (43) 14 (36)
Schizophrenia, disorganized 
type
5(14) 2 (5)
Schizophrenia, residual type 0 (0 ) 1 (3)
Schizophrenia, undifferentiated 
type
1 (3) 3 (8)
Schizoaffective disorder 1 (3) 5 (13)
Gender
Male 30 (86) 31 (79)
Female 5 (14) 8 (21)
Number of hospitalizations during the past year
0 times 8 (2 3 ) 9 (23)
1 time 25(71) 25 (64)
2 times 2 (6 ) 4 (10)
>2 times 0 (0) 1 (3)
Psychotropic medication stopped before study
Antipsychotics 22 (63) 22 (56)
Selective serotonin reuptake 
inhibitors
1 (3) 1 (3)
Lithium 0 (0) 1 (3)
Table 1. Baseline Characteristics o f All Randomized Patients (n = 74).
3.2. Efficacy
Changes in efficacy m easures are listed in table 3. Patients from  both 
groups had a sim ilar decrease in p a n s s  score, the primary outcom e m ea­
sure, com pared with baseline (p = 0.68) (table 4). The percentage o f patients 
showing a clinical response (20% im provem ent on the p a n s s )  was 61% for 
olanzapine and 60% for ziprasidone (p = 1.00). Thirty-five percent o f the 
olanzapine patients and 40% of the ziprasidone patients fulfilled the re­
m ission criteria (p = 0.80). Group differences on depression sym ptom s 
( c d s s ) ,  quality o f life ( h q l s ) ,  and clinical im pression ( c g i )  were also non­
significant.
3.3. Safety and Tolerability
The percentages of patients who reported adverse events and required con­
com itant drugs are shown in table 4. Treatm ent with olanzapine was as­
sociated significantly more often with weight gain and increased appetite. 
Treatm ent with ziprasidone led to m ore frequent use o f b iperiden as 
com edication and more frequent use o f antidepressants and propranolol.
3.4. M etabolic Side Effects
The analyses revealed significant differences between the two study groups 
in term s o f m etabolic risk (figure 2). O lanzapine patients had a m ean 
w eight increase o f 6.8 kg, whereas ziprasidone patients only had an in­
crease of 0.1 kg (p< 0.001). Additional analyses showed that 64.5% of the 
olanzapine patients had a weight gain of more than 7%, while this occurred 
in 3.3% o f the ziprasidone group (p< 0.001). Treatm ent w ith olanzapine 
was associated with an increase in levels o f cholesterol, triglycerides, and 
liver transam inases, whereas treatm ent with ziprasidone led to lower lev­
els o f cholesterol, triglycerides, and liver transam inases (p values < 0.001) 
(table 6). There were no group differences in fasting glucose and glycosy­
lated hem oglobin (Hb1ac).
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Baseline, 
Mean (SD)
Difference 
Score at End 
point, Mean 
(SD)
Difference 
Between Groups
F df P
PANSSa positive symptoms 
subscale
Olanzapine (N = 33) 21.95 (3.69) -6.70 (4.54) 0.01 1.58 .91
Ziprasidone (N = 34) 20.87 (5.54) -5.62 (4.97)
PANSS negative symptoms 
subscale
Olanzapine (N = 33) 19.68 (6.03) -2.76 (4.15) 0.02 1.58 .88
Ziprasidone (N = 34) 19.00 (5.85) -2.38 (4.79)
PANSS general 
psychopathology subscale
Olanzapine (N = 33) 39.03 (7.32) -7.82 (6.35) 0.59 1.58 .45
Ziprasidone (N = 34) 39.57 (7.77) -6.41 (7.62)
PANSS grand total 
subscale
Olanzapine (N = 33) 80.65 (13.41) -17.15 (10.25) 0.29 1.58 .68
Ziprasidone (N = 34) 79.43 (15.16) -14.86 (12.99)
Clinical Global Impressions 
Severity Scale
Olanzapine (N = 33) 5.00 (0.78) -0.97 (0.82) 0.19 1.56 .66
Ziprasidone (N = 34) 5.00 (0.75) -0.85 (0.82)
Heinrich Quality of Life 
Scale
Olanzapine (N = 30) 25.96 (8.15) -1.20 (6.04) 0.23 1.53 .63
Ziprasidone (N = 26) 28.44 (9.96) -2.42 (5.73)
Calgary Depression Scale 
for Schizophrenia
Olanzapine (N = 33) 4.42 (3.71) -1.27 (4.00) 1.73 1.57 .19
Ziprasidone (N = 33) 5.83 (3.99) -0.21 (4.32)
End Point 
Score
Difference 
Between Groups
Clinical Global Impressions 
Improvement Scale
Mean (SD) F df P
Olanzapine (N = 33) — 2.82 (0.81) 0.11 1.56 .75
Ziprasidone (N = 34) — 2.94 (0.74)
Drug Attitude Inventory
Olanzapine (N = 22) — 3.07 (3.89) 1.19 1.56 .28
Ziprasidone (N = 18) — 1.86 (4.55)
Note: End point is at 8 wk with last observation carried forward. 
a Positive and Negative Symptom Scale for Schizophrenia.
Table 3 Changes in Clinical Measures
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Olanzapine 
(n = 35), N (%)
Ziprasidone 
(n = 39), N (%)
P (Fisher 
Exact)
Any adverse events 33 (94.3) 36 (92.3) 1.0
Gastrointestinal disorders 11 (31.4) 18 (46.2) 0.23
Fatigue/sedation 16 (45.8) 22 (56.4) 0.49
Sexual side effects 5 (14.3) 5 (12.8) 1.0
Hypersalivation 2 (5.7) 5 (12.8) 0.44
Headache 7 (20.0) 11 (28.2) 0.43
Weight gain 20 (57.1) 5 (12.8) <0.001*
Increased appetite 5 (14.3) 0 (0 ) 0.02*
Extrapyramidal symptoms 
and tremors
20 (57.1) 20 (51.3) 0.65
Psychiatric symptoms 13 (37.1) 9 (23.1) 0.61
Suicide attempt/suicidality 
Concomitant medication
4 (11.4) 1 (2.6) 0.18
Biperiden 7 (20.0) 17 (43.6) <0.05*
Propanolol 0 (0.0) 5 (12.8) 0.06
Benzodiazepines 11 (31.4) 16 (41.0) 0.64
Lithium 0 (0.0) 1 (2.6) 0.47
Antidepressants 0 (0.0) 5 (12.8) 0.06
a Table only includes those adverse events that occurred at statistically different 
proportions in the 2 groups or in at least 10% of one of the groups.
*P  < 0.05.
Table 4 Patient-Reported Adverse Eventsa and Concomitant Psychotropics
Baseline to End point Baseline to Maximum Score
Baseline, 
Mean (SD)
Change in 
Score, Mean 
(SD)
Difference
Between
Groups
Change in Score, 
Mean (SD)
Difference
Between
Group
F df  P F df  P
Barnes Akathisia Rating Scale, overall score
Ziprasidone 1.36 (2.16) 0.03 (3.18) 0.03 1.56 .95 -0.38 (2.92) 0.0 1.56 .99
(n = 33)
Olanzapine 0.61 (1.27) -0.30 (2.05) -0.55 (1.95)
(n = 33)
Abnormal Involuntary Movement Scale, total score
Ziprasidone 1.6 (2.55) 0.58 (3.19) 2.07 1.58 .16 -0.15 (3.13) 0.41 1.58 .84
(n = 34)
Olanzapine 0.39 (1.09) -0.97 (2.47) -1.09 (2.37)
(n = 33)
St Hans Rating Scale, total score
Ziprasidone 6.94 (11.32) 1.59 (11.67) 0.30 1.58 .86 -0.15 (8.60) .81 1.58 .37
(n = 34)
Olanzapine 6.76 (10.92) -0.21 (9.05) -1.88 (8.39)
(n = 33)
UKU sexual side effects8
Ziprasidone 2.72 (3.84) 0.92 (3.40) 0.41 1.47 .53 - - - -
(n = 25)
Olanzapine 1.23 (2.20) 0.00 (0.89)
(n = 31)
Table 5 Changes in Extrapyramidal Side Effects and Sexual Side effects
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Difference Between Groups
Baseline, D ifference Score at End
Mean (SD) P o in t,M e a n (S D ) F df  P
W eight (kg)
Olanzapine (n = 31) 69.6 (11.2) 6.8 (4.1) 24.1 1.53 <.001*
Ziprasidone (n  = 30) 68.4 (10.4) 0.1 (3 .6 )
QTc (ms)
Olanzapine (n = 33) 400.4 (15.5) -1.7 (21.1) .06 1.59 .80
Ziprasidone (n = 35) 394.3 (16.1) 5.2 (18.2)
S ysto lic blood pressure (mm Hg)
Olanzapine (n = 33) 120.5 (10.4) 0.7 (15.3) 3.9 1.58 .05
Ziprasidone (n = 33) 116.2 (12.2 ) -0 .9  (10.2)
D iastolic blood pressure (mmHg)
Olanzapine (n = 34) 75.9 (7.6) 0.7 (9 .2 ) 1.2 1.60 .28
Ziprasidone (n = 35) 75.5 (8.4) 3.1 (9 .3)
Heart rate (beats per min)
Olanzapine (n = 32) 71.3 (10.7) 2.3 (14.5) 1.1 1.56 .30
Ziprasidone (n = 33) 73.8 (13.0) - 1.6 (12 .1)
SGO T/ASAT (U /l)
Olanzapine (n = 32) 23.4 ( 6 .8 ) 8 .0 (13.9) 10.6 1.56 .02*
Ziprasidone (n = 33) 35.0 (54.4) -10.7 (51.5)
SGPT/ALAT (U /l)
Olanzapine (n = 32) 26.5 (14.1) 21.8 (37.9) 14.0 1.56 <.001*
Ziprasidone (n = 33) 28.6 (25.1) -7 .3  (21.9)
C holesterol (m m o l/l)
Olanzapine (n = 30) 4.47 (0 .94) 0.48 (0 .72) 12.5 1.56 .001*
Ziprasidone (n = 31) 4.47 (1.15) -0 .2 4  (0 .87)
Trig lycerides (m m o l/l)
Olanzapine (n = 30) 1.42(1.04) 0.41 (1.00) 7.5 1.55 .008*
Ziprasidone (n = 31) 1.70 (1.50) -0.21 (1.41)
Fasting glucose (m m o l/l)
Olanzapine (n = 30) 5.50  (1.54) 0 .06  (0 .90 ) 2.1 1.56 .15
Ziprasidone (n = 31) 5.75 (2.14) 0.10 (0 .99 )
G lycosylated hemoglobin (H b lA c)
Olanzapine (n = 31) 5.12 (0 .35 ) 0.0 (0 .35 ) 0.72 1.55 .94
Ziprasidone (n = 33) 5.13 (0.34) -0 .3  (0 .35 )
Prolactin (U /l)
Olanzapine (n = 28) 0.81 -0.17 1.83 1.49 .18
Ziprasidone (n = 30) 0.69 -0 .4 0
Note: End point is a t 8 wk w ith  last observation carried forward. 
*P  < 0.05.
Table 6 Changes in Metabolic Parameters
3.5. M ovem ent Disorders.
There were no differences between the two groups in any of the extrapyra­
m idal side effect scales (table 5). Additional analyses com paring the pro­
portion of patients with clinically significant values ( “m oderate” on one of 
the s h r s  items) revealed no significant differences either (5 patients in 
each group). However, significantly more patients in the ziprasidone group 
used as needed biperiden to relieve extrapyramidal symptoms (table 4).
3.6. Sexual Dysfunction
As shown in table 5, there were no differences in the UKU Scale for sexual 
side effects. In both groups, there were 8 patients with at least one moderate 
score on one o f the items. As a substantial proportion o f the patients were 
on antipsychotics before the study entry, there was a decrease in prolactin 
levels th at w as sim ilar in both  groups. N evertheless, 60% and 40% o f 
patients on olanzapine and ziprasidone, respectively, m et the criteria for 
hyperprolactinem ia at end point (figure 2).
5 0
4. Discussion
Figure 2 . Percentage o f Patients on Olanzapine and Ziprasidone W ith Clinically sign ificant 
Metabolic symptoms at 8 wk. Weight change 7% increase of total body weight. Hyperglycemia 
5.5 m m ol/l. Hypertriglyceridemia > 1.69 m m ol/l. Hypercholesterolemia > 5.17 mmol/l. 
Hypertension > 130/85 mm Hg. Elevated sgpt > 37 U /l. Elevated sgot (>40 U /l) . *p  < 0.05 . 
Hyperprolactinemia > 18 ng/l, > 25 ng/l.
3.7. Cardiac Side Effects
There were no e c g  abnorm alities in any of the patients. Group differences 
in q t c  were not statistically different.
3.8. Patient’s Opinion
The results o f the d a i - 1 0  indicate that there was no significant difference 
in the patients’ opinion regarding their m edication (table 3).
This study is the first head-to-head, double-blind com parison of olanza­
pine and ziprasidone in patients with recent-onset schizophrenia. The re­
sults suggest that both agents have com parable clinical efficacy but show 
differences in the side effects profile.
About two-thirds of the patients in both groups m et the response crite­
ria, defined as 20% im provement on the p a n s s ,  and one-third fulfilled re­
m ission criteria defined by Andreasen et al.22 The high response rates in 
our study are consistent with the literature on recent-onset schizophrenia.11 
The attrition rates did not differ significantly between the two groups, but 
num erically there were more com pleters on olanzapine. Effects on the de­
pression and quality-of-life scales were marginal in both groups, which may 
be explained by the low baseline values and the short period of treatment.
We realize that we have included a relatively sm all num ber of patients 
in this study. However, the differences between the two patient groups in 
the prim ary outcom e m easure, the difference score on the total p a n s s  
score, are extremely sm all (effect size d = 0.10, p = 0.82). A sam ple o f more 
than 3000 patients w ould have been required to find this sm all effect sig­
nificant at the.05 level. We conclude that the primary results are not biased 
by insufficient statistical power. Several secondary outcom e m easures, 
such as the d a i - 1 0  and the dropout rate, may be prone to type II error. The 
present difference in dropout rate w ould have been statistically significant 
at the 0.05 level if  we had included at least 590 patients in our study.
The w eight gain findings in the olanzapine group are consistent with 
the literature.27
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However, the m ean increase of 6.8 k g w e found in the olanzapine group 
is high in com parison with other studies. The relatively high m ean dose of 
14 m g olanzapine may have contributed to the higher weight gain. The re­
cent onset o f the symptoms and the lim ited history of antipsychotics in our 
patient population may explain the difference with previous data as well. 
This study showed that half o f the olanzapine patients had laboratory ab­
normalities within 8 weeks, whereas this proportion was lower with ziprasi- 
done treatm ent. This pattern has been previously described in chronic 
patients as w ell.28 We also found a differential effect on transaminases; to 
our knowledge, this is the first recent-onset study reporting effects on liver 
enzymes. The increase in transam inases seen w ith olanzapine may be a 
transient effect, but it would be worthwhile exploring its clinical im plica­
tions in future studies. This holds for the increase in prolactin levels as well, 
although it should be noted that the blood sam ples were taken in the mor­
ning (levels are relatively high at that tim e o f the day).
Significantly m ore anticholinerigc drugs were adm inistered for ex­
trapyram idal sym ptom s in patients treated w ith ziprasidone. This con­
com itant m edication appeared to relieve the symptoms, as there were no 
differences in the num ber of patients with clinically m anifest extrapyra­
m idal sym ptom s. However, long-term  biperiden use may result in other 
problem s, such as low er cognitive fun ction.29 The prescription o f other 
concom itant drugs in both groups did not differ significantly. Although 
there were more prescriptions o f antidepressants in the ziprasidone group, 
this did not reach statistical significance. Nonetheless, this deserves fur­
ther attention because the association betw een depression and ziprasi­
done has been made previously.30
It is important to underline that our study population had a recent onset 
o f the syndrome. In this way, there is a smaller chance of a patient selection 
bias, ie, including subpopulations o f severe, untreatable patients. More­
over, studies w ith recent-onset schizophrenia populations offer the op­
portunity to examine the effectiveness w ithout the confounding effects of 
long-term  m edication use.4
Recently, m etabolic syndrom e has been the focus o f considerable at­
tention. Unfortunately, we were not able to determ ine the prevalence of 
m etabolic syndrome in our sam ple because we did not evaluate w aist cir­
cum ference, low-density lipoprotein, and high-density lipoprotein. The 
m etabolic syndrome is considered a constellation of cardiovascular risk 
factors linked by insulin resistance, w hich include obesity, dyslipidemia, 
glucose tolerance, and hypertension. Antipsychotics, especially those from 
the second generation, increase the risk o f cardiovascular incidents in 
schizophrenia. This risk is already higher in this population due to heavy 
sm oking, low treatm ent adherence for som atic m edication, less access to 
m edical care, and a (genetic) higher prevalence of diabetes. It is estim ated 
that patients with schizophrenia have a 20% reduced life expectancy com ­
pared w ith the general population and that two-thirds of schizophrenia 
patients die o f cardiovascular incidents.31
Taken together, ziprasidone and olanzapine have com parable efficacy, 
resulting in rem ission rates o f around 40% within 8 weeks. This study fur­
ther dem onstrates that abnorm alities o f m etabolic parameters, which are 
risk factors for developing m etabolic syndrome in the long term, can be 
detected in substantial proportions of recent-onset schizophrenia patients 
at an early stage of treatment.
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Abstract
introduction
Methods
Results
Discussion
Cognitive deficits are a core feature in schizophrenia. Cognitive deficits 
appear to be present at the onset of schizophrenia and persist after 
remission of psychotic symptoms. As cognitive deficits are associated with 
poor functional outcome, they form an important focus of treatment. There 
are relatively few head-to-head comparisons of the effects of second- 
generation antipsychotics on cognition in recent onset schizophrenia. This is 
the first study to compare the effects of a short-term treatment of 
olanzapine versus ziprasidone on cognitive functioning in recent onset 
schizophrenia. An earlier study conducted in chronic patients revealed an 
enhancement of cognition after treatment for both agents, but the extent of 
improvement was not significantly different between ziprasidone and 
olanzapine.
Patients with recent onset schizophrenia with limited previous exposure to 
medical treatment underwent a double blind randomized controlled 
treatment trial. Fifty-six patients completed the neuropsychological testing 
procedure prior to randomization and after eight weeks of treatment and 
were included in the analysis. We tested cognitive functioning in general and 
verbal memory in particular. We calculated a single unweighted composite 
score based on nine cognitive tests to determine general cognitive 
functioning.
Cognition appeared enhanced after treatment, but was not significantly 
different between treatment groups, neither for the verbal memory 
measures, nor for the neurocognitive composite score. Furthermore, 
cognitive enhancement did not correlate to clinical improvement.
Cognitive deficits are not a reason for preferentially prescribing one of the 
two second-generation antipsychotics tested over the other.
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1. Introduction Cognitive im pairm ents are a core feature of schizophren ia1-4. Over 85% of 
patients with this disorder show clinically significant im pairm ent in some 
dom ains o f cognition.5;6 W hile these cognitive deficits are m odestly asso­
ciated with negative and disorganized sym ptom  dim en sion s,7-10 they are 
not consistently related to positive sym ptom s11;12 and continue to be pres­
ent after rem ission o f psychosis.13-15 Cognitive deficits are present in m e­
dication naive patients,16;17 early in the course o f schizophrenia18-23 and are 
found preceding the m anifestation o f psychosis.24-27 Importantly, there is 
considerable evidence that cognitive deficits are associated with functional 
disability and im paired outcome, underlining the relevance of treating the 
cognitive deficits in schizophrenia.28-32
Although cognitive deficits are a core feature of schizophrenia, no sin­
gle test or cognitive construct com pletely discrim inates patients with 
schizophrenia from  healthy controls.33 The cognitive dom ains that are 
com m only described as deficient and that discrim inate patients from  
healthy controls include attention, memory, executive function and pro­
cessing speed.34-36 These dom ains are particularly affected in first episode 
schizophrenia37;38 and deficits are substantial, often 1-2  standard devi­
ations below that o f healthy com parison subjects.39-43
In the current study, we tested general cognitive functioning in recent- 
onset schizophrenia, adm inistering cognitive tests w ithin five cognitive 
dom ains (speed of processing, attention, visual learning and memory, ver­
bal learning and m emory, and executive functioning). Moreover, we fo­
cussed on verbal learning and m em ory since these dom ains have been 
specifically im plicated as a m ediator of poor clinical outcom e in schizo- 
phrenia29;44 and are am ong the m ost severe cognitive im pairm ents in 
chronic schizophrenia.45-50
An increasing num ber o f studies have addressed the question o f the po­
tential benefit o f antipsychotic m edication on cognitive dysfunction. Ini­
tial results o f  clin ica l tria ls51-53 and m eta-analyses54;55 favoured 
second-generation antipsychotics ( s g a ’ s )  over first-generation antipsy­
chotics ( f g a ’ s )  in the enhancing effects on cognitive functioning in schi­
zophrenia. Later studies however have not confirm ed these findings.14;56;57
O lanzapine is probably the best studied s g a  in respect o f cognitive im ­
provem ent in schizophrenia. However, the current study is the first dou­
ble blind study to com pare the effect o f olanzapine and ziprasidone, both 
s g a ’ s , on cognition in recent-onset schizophrenia.
O lanzapine has been shown to im prove cognitive function in both 
chronic58-61 and first episode patients.62-66 Ziprasidone is less frequently 
studied, but has also been found to improve cognitive function in chronic 
patients suffering from  schizophrenia.67-69 Head-to-head com parisons of 
olanzapine and ziprasidone were conducted exclusively in chronic patients 
with schizophrenia.70;71 In a double-blind random ized controlled trial of 
six weeks com paring the effect o f o lanzapine and ziprasidone on cogni­
tion, no differences in cognitive change were found in the dom ains o f at­
tention, memory, executive functioning or verbal fluency.72 The six month 
extension of this study did not reveal statistically significant differences in 
the enhancem ent of cognition either.71
There are still relatively few studies that com pare the effects o f s g a ’ s on 
cognition in first episode schizophrenia head-to-head in double blind ran­
dom ized trials.73-75 The aim  of this study was to com pare the effects o f an 
8-week treatm ent trial o f ziprasidone versus olanzapine on cognitive func­
tion in general and on verbal mem ory in particular, in early episode psy-
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2. M ethods
chosis. The advantage of studying cognitive deficits in first episode schiz­
ophrenia is that confounding factors such as long-term prior exposure to 
antipsychotic drug treatm ent, effects of institutionalisation and chronic- 
ity o f illness can be excluded.
2.1. Study design
The study was an 8-week, double blind, double-dum m y, parallel-group, 
randomized, controlled m ulticenter trial. The effects on clinical measures 
are described elsewhere.76 This study was part o f a larger study extending 
to 52 weeks (the extended part of the study had a cross-over design and will 
be described elsewhere).
After a screening period of less than 10 days, patients were tapered off 
m edication, if  applicable, and were drug free fo r> 12  hours after which 
they were random ized to one of the two treatm ent groups. Patients re­
ceived a fixed dose of either ziprasidone 40 m g twice a day, or olanzapine 
10 m g once a day in the first two days. From day 3 onwards the m edication 
regim en w as flexible in three doses (‘low ’, ‘m edium ’,’ h igh ’: ziprasidone 
40, 60 or 80 m gb.i.d ., or olanzapine 10 ,15  or 20 mg/day).
Neurocognitive tests were adm inistered at baseline, before drug treat­
m ent was started, and a second time at week 8, or at discontinuation of the 
study (at >7 weeks from  baseline). At week eight, four subtests o f the w a i s -
i i i  were administered to make an estimation of intelligence. Clinical ratings 
( p a n s s 77)  were also obtained on the day o f neurocognitive testing. W hen 
needed, anticholinergic agents or propranolol was adm inistered. For pa­
tients using stable doses of anticholinergic agents prior to randomization, 
the anticholinergic agents were withdrawn a week after randomization. If 
additional sedation was necessary, temazepam or oxazepam up to 20 mg/day 
was permitted. Concurrent treatment with psychopharm acological agents 
was not allowed, whereas washout periods were perm itted depending on 
the type of pharm acological agent (antidepressants or m ood stabilizers >7 
days of randomization, MAO-inhibitors > 2 weeks, fluoxetine > 5 weeks, oral 
antipsychotics >12 hours, depot agents > 2 weeks or one cycle).
2.2. Subjects
Patients were recruited from  4 centres in the Netherlands and Belgium. 
All patients gave written inform ed consent before screening took place. A 
diagnosis o f schizophreniform  disorder, schizophrenia or schizo-affective 
disorder was confirm ed using the Structured Clinical Interviews for d s m -
i v  ( s c i d - i ) . 78 Patients were 18-40 years of age at random ization and were 
included w hen the duration o f illness was less than 5 years, the CGi-sever- 
ity score was >4 (‘at least m oderately ill’) and the m axim um  life tim e ex­
posure to antipsychotics was less than 16 weeks.
Patients were excluded w hen they had a d s m - i v  diagnosis o f substance 
dependence within three m onths before screening or when they had a pos­
itive urine drug screen for amphetam ines, cocaine or opioids at screening. 
Furthermore, patients were excluded if they had an organic m ental dis­
ease, m ental retardation, clinically significant physical illness, abnormal 
laboratory values, significant e e g  abnorm alities, includin g a QTc > 500 
m sec or m edication that prolongs the QT interval. Moreover, w om en who 
were pregnant, breast-feeding or not using reliable contraceptive methods 
were excluded. Patients who were unlikely to follow the study protocol or 
were at im m ediate risk of harm ing them selves or others were excluded as 
well.
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2.3. Neurocognitive m easures 
Several m easures of the California Verbal Learning Test ( c v l t )  were se­
lected as the primary outcom e measure of the study. A larger cognitive bat­
tery was adm inistered for w hich a com posite score was developed. The 
dependent m easures used in this study are given in the follow ing section.
Verbal learning and memory:
—  California Verbal Learning Test ( c v l t )  (Dutch version )79.
Dependent m easures: Total num ber correct im m ediate recall (list A), 
num ber correct short delay free recall list A, num ber correct long delay 
free recall list A.
—  Wechsler memory Scale-Revised: Verbal Paired Associates (WMS-R, Verbal 
Paired Associates) (Dutch version).80;81
Dependent measure: Total num ber of correct easy and hard associations.
Speed of processing:
—  Trail Making Test-part A ( t r a i l s  a) . 82
Dependent measure: Tim e to com plete test (connect digits).
—  Fluency: Category fluency (Dutch version).83
Dependent measure: total num ber o f correct words generated.
Letter fluency.84
Dependent measure: total num ber o f correct words generated.
Attention:
—  Continuous Performance Test-identical pairs version ( c p t - I P ) . 85 
Dependent measure: Response sensitivity (d-prime).
Visual memory:
—  Wechsler Memory Scale-Revised, visual reproduction with delayed recall 
(WMS-R, visual reproduction).86’86
Dependent measure: scores from  the im m ediate and delayed recall.
Executive functioning:
—  Wisconsin Card Sorting Test ( w c s t ) . 87;87 
Dependent measure: Num ber of perseverative errors.
—  Trail Making Test-part B ( t r a i l s  b ) .88 
Dependent measure: Tim e to com plete test.
—  Stroop Colour Word Test(sTROOP) (Dutch version).89
Dependent measure: Interference (i.e. tim e condition III [colour-word] -  
condition II [colour])
IQ:
—  An estim ation of full scale IQ was calculated from  four subscales of the 
w a is-iii : Information, Block Design, Arithmetic & Digit Symbol -  Coding.90;91
2.4 Statistical analysis 
The two treatm ent groups were tested for differences in dem ographic, cli­
nical or cognitive m easures at baseline.
Two tailed t-test com parisons were perform ed over c v l t  change-scores 
(raw scores, w eek 8-baseline). In addition to the analysis o f the c v l t ,  an 
exploratory analysis on the other cognitive m easures was done. To facili­
58
3. Results
tate com parison between the two groups, a single unw eighted com posite 
score was developed based on adjusted z-scores of the nine cognitive tasks. 
The raw scores were transform ed into z scores (mean=0, SD=1) based on 
the m eans and standard deviations on the baseline assessm ents of the en­
tire sam ple. For neurocognitive tasks with more than one measure, a sum ­
mary score was calculated by averaging z scores from  individual measures, 
resulting in nine neurocognitive test sum m ary scores. The effect size of 
im provem ent over eight w eeks was also calculated for each treatm ent 
group (Cohen’s formula, using the pooled standard deviation).
To rule out the confounding effect o f anticholinergic m edication on 
cognitive functioning92 additional analyses were run excluding patients on 
anticholinergic m edication from  the analysis. An additional a n c o v a  was 
perform ed to rule out the effect o f baseline antipsychotic treatment.
Additionally, paired sam ple t-tests were run to exam ine if  cognitive 
scores im proved over 8 w eeks in the separate treatm ent groups. We ex­
plored the association betw een clin ical (im provem ent on p a n s s  total 
scores) and cognitive changes through Pearson’s correlational analysis.
3.1. Patient characteristics
Eighty-one patients were screened for eligibility, o f them  74 were ran­
dom ized, 39 to the ziprasidone arm, and 35 to the olanzapine arm.
Eighteen patients discontinued treatm ent during the first 8 weeks, or 
did not have follow-up neurocognitive testing. These patients were not sig­
nificantly different from  those com pleting the 8 weeks study in terms of 
dem ographic data, clinical -or cognitive m easures (Table 1).
Fifty-six patients (olanzapine, n=29, ziprasidone, n=27) continued study 
treatment, performed neuropsychological testing and were included in the 
analyses. The mean exposure to antipsychotics before randomization of the 
patients com pleting the study was 20.66 (± 3.52) days. There were no sig­
nificant differences between the two groups in the baseline characteristics 
in terms of dem ographic features, severity o f symptoms, co-m edication at 
baseline. However, the use of anticholinergic m edication atw eek 8 testing 
was significantly more frequent in the ziprasidone group (Table 2). The an­
tipsychotics used at baseline are presented in table 2. The percentage o f pa­
tients who were randomized to the same antipsychotic they used at baseline 
was 4.8% for olanzapine. Ziprasidone was not used before randomization.
Baseline neurocognitive functioning ( c v l t  and com posite score) was 
not significantly different between the two groups (Table 3).
3.2. Neurocognitive change
Change scores on the c v l t :
Cognitive change scores after 8 weeks of treatm ent were not significantly 
different for ziprasidone or olanzapine on any measure o f the c v l t  ( c v l t  
im m ediate recall: p = 0.59, c v l t  short delay free recall: p = 0.67, c v l t  long 
delay free recall delayed: p = 0.41, Table 3).
D iscarding the 7 patients (all in the ziprasidone treatm ent arm) who 
used anticholinergic m edication at 8 weeks from  the analysis did not sig­
nificantly alter results: c v l t  total recall: patients on ziprasidone (without 
an anticholinergic): mean: 5.06 (± 9.65), olanzapine: mean: 6.31 (± 7.94), 
t(45)= -.50, p= 0.63. c v l t  free recall immediate: ziprasidone: mean: 1.14  
(± 1.65), olanzapine:m ean: 1.21 (± 2.43), t(43) =-0.92, p = 0.36. c v l t  free 
recall delayed: ziprasidone: mean: 1.44 (±2.70), olanzapine: mean: 0.86 
(±2.44), t(45) = 0 .75,p  = 0.45.
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Demographic and clinical data Drop out (n = 18) mean (sd)
Continued 
(n = 56) 
mean (sd)
p-value
Male
Age 23.17 (4.65) 23.91 (4.42) P = 0.54
CGI severity score 5.39 (.85) 5.00 (.76) P = 0.07
Global Assessment of Functioning 
Scale (GAF) 28.89 (7.77) 34.13 (12.76) P = 0.11
Subtotal positive PANSS 21.28 (4.95) 21.75 (4.56) P = 0.71
Subtotal negative PANSS 21.56 (6.93) 19.07 (5.60) P = 0.13
Subtotal general PANSS 39.89 (6.63) 39.22 (7.42) P = 0.73
PANSS total score 82.72 (13.26) 80.04 (13.67) P = 0.47
CDSS total score 3.78 (3.37) 5.11 (3.87) P = 0.19
Schizophreniform disorder 8 19
Schizophrenia, paranoid type 5 24
Schizophrenia, disorganized type 2 5
Schizophrenia, undifferentiated type 2 3
Schizoaffective disorder 1 5
Reason for discontinuation:
Adverse event zip: n = 5 olanz: n = 2
No longer willing to participate zip: n = 4 olanz: n = 3
Protocol violation zip: n = 3 olanz: n = 1
Table 1 Demographic and clinical data of patients who continued the study > seven weeks and 
of patients who discontinued before the final visit. The 18 patients tha t did not continue with 
medical treatm ent were not sign d iffe rent from those who did continue on demographic data, 
clinical data or cognitive measures.
After 8 weeks, c v l t  im m ediate recall and short delay free recall improved 
significantly in both the ziprasidone- and the olanzapine-treated group (re­
spectively p = 0.006, and p < 0.0001 for im m ediate recall, and p = 0.017 and 
p = 0.014 for short delay recall). For the long delay recall, the ziprasidone- 
treated group im proved significantly (p = 0.011) w hile for the olanzapine- 
treated group this did not reach significance (p = 0.068).
Demographic and clinical data
Olanzapine 
(n  = 29) 
mean (sd)
Ziprasidone 
(n = 27) 
mean (sd)
p-value
Male 26 20
Age 23.38 (4.67) 24.48 (4.15) p = 0.36
CGI severity score 4.97 (.78) 5.04 (.77) p=  0.73
Global Assessment of Functioning 
Scale (GAF) 32.79 (13.94) 35.56 (11.40) p=  0.42
Subtotal positive PANSS 21.89 (3.76) 21.59 (5.33) p=  0.81
Subtotal negative PANSS 18.89 ( 5.73) 19.26 (5.57) p=  0.81
Subtotal general PANSS 38.36 (7.30) 40.11 (7.57) p=  0.38
PANSS total score 79.14 (13.24) 80.96 (14.29) p=  0.63
CDSS total score 4.29 (3.67) 5.96 (3.95) p=  0.11
Schizophreniform disorder 10 9
Schizophrenia, paranoid type 13 11
Schizophrenia, disorganized type 4 1
Schizophrenia, undifferentiated type 1 2
Schizoaffective disorder 1 4
IQ at 8 weeks 89.63 (3.39) 90.39 (3.82) p=  0.88
Illness duration prior to randomization 
(months)
13.08 (16.34) 14.65 (15.98) p = ° .70
Exposure to antipsychotics before 
randomization (days)
17.90 (3.97) 23.63 (5.95) p=  0.42
Antipsychotics prior to randomization: p=  0.31
Haloperidol 1 3
Risperidone 7 3
Quetiapine 1 1
Olanzapine 6 3
Thioridazide 1
Zuclopenthixol 4
Amisulpride 1
Benzodiazepine (at baseline testing) (n) 1 2 p=  0.54
Anticholinergic (at baseline testing) (n) 0 3 p=  0.08
Benzodiazepine (at week 8 testing) (n) 1 1 p=  0.98
Anticholinergic (at week 8 testing) (n) 0 7 p=  0.005
Table 2 Demographic characteristics a t baseline (or at 8 weeks) o f patients included in 
analyses on neurocognitive measures (n= 56 ) (indep t-tes t).
Change scores of the com posite score:
The com posite score for cognitive change after 8 weeks was not signifi­
cantly different between ziprasidone: mean: 0.25 (± 0.45) and olanzapine: 
mean: 0.20 (± 0.43), t(54) = 0.42, p = 0.67 (Table 3, in this table the outcom e 
of the explorative analysis o f the separate cognitive tasks (raw scores) are 
also described).W hen discarding the patients who used anticholinergic 
m edication at w eek eight during testing, results were not significantly dif­
ferent: patients on ziprasidone w ithout an anticholinergic: mean: 0.27 
(± 0.48) vs. patients in the olanzapine arm: mean: 0.20 (± 0.43), t(45) = 0.55, 
p = 0 .5 8 .
After 8 weeks, the com posite score for the ziprasidone-treated group as 
well as the olanzapine treated-group improved significantly (respectively p 
= 0.001 and p = 0.005). The effect sizes are also indicated in Table 3.
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4. Discussion
Improvement on cognitive tasks after 8 weeks of 
teatm ent with ziprasidone and olanzapine
n
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Figure 1 E ffect sizes o f cognitive change a fte r 8 weeks of treatm ent. Effects sizes of change 
after 8 weeks were calculated fo r separate tasks and fo r the neurocognitive composite score 
fo r the ziprasidone group and olanzapine treated group. scores were adjusted so tha t positive 
scores reflect improvement.
Correlations:
—  Improvements on c v l t  m easures were not significantly correlated with 
im provem ent on the total p a n s s  score, cvLT-tot recall: r = 0.04, p = 0.77 
and cvL T free recall delayed: r = 0.17, p = 0.21.
—  The correlation between change in the cognitive com posite score and 
the change in total p a n s s  score from  baseline to the 8-week follow-up 
was not significant, r = 0.06 p = 0.66.
—  Im provement on the c v l t  im m ediate recall correlated to im provement 
on the g a f  (r = 0.29, p = 0.03). (The m ean tim e for g a f  baseline visit-GAF 
final visit was 7.9 (± 4.3) months). Other c v l t  m easures were not sig­
nificantly correlated.
—  Im provem ent on the com posite score correlated to the im provem ent 
on the QoLs (-interpersonal relations element) (r = 0.27, p = 0.05).
This is the first random ized controlled double blind trial com paring the 
effects o f olanzapine and ziprasidone on neurocognitive fun ctionin g in 
patients w ith recent-onset schizophrenia. N eurocognitive perform ance 
was m easured at random ization and at 8 weeks follow-up, in patients who 
had lim ited previous exposure to antipsychotic m edication (mean o f 20.66 
(± 3.52) days). The primary outcom e m easure o f the study was the Califor­
nia Verbal Learning Test ( c v l t ) .  In addition, a larger cognitive battery was 
adm inistered for w hich a com posite score was developed based on ad­
justed  z-scores of differential cognitive tests. The cognitive tests included 
were Trailm aking Test -  part A, Verbal fluency (Category fluency and Letter 
fluency), c p t - i p ,  WMS-R Visual Reproduction, WMS-R Verbal Paired asso­
ciates, California Verbal LearningTest, W isconsin Card SortingTest, Trail- 
m aking Test -  part B and Stroop Color-Word Test.
We found a considerable effect-size for the change in c v l t  scores. 
Specifically, effect sizes ranged between 0.4 and 0.6 for total and free de­
layed recall respectively. However, these effects were not different for the 
two drugs tested. The effect size for the change in the com posite score for 
ziprasidone and olanzapine (0.31 and 0.28 respectively) were not signifi­
cantly different either. Im portantly, the cognitive en han cem ent in this 
study was unrelated to the im provem ent in clinical symptoms, since nei­
ther the com posite change-score nor the c v l t  change-scores were corre­
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lated with sym ptom  am elioration. Although the use o f anticholinergic 
m edication was significantly different between groups, it did not affect the 
results o f the study. We found a (weak) correlation between the c v l t  im ­
m ediate recall and g a f  improvement, as well as a correlation between the 
com posite change score and the QoLs (-interpersonal relations element). 
This may indicate that cognitive im provem ent confers to im provem ent of 
functional outcom e, independently from  clinical measures.
Our findings are consistent with the two previous studies failing to find 
a differential effect o f ziprasidone and olanzapine in chronic patients.'71:93 
Our results also corroborate findings from  earlier studies where no diffe­
rences were found between s g a ’ s on cognition in recent-onset schizophre­
nia.94-97 Moreover, the effect size found in our study is sim ilar to that 
reported in studies exam ining cognitive en han cem ent in first episode 
schizophrenia. Goldberg 98 after a six weeks treatm ent trial, found an ef­
fect size o f the com posite score of .36 and an effect size of the c v l t  (total 
trials) o f 0.40. Crespo-facorro and colleagues,99 usingthe Rey Auditory Ver­
bal Learning Test, found an effect size of 0.48 in the olanzapine and o f 0.30 
in the risperidone treated group respectively, after a six m onth treatm ent 
trial.
Our results need to be interpreted in the context o f several lim itations. 
First, we cannot rule out that the im provem ent in cognitive functioning 
was (partly) due to a practice effect, since no healthy com parison subjects 
were included. Indeed, G oldberg et al. addressed the problem  o f retesting 
in cognitive functioning com paring first episode schizophrenia patients 
and healthy controls in a six w eek trial o f olanzapine versus risperidone.100 
The cognitive im provem ents observed in patients in this trial were con­
sistent in m agnitude w ith practice effects observed in healthy controls, 
with effect sizes of 0.36 for patients versus 0.33 for healthy controls. In that 
study, only visual reproduction/m em ory and trail m aking perform ance 
gains o f patients exceeded the im provem ent in healthy controls. In addi­
tion, Crespo-Facorro et al. studied cognitive change in first episode pa­
tients who were treated with haloperidol, risperidone or olanzapine and 
healthy controls during treatm ent o f a year.101 Likewise, they found that all 
three treatm ent groups im proved significantly across tim e, w ithout sig­
nificant differences in cognitive enhancem ent betw een groups. W hen 
com paring patients to healthy controls, the Trailm aking Test -  part B, the 
Rey Com plex Figure Test and the Finger Tapping Test showed a rate o f im ­
provem ent above practice effects. Other measures, like the Verbal Fluency 
Test and the Rey Auditory Verbal Learning Test, did not differ between pa­
tients and healthy controls. Since both studies were conducted in first 
episode patients, this may indicate a practice effect on at least som e cog­
nitive variables in our study. However, even if the enhancem ent in cogni­
tive performance can be (in part) explained by a practice effect, the practice 
effect does not explain the absence o f a differential effect on cognition by 
both drugs.
Secondly, we cannot be beyond doubt that the results are partly ex­
plained by a lack o f statistical power, although the effect sizes we found 
are consistent w ith those described previously. In conclusion, although 
both ziprasidone and olanzapine improved cognition in early onset schiz­
ophrenia in this 8-week double-blind, random ized trial they did not differ 
significantly in this effect.
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Variabele Ziprasidone Olanzapine Ziprasidone Olanzapine
n Baseline n Baseline Change from 
baseline
Effect
size
Change from 
baseline
Effect
size
M  sd M  sd p M  sd M  sd p
Domain: verbal ¡earning and memory
CVLT:
Immediate recall 27 44.15 12.25 29 44.55 11.62 0.9 5.11 8.92 0.42 6.31 6.94 0.52 0.59
Short delay free 
recall 27 8.96 2.82 29 9.24 3.90 0.76 0.88 3.25 0.28 1.21 2.55 0.37 0.67
Long delay free 
recall 27 8.81 3.13 29 9.21 4.00 0.68 1.44 2.74 0.43 0.86 2.44 0.24 0.41
WMS-R, verbal
paired
associates (easy 
and hard pairs)
26 17.23 3.66 27 18.18 3.69 0.35 1.65 2.95 0.43 0.92 2.54 0.25 0.36
Domain: speed ofprocessing
TRAILS A 27 34.66 15.01 29 39.96 34.48 0.47 -  5.14 12.64 0.34 -  10.52 34.02 0.42 0.45
Verbal fluency:
Category
fluency 26 16.72 4.00 28 15.86 4.47 0.47 0.63 3.05 0.26 1.00 2.78 0.27 0.65
Letter fluency 27 9.06 3.41 29 8.81 2.80 0.76 0.93 2.64 0.17 0.71 2.27 0.17 0.74
Domain: attention/vigilance
CPT-IP
(d-prime) 27 1.48 0.69 27 1.14 2.14 0.42 0.48 0.62 0.29 0.65 2.50 0.22 0.74
WMS-R, visual reproduction
Immediate recall 27 32.59 5.76 29 34.24 6.10 0.30 1.58 4.98 0.3 1.24 5.21 0.23 0.81
Delayed recall 27 29.15 9.32 29 31.10 8.18 0.41 2.54 9.53 0.28 0.79 5.98 0.11 0.42
Domain: problem solving/executive functioning
WCST
(perseverative
errors)
25 15.16 10.21 27 22.41 14.36 0.04 -  3.42 11.27 0.35 -  5.92 10.79 0.39 0.43
TRAILS B 26 70.04 29.58 29 83.37 66.04 0.35 -  8.59 23.06 0.33 -  17.61 60.85 0.35 0.48
STROOP
(interference) 27 34.26 21.84 27 38.66 33.98 0.57 -2.15 21.43 0.08 -6 .5 7 39.19 0.16 0.61
Composite score 
neuro 27 -  0.02 0.39 29 0.05 0.43 0.52 0.25 0.45 0.31 0.20 0.43 0.28 0.67
cognitive tasks
Table 3.Baseline cognitive scores and cognitive change scores after eight weeks o f treatment. 
Means, standard deviations (sd) and significance fo r neurocognitive tests (raw scores) and 
composite score (expressed in z-scores) for ziprasidone and olanzapine at baseline, and as 
change score after 8 weeks of treatment. E ffect sizes are also indicated. (Scores were 
adjusted so tha t positive scores reflect improvement).
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Abstract
introduction
Methods
Results
To enhance functional outcome in schizophrenia improvement of cognitive 
symptoms is crucial.
Using a comprehensive test battery, this follow-up examines cognitive 
effects in patients with recent-onset schizophrenia after a change of 
medication following insufficient clinical response and intolerance.
After eight weeks cognitive outcomes had not improved in the patients 
having switched from olanzapine to ziprasidone (n = 11; mean dose 136 mg) 
nor in those having switched from ziprasidone to olanzapine (n = 10; mean 16 
mg), while the symptoms of patients maintaining olanzapine (n = 18; mean 
10.9 mg) or ziprasidone (n = 18; mean 88.9 mg) treatment had not improved 
further.
Discussion The findings suggest that also in early-stage schizophrenia the
antipsychotics tested affect cognitive symptoms similarly.
1. Introduction
2. M ethods
Cognitive dysfunction is regarded as a core sym ptom  o f schizophrenia. 
The deficits tend to remain relatively stable over time, occur independently 
of clinical sym ptom s,112 are already present in the earliest stages of the syn­
drome, even at pre-onset, and are found in non-affected relatives.3-5 The 
sym ptom  com plex has accordingly been proposed as a new criterion for 
schizophrenia in the d s m - v .6
Im provem ent of cognitive symptoms is pivotal to enhance functional 
outcom es in patients.1 Effects o f pharm acotherapy on cognitive dysfunc­
tion are increasingly being studied, possibly prom pted by the introduction 
o f ‘second-generation’ antipsychotics and research initiatives such as 
m a t r i c s  (Measurement and Treatm ent Research to Improve Cognition in 
Schizophrenia) and c n t r c s  (Cognitive Neuroscience Treatm ent Research 
to Improve Cognition in Schizophrenia.718 The effects o f antipsychotics on 
cognition are still a m atter of debate.9 Initially, second-generation an­
tipsychotics were thought to have a m odest, beneficial effect in com pari­
son to the first-generation agents,io  but recent larger-scale studies suggest 
that no one specific antipsychotic is superior to another in their ability to 
improve cognitive dysfunction.11-13
Few studies have evaluated the effects o f second-generation antipsy­
chotics on cognitive dysfunction in the early stages o f schizophrenia. Keefe 
et al. recorded significant im provem ent fo llow ing treatm ent w ith  olan­
zapine, quetiapine, and risperidone,14 while Davidson et al. recently reported an 
equally sm all beneficial effect for haloperidol and various second-genera­
tion agents.12 Two recent papers report on trials conducted w ithin the 
framework of a comprehensive research programme (Part I) in which the ef­
fects o f two antipsychotics, olanzapine and ziprasidone, are investigated in 
patients with recent-onset schizophrenia.15116 The two agents were found to 
be equally effective in improving cognition and clinical response after eight 
weeks of treatment, although they had rather dissimilar side-effect profiles.
Characteristic o f the study design was the possibility to switch between 
the two agents after eightw eeks in case of insufficient clinical response or 
intolerance. In the current report, we present the data obtained in Study 
Part II, specifying the effects on cognitive fun ctionin g in those patients 
that switched drugs and those recorded for patients that continued their 
initial treatm ent (see Figure 1). Although in the c a t i e  study no differences 
were found betw een various antipsychotics in chronic patients after 
sw itching regim ens,4 to our know ledge, ours is the first double-blind 
crossover trial reporting effects on cognition in patients with recent-onset 
schizophrenia.
The goal o f our trial was threefold: to see 1) w hether the ‘new’ antipsy­
chotic regim en (ziprasidone or olanzapine) w ould improve the patients’ 
cognitive perform ance, 2) w hether the agents w ould show differential ef­
fects after switching, and 3) w hether in the group o f clinical responders 
maintenance o f their regimen would further improve cognitive functioning.
2.1 Study design
The present report describes the results o f the 8-week crossover follow- 
up o f our 8-week, double-blind, m ulticentre r c t  (NCT00145444; Figure 1) 
into the cognitive effects o f olanzapine and ziprasidone, the m ethod and 
results o f w hich have been published elsew here.15116 At w eek 8, patients 
were classified as candidates for drug crossover based on their poor clini­
cal response and intolerance for the current drug, with clinical response 
being defined as >20% reduction in total p a n s s  scores and intolerance as
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a weight gain of > 4 kg, a score o f 5 on the modified patient preference scale 
or a significant (> 3x upper lim it o f normal) elevation in hepatic transam ­
inases or any other clinically significant laboratory abnormality.
Figure 1. Study flow  chart. Patients completed the cognitive test battery at baseline (Study 
Part I) and again after eight weeks (baseline Study Part II). Patients tha t switched treatment 
were retested eight weeks after crossover and patients tha t continued the initial treatm ent at 
24 weeks into the ir treatment.
Patients were treated with olanzapine or ziprasidone in a flexible 3-dose 
(low, m edium  and high) regim en w ith three doses (‘low, ‘m edium ’ and 
‘h igh ’: 10 ,15  or 20mg/day olanzapine 10 ,15  or 20 mg/day or 40,60 or 8omg 
b.i.d. ziprasidone 40, 60 or 80 m g b.i.d.), w ith the m edication bein g dis­
pensed in a double-dum m y design. After eight weeks, 21 o f the initial 74 
patients were offered to a double-blind switch o f agents. We adhered to 
the study protocol used in Part I with the same cognitive assessm ent being 
adm inistered after eight (crossover) and 24 (responders) weeks.
2.2 Patients
In Part I o f the study, male and fem ale adult patients (18-40 years) were re­
cruited from  four hospitals in the Netherlands and Belgium  and written 
inform ed consent obtained from  all. A diagnosis o f schizophrenia, 
schizoaffective disorder or schizophreniform  disorder was confirm ed in 
Structured Clinical Interviews for d s m - i v  ( s c i d - i ) .  Patients were included 
in Part I if  their m axim um  lifetim e exposure to antipsychotics was <16 
weeks, the duration of illness <5 years, and the c g i  Severity score3 >4 (i.e. as 
a m inim um  ‘m oderately ill’). Patients were excluded if they had a d s m - i v -  
diagnosis o f substance dependency <3 m onths prior to screening, a posi­
tive drug screen for am phetam ines, cocaine or opioids at screening, or 
significant m edical illness (e.g. epilepsy).
Any concom itant drug treatm ent was kept constant throughout the 
study and no new drug started unless considered m edically necessary. 
Drugs potentially affecting cognition (e.g. biperiden and benzodiazepines)
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were not allowed on the assessm ent day. Patient characteristics are des­
cribed in Table 1. Effects on clinical sym ptom s and reasons for dropout 
are described elsewhere
2.3. Cognitive assessm ent 
The patients com pleted a com prehensive battery of cognitive tests (Table 
2; see also chapter 4 o f this thesis for a full description and references), 
which, as proposed by the m a t r i c s  com m ittee,7 addressed five of the six 
cognitive dom ains. To facilitate com parison betw een the m edication 
groups, Van Veelen et al. com piled a single, unw eighted com posite score 
based on adjusted z-scores of the nine tasks.16 The raw scores were trans­
form ed into z-scores (mean = 0, s d  = 1) based on the m eans and standard 
deviations on the baseline assessm ents of the entire sample. For the neu­
rocognitive tasks with more than one measure, a sum m ary score was cal­
culated by averaging z-scores from individual m easures, resulting in nine 
cognitive test sum m ary scores.
Switched from 
olanzapine lo 
ziprasidone
(n* U)
Mean (Sd)
Switched from 
ziprasidone to 
olanzapine 
(n- 10)
Mean (sd)
Continuous 
olanzapine 
treatment 
<n* 18) 
Mean (sd)
Continuous 
liprasidone 
treatment (n=18) 
Mean (sd)
Male/ female 
Age (yrs)
Subtotal positive PANSS 
Subtotal negative PANSS 
Subtotal general PANSS 
PANSS total score 
CDSS total score 
Diagnosis 
Schizophreniform disorder 
Schizophrenia, paranoid type 
Schizophrenia, disorganized type 
Schizophrenia, undifferentiated type 
Schizophrenia residual type 
Schizoaffective disorder 
Mean daily dose at start (mg)
Mean daily dose after 8 weeks (mg) 
Mean daily dose after 24 weeks (mg)
8/3 7/3 17/1 13/5
23.6 (6.1) 26.8(4.4) 23.4(3.8) 24.2(4 5)
18.0(3.1) 19.0 (4.5) 12.7(2.8) 12.1(3.1)
19.1(4 5) 19.7(8.1) 16.1(5.6) 14.9(2.9)
34.6 (6.9) 36.7 (8.0) 29.1(7.2) 29.2 (5.2)
71.6(10.4) 75.4(18.1) 57.8(13.1) 56.2 (8.9)
5.1 (5.3) 6.2 (3.7) 1.9 (2.6) 5.5 (4.5)
15.0(3.5) (olan.) 125.7 (27.6) (zip.) 10.9(2.0) 88.9(17.1)
136.0 (35.7) (zip.) 16.0 (4.2) (oUn.) • •
• • 10.9(2.0) 88.9(17.1)
Table 1: Demographic and clinical details o f the recent-onset schizophrenia study population 
(n=57 ) per subgroup.
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3 . Results
COGNITIVE DOMAIN TASK OUTCOME MEASURE
SPEED OF 
PROCESSING
-TRAILS A
- W AIS-III, DSST
- CATEGORY FLUENCY
- Tim e to complete test
- Total o f correct responses
- Number o f correct responses 
(Animals and professions)
ATTENTIO N/
VIGILANCE
• CPT d-prime SFN
WORKING MEMORY - W AIS-III LETTER­
NUMBER SEQUENCING
Number o f correct responses
VISUAL LEARNING 
AND MEMORY
- WMS, VISUAL 
REPRODUCTION
Scores from both immediate  
and delayed recall
VERBAL LEARNING 
AND MEMORY
* CVLT
- WMS, PAIRED ASSOCIATIONS
- Delayed free recall response
- Sum of all correct associations 
(easy and hard associations)
PROBLEM SOLVING/
EXECUTIVE
FUNCTIONING
- WCST
- TRAILS B
- STROOP
- Perseverative errors
- Tim e to complete test
- Interference 
(tim e-colour/word-colour)
Table 2 : Cognitive test battery.
2.4. Analysis
We first com pared the cognitive outcom es in the patients w ho had 
switched drugs by perform ing separate paired t-tests for the various tasks 
with the m ean scores at baseline part II and 8 weeks as the dependent vari­
ables. Next, we ran m ixed m odel a n o v a s  w ith the com posite scores at 
‘crossover’ and ‘8-week-post-crossover’ as the dependent and ‘ziprasidone 
to olanzapin e’ and ‘olanzapine to ziprasidone’ as the independent vari­
ables. Third, we ran a sim ilar analysis in the responder group continuing 
their regim en at 24 weeks after the Part-I baseline assessment.
Fourteen o f the 21 patients w ho sw itched m edication com pleted the 
crossover trial. No effect o f treatm ent group was found (Table 3). Figures 
2 and 3 show the results o f the com posite scores. The mixed-model a n o v a  
did not yield significant differences in Tim e (crossover vs. 8-week-post- 
crossover; F ( i , 9 )  = 1.05, p = 0.33) or M edication (neither direction; F ( i , 9 )  =  
0.83, p = 0.39).
The 36 patients continuing treatm ent had not im proved further after the 
8-week assessm ent. The m ixed-m odel a n o v a  again failed to show a sig­
nificant difference in Tim e (8 w eek vs. 24 weeks; F ( i , 1 3 )  =  1.00, p = 0.50) 
and M edication (neither drug; F(1,13) = 0 .11, p = 0.75).
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TASK Mean raw score 
a t crossover 
(S ta rt PART II)
Mean raw 
score 8 
weeks a fte r 
crossover
S ta tis tic  t  o f S ta tistica l 
D ifference p signifcane
Effect
size
Power
MEAN SD N MEAN SD N t ( d f ) p dz 1- beta
TRAILS 31.95 11.02 20 26.85 9.97 13 1.62 (11) 0.13 0.47 0.32
WAIS-III, DSST 58.60 19.32 20 65.15 12.69 13 -1.34 (11) 0.21 0.38 0.23
CATEGORY FLUENCY 
Animals
19.45 5.37 20 18.57 5.70 14 4.5 (12) 0.01 * 1.25 0.98
Professions 14.65 5.84 20 13.36 5.03 14 1.48 (12) 0.16 0.41 0.28
CPT 1.81 0.85 19 2.02 1.28 14 -0 .32  (11) 0.76 0.09 .06
WAIS-III LETTER­
NUMBER SEQUENCING
9.37 2.71 19 9.31 2.46 13 0.89 (11) 0.39 0.26 0.13
WM S, VISUAL 
REPRODUCTION 
D irect recall
25.35 5.33 20 36.00 5.48 13 -0 .28(11) 0.78 0.08 0.06
WM S, VISUAL 
REPRODUCTION 
Delayed recall
31.80 9.32 20 34.23 6.69 13 -0.91 (11) 0.38 0.26 0.13
CVLT 10.55 3.55 20 10.36 4.89 14 0.00 (12) 1.00 0 0.05
WM S, PAIRED 
ASSOCIATIONS
18.22 4.61 18 19.46 3.07 13 -0 .67  (11) 0.52 0.20 0.09
WCST 12.79 8.66 19 12.75 13.19 12 -.074 (10) 0.48 0.22 0.10
TRAILS B 69.76 33.41 20 61.37 21.40 13 10.5 (11) 0.32 0.30 0.16
STROOP Interference 36.25 20.50 20 38.69 24.00 13 -0 .86  (11) 0.41 0.25 0.12
Table 3: Changes in cognition in the crossover group.
0,7 
0.6 
0.5 
0.4
a*
S 0.3
S 0.2 
141 0.1 
0 
-0.1 
*0.2
baseline 8 weeks 24 weeks
-♦-olanzapine -A-ziprasidone
Figure 2 : Changes in cognition (in terms of composite score, mean/standard error o f the mean) 
a fter eight weeks in a subgroup of patients w ith  recent-onset schizophrenia receiving 
maintenance treatment.
74
4. Discussion
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- • - s w it c h e d  from  ziprasidone to  olanzapine
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Figure 3 : Changes in cognition (in terms of composite score, mean/standard error o f the mean) 
a fter eight weeks in a subgroup of patients w ith  recent-onset schizophrenia who switched 
antipsychotics.
The results o f our follow-up demonstrate that switching between two an­
tipsychotics, olanzapine and ziprasidone, did not improve cognitive outcome 
in our patients with recent-onset schizophrenia whose 8-week response to 
the earlier drug had failed. The patients who continued their original treat­
m ent also failed to show further improvement at 24 weeks. The overall lack 
of additional improvement suggests that any cognitive improvement takes 
place in the first eight weeks of treatment and subsequently remains at more 
or less the same level irrespective of the choice of drug or clinical treatment 
effects (i.e., clinical responders and non-responders). The pattern of a m o­
dest improvement in cognition is consistent with the literature.'11:12:14 In both 
the CATiE and the e u f e s t  studies no significant differences were found for 
the various first- and second-generation antipsychotics11'12 nor in a 52-week 
comparison of olanzapine, risperidon and quetiapine.14
Several methodological issues warrant consideration. Our patient popu­
lation was small, resulting in the risk of a type II-error. Particularly the analy­
ses comparing the two switch directions were underpowered. Second, our 
population was biased toward a select group of patients who had insuffi­
ciently responded to the initial treatment. Moreover, additional cognitive im­
provement may not have been possible due to ceiling effects. Third, a fair 
number of patients left the study prematurely. Finally, it needs emphasizing 
that ours was a select population of patients with recent-onset schizophrenia 
and schizoaffective disorder.
It is also a matter of debate whether ‘cognitive improvement’ can be con­
sidered a direct effect o f drug treatment; Godlberg and colleagues for in­
stance, attributed changes in cognition to a practice effect.17 We had no 
control group in our trials and recommend that potential practice effects of 
the current cognitive battery are verified in healthy controls or non-medicated 
patients.
In conclusion, switching between olanzapine and ziprasidone does not en­
hance cognitive outcomes in patients with recent-onset schizophrenia and the 
results thus add to the growing body of evidence that the various antipsychotics 
have similar effects on cognitive symptoms in schizophrenia, irrespective of 
disease stage.
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Abstract
Introduction
Methods
Results
Discussion
The aim of this study was to examine whether patients with borderline 
personality disorder (BPD) have deficits in cognitive inhibition as measured 
with an anti-saccade eye task similar to patients with schizophrenia (Sz). 
Furthermore, we investigated whether these inhibition errors were more 
prominent among BPD patients with psychotic-like symptoms than among 
BPD patients without these symptoms.
An anti-saccade task was administered in 32 BPD patients (among them, 20 
had with psychotic-like symptoms), 21 patients with recent onset 
schizophrenia (Sz), and 25 healthy controls (HC). The percentage inhibition 
errors in the anti-saccade task were the primary outcome variable, in 
addition, the percentage of anticipatory errors was measured.
Sz patients showed more inhibition errors than HC and BPD (p < 0.001 and p 
< 0.05 resp.), whereas BPD patients scored in between Sz and HC. The 
difference with HC was significant as well (p < 0.05). BPD patients with 
psychotic-like symptoms showed more inhibition errors than BPD patients 
without these symptoms (p < 0.05). BPD patients showed more anticipatory 
errors than HC (p < 0.001), whereas Sz patients did not (p < .26).
The data demonstrate that inhibition deficits, as measured with anti- 
saccadic eye movement task, may be characteristic among BPD patients and 
in a larger extent in patients with psychotic-like symptoms. This inhibition 
deficit was distinct from a general predisposition to response impulsively as 
measured by anticipatory errors, which was found in the whole group of BPD 
patients. Psychotic-like symptoms may be an important target dimension for 
future BPD research and treatment.
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1. Introduction Borderline personality disorder ( b p d )  is a complex psychiatric disorder 
characterized by a pervasive pattern of instability in interpersonal rela­
tionships, self-image, affect and impulse control.1 Self-destructing behav­
ior is a key feature of b p d , resulting in suicide rates of 8-io% .2 b p d  usually 
starts in early adulthood and is estimated to occur in about 1%  of the po­
pulation, most predominantly in women.3 Although b p d  is the most com­
mon personality disorder in psychiatric settings, our understanding of its 
neurobiological basis is still limited.4
Recent neuroimaging research suggests that a dysfunctional frontolim- 
bic network plays an important part in the pathophysiology of b p d .  This net­
work encompasses the amygdala, the hippocampus, the anterior cingulate 
cortex, and the orbitofrontal and dorsolateral prefrontal cortex.5;6 Data on 
executive dysfunction in b p d  is still limited and findings are conflicting. Sup­
portive evidence is that b p d  patients, when compared to healthy subjects, 
have longer response times on the Porteus maze task and the trail-making 
test. Furthermore b p d  patients exhibited more errors on the Stroop color- 
word test.7 Other studies, however could not always replicate these findings, 
which suggests clinical and neurobiological heterogeneity in b p d .8;9
The present study was designed to further examine a specific domain of 
executive functioning in b p d  by focusing on a task that assesses inhibi­
tion. We used in particular the anti-saccade task, in which participants vi­
sually fixate a central stimulus that is replaced by a sudden onset target 
that appears either to the left or the right. The participants are required to 
inhibit a reflexive pro-saccade to the peripheral target and to execute an 
alternative, voluntary eye-movementto the opposite direction: an anti-sac- 
cade.10 The neural circuitry behind saccadic eye movements is well under­
stood.11 Lesion studies show a particular involvement of the dorsolateral 
prefrontal cortex ( d l p f c )  and the anterior cingulate cortex (a c c )  in the 
performance on the anti-saccade task.12-16
The first aim of this study was to examine whether patients with bor­
derline personality disorder ( b p d )  have deficits in cognitive inhibition as 
measured with an anti-saccade eye task, in sim ilar to patients with schi­
zophrenia (S z ) . Inhibition abnormalities in the anti-saccade task have con­
sistently been found in the schizophrenia spectrum, especially in patients 
with negative symptoms, and are even regarded as an endophenotype.10;17;18 
Since anti-saccadic errors have been found in other patient groups as well 
(e.g. a d h d , Bipolar disorder, Huntington’s disease), Hutton and Ettinger 
concluded that ‘anti-saccade errors are increased in neuropsychiatric dis­
orders that implicate frontal lobe dysfunction’.10 Previous research showed 
that b p d  patients made more errors in response inhibition in the Wis­
consin Card Sorting test7;19 and more slowing and errors of omission on 
the go/no-go task.20 In addition, b p d  traits have been related to response 
inhibition in a stop-signal task as well.21 As b p d  has been related with 
frontal dysfunction, we expected b p d  patients to have more deficits than 
healthy controls. We added schizophrenia patients as a patient compari­
son group, because the deficit has been well documented for schizophre­
nia. Moreover, this comparison gives an indication of the extent of the 
putative inhibition deficit.
In addition to inhibition errors, the number of ‘too fast’ , impulsive re­
sponses was measured. Since b p d  patients generally exhibit impulsive be­
havior,22 we did expect to find a faster anticipatory response style. Recently, 
it has been found that b p d  patients show more problems in learning from 
their own errors.23
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2. Methods
Another im portant characteristic o f b p d  is the proneness to develop 
psychotic-like symptoms. In fact, the term ‘borderline’ was actually put 
forward, because clinicians believed that such patients lie on the border of 
psychotic functioning.24 However, the criterion “transient, stress-related 
severe dissociative symptoms or paranoid ideation” was incorporated in 
the classification for b p d  not until the publication of d s m - i v  in 1994.1 The 
presence of psychotic-like symptoms in b p d  is of clinical importance as 
well. The prevalence of major psychotic disorders is low, but transient psy­
chotic-like symptoms (‘quasi’-hallucinations, ideas of reference or para­
noid ideation) in response to stress occur in about 40% of b p d  patients.25 
The tendency to develop such psychotic-like symptoms is persistent over 
time26 and is considered to be associated with chronic impairment.27
As schizophrenia and b p d  share the vulnerability to develop psychotic 
symptoms, our second research question focuses on the relationship be­
tween psychotic symptoms and inhibition deficits. We expect that cogni­
tive deficits would be more prominent in the subgroup with psychotic-like 
symptoms, because of the clinical concordance. We hypothesized a priori 
that BPD-patients with psychotic-like symptoms would show more inhibi­
tion errors than b p d  patients without these symptoms.
2 .1. Participants
We recruited 32 patients with Borderline Personality disorder ( b p d )  and 
2 1  with recent-onset schizophrenia (Sz) from the in- and out-patient cli­
nics of the two participating centers (Radboud University Nijmegen Med­
ical Centre and GGNet Apeldoorn). We recruited 25 healthy controls ( h c ) 
without a personal and family history of psychiatric disorders through ad­
vertisements in newspapers. Since the group of b p d  patients consisted 
mainly of women and the schizophrenia group of men, we choose to in­
clude both men and women in the control group. Furthermore, age be­
tween 18  and 50 was an inclusion criterion in all groups.
The clinical diagnosis of the patients was confirmed by a trained re­
search physician with the Structural Clinical Interview for d s m - i v  axis I 
( s c i d - i )  and axis II ( s c i d - i i )  disorders.28129 Since schizotypal traits are re­
lated to anti-saccade performance, we excluded patients with a co-morbid 
schizotypal personality disorder.30 During the psychiatric interview, extra 
attention was focused on psychotic-like symptoms. The existence of psy­
chotic-like symptoms in the past year was assessed on the basis of the cog­
nitive section of the Revised Diagnostic Interview for Borderline ( d i b - r ) .31 
Examples of psychotic-like symptoms are transient paranoid or somatic 
delusions, hallucinations or depersonalization. Among the 32 patients 
with b p d ,  20 appeared to have had a pattern of several, consistent psy­
chotic-like episodes related to stress in the past year ( b p d  + p s y c h ) ,  al­
though none of them had any psychotic symptoms just before or during 
the measurement. 12  b p d  patients reported not to have had any of such 
symptoms ( b p d  -  p s y c h )  ‘Recent onset Schizophrenia’ was defined as pa­
tients with schizophreniform disorder or schizophrenia disorder, less than 
1  year after first onset of positive symptoms (see Table 1  for demographic 
characteristics). The three groups did not differ with respect to age (F(2,74) 
= 2.79, p = 0.07), but they differed significantly in sex distribution, with 
more females in the b p d  group and more males in the schizophrenia 
group (x2 = 27.4, df = 2, p < 0.001).
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N Sex
(M /F )
Age (mean, 
SD/median)
M edication use1
Healthy subjects 25 14/11 25.7(5.5/24 .0) None (n = 25).
Schizophrenia patientsb 21 17/4 27.0 (9.1/25.0) 3)=(nP
<<
e
( 
n
P
 
o 
<
 
Z 
O
BPD patients 32 3/29 29.4 (5.9/28.0)
BPD patients with
psychotic-like
symptoms
20 1/19 29.5(6.3/30 .5) None (n = 11), SSRI (n = 6), 
AAP (n = 2), TCA (n = 2), 
CAP (n = 2)
BPD patients without
psychotic-like
symptoms
12 2 / 10 27.6 (6.1/27.0) 4 =(nRI5 S==
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S
BPD = Borderline Personality Disorder. N = number of patients. SSRI = selective serotonin inhibitor. 
TCA = tricyclic anti-depressant. AAP = Atypical anti-psychotic. CAP = classical antipsychotic.
SNRI = Serotonin-norepinephrine reuptake inhibitor.
a Medication use was not allowed 12 h before measurements.
b = 8 patients with schizophreniform disorder, 13 patients with schizophrenia.
Table 1. Demographic characteristics
Neurological, ophthalmologic and vestibular disorders were exclusion cri­
teria, as well as comorbidity with alcohol- or substance dependence or 
major depressive disorder according to sciD-i. If there was a self-reported 
use of any cannabis, illicit drugs or frequent alcohol (> 3 units/day) in the 
week before measurements, appointments were rescheduled. None of the 
subjects had used alcohol, benzodiazepines or any other psychotropic 
drugs in the 12  hours before measurement. The subjects’ daily medication 
use is presented in Table 1 . All medication was stopped 12  hours before 
measurements. Subjects were further asked to abstain from caffeine and 
nicotine 6 hours before measurement, although it was reported that in­
hibitory dysfunction in anticipatory saccades appeared to be unrelated to 
smoking.32
Approval for this study was obtained from the local ethics committee. 
All subjects gave written informed consent and were paid€io,-/hour.
2.2. Laboratory procedures 
The subjects were seated in a darkened room, 50 cm from a bar containing 
three equally spaced horizontal light-emitting diodes ( l e d ) .  A chin/fore­
head rest was used to prevent head movements. Target lights were located 
at 15 ° , right and left from the central fixation point. Horizontal eye move­
ments were recorded by electro-oculography ( e o g )  with electrodes at­
tached on the outer canthi. A ground electrode was placed at the forehead. 
Low pass filters were set at 500 Hz. Windaq Acquisition software and in­
terface and a universal psychophysiological amplifier were used to record 
the e o g  signal and stimulus presentations.
4 series of 40 trials each were presented to the subjects. The task order 
was: pro-saccade/anti-saccade/anti-saccade/pro-saccade. Each trial con­
sisted of the illumination of the central l e d  for randomly 1000-1200 msec, 
followed by the simultaneous extinguishment of the central l e d  and the il­
lumination of one of the peripheral l e d s  for 800 ms without overlap. The 
peripheral target light appeared left or right in a random order. The in­
struction of the pro-saccade task was to make an eye movement to the il­
luminated peripheral l e d . The instruction of the anti-saccade task was to 
make an eye movement in the direction opposite to the l e d . Subjects were 
instructed to respond as fast and accurate as possible.
84
3. Results
2.3. e o g  analysis
e o g  segments were analyzed with interactive custom-made software. The 
eye movements were visually assessed, blinded to group status, and di­
vided in different response categories: ‘correct response’ (a linear eye 
movement >80 msec after baseline in the correct the direction-depend­
ing on (pro-saccade or anti-saccade) task instruction), ‘inhibition error’ 
(reflexive saccade to the same side as the stimulus) and ‘anticipatory sac­
cade’ (anticipatory response in either direction between < 500 ms before 
baseline and < 80 msec after baseline). Trials with eye blinks, m issing eye 
movements and movement artifacts were removed from the analyses.
2.4. Statistical analysis
Dependent measures were the percentages of inhibition errors, anticipa­
tory (too early) errors, percentage of correct responses and latency times.
All dependent variables were analyzed in two steps. First, the effect of 
the factor group (b p d , Sz, h c )  was compared with an a n o v a , followed by 
post-hoc tests (Fisher’s l s d ) . Secondly, differences between the b p d  group 
with and without psychotic-like symptoms ( b p d  + p s y c h  and b p d  -  psych 
respectively) were tested with a n o v a . Since sex was differently distributed 
in the groups, it was included as a between-subject factor in all analyses. 
Pearson correlations were used to investigate the relationship between in­
hibition and anticipatory errors. The level of significance was set at p < 0.05 
(two-tailed). spss 14.0 software was used.
3 .1. Demographics 
The demographic data are presented in Table 1 . Its statistical evaluation 
showed that the three groups did not differ significantly with respect to 
age, however, the sex distribution was not equal in all groups (x2 = 27.4, df 
= 2, p < 0.001). There were more females than males in the b p d  group, and 
more males than females in the schizophrenia group (Table 1). Therefore, 
sex was included as a between subject-factor in the subsequent analyses.
Table 2 and Table 3 show the descriptive statistics of the pro-saccade 
and anti-saccade task (percentages correct responses and errors, and la­
tencies for the correct responses and inhibition errors).
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% anticipatory 
responses (mean, 
SD)
% correct 
responses 
(mean, SD)
Latency time correct 
responses (ms) 
(mean, SD)
Healthy subjects 2.2 (2.4) 92.6(5.1) 179.6 (22.8)
Schizophrenia
patients
4.8 (4.7) 77.5 (12.6) 204.1 (51.2)
BPD patients 6.5 (4.9) 86.3 (12.7) 190.9 (30.6)
BPD w ith psychotic- 
like symptoms
6.9 (5.1) 84.4 (14.7) 188.6 (28.4)
BPD without
psychotic-like
symptoms
5.8 (4.7) 89.1 (6.9) 194.9 (35.0)
Table 2 Eye movements in pro-saccade task
%
inhibition
errors
(mean,
SD)
%
anticipatory 
responses 
(mean, SD)
% correct 
responses 
(mean, SD)
Latency
time
inhibition 
errors (ms) 
(mean, SD)
Latency 
time correct 
responses 
(ms) (mean, 
SD)
Healthy
subjects
12.3(8.2) 1.1 (1.3) 86.6 (6.5) 187.4 (45.1) 271.6 (68.4)
Schizophrenia
patients
30.4 (18.9) 4.2 (5.4) 63.3 (16.4) 256.8
(104.0)
358.6(139.1)
BPD patients 20.8 (14.3) 5.8 (4.7) 71.3 (16.5) 218.9(67.4) 284.4 (62.4)
BPD with
psychotic-like
symptoms
24.3(14.7) 5.7 (4.4) 68.4 (17.6) 226.9(81.7) 282.0 (62.5)
BPD without
psychotic-like
symptoms
15.0(12.0) 6.0 (5.3) 76.0 (14.0) 204.4 (24.7) 287.9 (64.9)
Table 3 Eye-movements in anti-saccade task
3.2. Introductory analyses 
We removed unusable trials due to m issing eye movements, eye blinks or 
artifacts. The percentage of unusable trials was higher in Sz than in the 
other groups (3.9% vs both 1.8%), but in the a n o v a  the group differences 
were not significant (F(2,72) = 2 .71, p = 0.07).
In the pro-saccade task, the a n o v a  with the percentage of correct re­
sponses as dependent variable revealed a main group effect ( b p d , Sz, h c ) 
(F(2,72)= 6.9, p<0 .0 1). Post hoc tests indicated that both b p d  and Sz pa­
tients made less correct responses than h c  (both p< 0.01). The difference 
between Sz and b p d  patients was not significant (p = 0.97). In the anti-sac­
cade task, the a n o v a  with the number of correct responses as dependent 
variable revealed a main group effect as well (F(2,72) = 13 .6 , p = 0.07). h c  had 
more correct responses than both Sz patients (p <0.001) and b p d  patients 
(p < 0.001). The two patient groups did not differ to this respect (p = 0.08).
The a n o v a  with ‘latency time of the correct responses’ as the depend­
ent variable did not reveal a group effect in the pro-saccade task (F(2,72) = 2.14, 
p = 0.12), but a significant group effect in the anti-saccade task (F(2,72) =
6.2, p < 0.01). Sz patients had longer initiation times than h c  (p < 0.01) and 
b p d  patients (p<0.01). The latter two did not differ from each other 
(p = 0.59). Latency times of b p d  + p s y c h  patients did not differ from b p d  -  
p s y c h  patients (p = 0.87 and 0.52 for the pro-saccade and anti-saccade task 
respectively).
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4. Discussion
3.3. Inhibition errors
The primary outcome measure of this study was the percentage of inhibi­
tion errors in the anti-saccade task; the a n o v a  revealed a significant group 
effect (F(2,72) = 10 .3 , p < 0.001). The data are depicted in Figure 1 . Sz pa­
tients had more errors than h c  (p < .001) and b p d  patients (p < 0.05). The 
difference between b p d  patients and h c  was significant as well (p < 0.05). 
The effect for sex was not significant (p = 0.92).
Subsequent analysis revealed that b p d  patients with psychotic-like 
symptoms had more inhibition errors than b p d  patients without psy­
chotic-like symptoms (F(1,28) = 10.2, p < 0.01). The effect for sex within the 
b p d  groups was significant as well (F(1,28) = 7.42, p<0.05). An additional 
post hoc a n o v a  analysis revealed that b p d  + p s y c h  patients did not differ 
from the Sz patients (p = 0.41), while b p d - p s y c h  differed significantly 
from Sz (p < 0.01). When the analyses on inhibition errors were restricted 
to only females or to only medication-naive patients, the results were es­
sentially similar, though p-values were higher due to loss of power.
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Figure 1. Percentage inhibition errors in anti-saccade task and pooled anticipatory errors in pro-saccade 
and anti-saccade task (Standard deviation shown in figure). ‘bpd + psych’ and ‘bpd -  psych’ refers to the 
presence and absence of psychotic-like symptoms respectively.
3.4. Anticipatory errors 
The percentage of anticipatory errors did not differ between the pro- and 
anti-saccade task (F(1,65) = 1.98, p = 0.16), therefore the data of both tasks 
were pooled in further analyses.
In the a n o v a  with percentage of anticipatory errors as dependent vari­
able, a significant group effect was found (F(2,72) = 4.60, p < 0.05); the post­
hoc tests showed that b p d  patients had higher percentages of anticipatory 
errors than healthy controls (p<0.01), while the differences between Sz 
and b p d  (p = 0 .13) and h c  (p = 0.30) were not significant. There was no dif­
ference between b p d  patients with and without psychotic-like symptoms 
(p = 0.70). In addition, there was no significant correlation between the per­
centage of anticipatory and inhibition errors (r = 0.23, p = 0.25).
In the present study, we demonstrated that b p d  patients scored in between 
schizophrenia and healthy controls on an inhibition task (hypothesis I). 
Moreover, b p d  patients with psychotic-like symptoms had significantly 
more inhibition errors than b p d  patients without these symptoms (hy­
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pothesis II). The b p d  patients with psychotic-like symptoms had a similar 
rate of inhibition errors as patients with Sz, whereas b p d  patients without 
psychotic-like symptoms resembled healthy controls. The inhibition 
deficit was distinct from a general predisposition to respond impulsively, 
which was found in the whole group of b p d  patients.
There may be similar underlying dopaminergic alterations in b p d  and 
schizophrenia. Recently, an essential role for dopamine in b p d  patho­
physiology has been proposed in that dopaminergic pathways projecting 
to the p f c  may be involved in disturbed cognitive perceptual responses 
and planned behaviors in b p d .33 Psychotic-like symptoms have been re­
garded as one of the clinical dimensions in the neurobiological research of 
b p d .4 Moreover, antipsychotic drugs have secured a position in the phar­
macological treatment of b p d .34
Our results raise the question whether the anti-saccade error is a spe­
cific marker for schizophrenia or a marker for psychosis in general. These 
deficits has also been found in patients with bipolar disorder.35136 In addi­
tion, the association between psychotic-like symptoms and inhibition 
errors has been found earlier in a groups of students with questionnaire- 
identified schizotypy.37:38 The percentage of inhibition errors and latency 
times found in the schizophrenia group are in line with percentages pre­
viously found by others.17:39 Of importance is the fact that the Sz patients in 
our sample had a recent onset of the syndrome. Our results show that in­
hibition abnormalities can be established in early stages of the syndrome 
in patients without a history of long-term medication.
Another way of interpreting the shared high number of inhibition er­
rors of both b p d  and Sz in the anti-saccade task is to take the develop­
mental perspective, because both b p d  and Sz have an early age of onset. 
In healthy subjects, there is a clear relation between age and anti-saccadic 
performance, in that a dramatic improvement in the performance of the 
anti-saccade task has been found between from age 5 to 15 .40-42 The ability 
to inhibit prepotent responses is viewed as a direct result of structural and 
functional maturation of the prefrontal cortex and its connections, that 
gradually improves through childhood and adolescence.42 One might sug­
gest a disturbed functional development of the p f c  or associated neuro­
circuitry in both Sz and a subgroup of b p d  patients, a hypothesis which is 
in line with previous finding.2343-48 Since normal anti-saccadic perfor­
mance reflects normal p f c  development, the poor performance on this 
task has been regarded as a biological marker for several neuropsychiatric 
disorders. Not necessarily only biological, but also psychological events may 
interfere with normal brain development in b p d . Therefore, it is interes­
ting to examine the relationships between severe negative life events, dis­
inhibition and psychotic-like symptoms in b p d  in the future.
Next to inhibition errors, we found a higher percentage of anticipatory 
errors in b p d  patients in comparison to healthy subjects. In contrast to the 
inhibition deficit, subtyping for the presence or absence of psychotic 
symptoms did not differ with regard to the number of anticipatory errors. 
The tendency to make ‘false alarm s’ can be viewed as a form of disinhibi­
tion as well. However, it is not an automatic response to a stimulus that is 
inhibited, but a disinhibition of a motor response to an internal cue. The 
absence of a correlation between anticipatory and inhibition defects indi­
cates that the two error types are essentially different. It is an interesting 
question whether anticipatory errors reflect clinical impulsivity, which is 
traditionally viewed as a core feature of b p d . Since 3 1  of 32 b p d  patients of
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our sample were positive for the d s m - i v  criterion for impulsiveness (‘at 
least two potentially self-damaging impulsive behaviors’), it was not pos­
sible to further analyze the association between the anticipatory response 
style and clinical impulsivity.
As expected, the pro-saccade task revealed no differences between the 
three groups in latency time. However, the low percentage of correct re­
sponses -  especially in the two patient groups -  is atypical in comparison 
to previous reports.17 We think our strict definition of ‘correct response’ 
may have attributed to this: next to eye movements in the wrong direction, 
we labeled all trials with non-linear eye movements (with ‘steps’) or with a 
latency outside the timeframe 80-500 msec as incorrect.
A possible limitation to our findings is the effect of drug treatment. Al­
though recent literature suggests that anti-saccade errors in schizophre­
nia remain even after drug treatment, it is possible that medication effects 
did occur in our study.49 However, in an extra post hoc omnibus analysis 
with different drug types as co-factor, we did not find any effects o f me­
dication, suggesting that recent use of medication did not confound the 
findings of our study. Moreover, acute drug effects were excluded because 
there was a 12-hour medication-free period prior to the assessments. In 
addition, the latency and duration times did not indicate that sedative ef­
fects were present. Another possible limitation is the sex distribution of 
the three groups. Our sample reflected the rather typical sex distribution 
of a male preponderance of Sz and a female preponderance of b p d . To ad­
just for this as much as possible, we run all our analyses including sex as a 
cofactor. The outcomes of our analyses do not show that the differences 
in sexjeopardize our conclusions.
In conclusion, our data suggest that inhibition deficits may be charac­
teristic among b p d  patient with psychotic-like symptoms, but do not re­
flect the whole group of b p d  patients. The resemblance with schizophrenia 
is striking and possibly implicates a shared involvement of dopaminergic 
pathways in the dorsolateral p f c  and/or a c c . Therefore our results are in 
line with a prefrontal-dysfunction hypothesis for b p d . Psychotic-like symp­
toms may be an important target dimension for future b p d  research and 
treatment.
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Abstract
Introduction
Methods
Results
Discussion
The authors explore sensory gating deficits in borderline personality disorder 
patients, such as those described in schizophrenia, in patients with 
borderline personality disorder.
Gating of the P50, N100, and P200 auditory evoked potentials and prepulse 
inhibition of the startle response (PPI) were measured in borderline patients 
and a group of healthy comparison subjects.
Borderline patients did not show lower sensory gating, but showed higher 
P50, N100, and P200 gating than comparison subjects. This was mainly due 
to the increased response after the first stimulus. There were no group 
differences in PPI.
Unlike in other major psychiatric disorders, such as schizophrenia, sensory 
(motor) gating is intact in borderline personality disorder. The higher early 
preattentive and mid-latency evoked potentials suggest a higher response 
tendency in borderline personality disorder, but this needs further 
replication.
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1. Introduction Borderline personality disorder is characterized by a pervasive pattern of 
instability in the regulation of emotion, interpersonal relationships, self­
image, and impulse control. The broad clinical heterogeneity and the com­
plex multifactoral etiology complicate the elucidation of the underlying 
pathophysiology.1
Neurobiological research suggests that a fronto-limbic network is re­
lated to borderline personality disorder symptoms, causing a weakening of 
prefrontal inhibitory control and amygdala hyperactivity.2 Next to affective 
dysregulation, several research groups recently found evidence for cogni­
tive deficits in borderline personality disorder.314 In a recent meta-analy­
sis, Ruocco concluded that borderline patients generally perform more 
poorly than healthy comparison subjects on global dimensions of atten­
tion, cognitive flexibility, learning, and memory.5 But looking in more de­
tail, the few neurocognitive studies undertaken have led to a broad but 
inconsistent pattern of impairments. While some authors report deficits 
in almost all classical neuropsychological tests, others found no diffe­
rences between borderline patients and healthy comparison subjects.6-8
The goal of the present study is to investigate if patients with border­
line personality disorder show deficits in sensory gating, a normal preat- 
tentive inhibitory mechanism that prevents the brain from being overtaxed 
by sensory input. This research approach has led to deeper understanding 
of the underlying neural pathophysiology in schizophrenia. Decreased sen­
sory gating in schizophrenia patients and their first degree relatives has 
been found repeatedly.9110
Two paradigms are widely used for establishing sensory gating: P50 ga­
ting and prepulse inhibition of the startle response ( p p i ) .  In P50 gating, au­
ditory evoked potentials are measured in a double click paradigm, with a 500 
msec interstimulus interval. Sensory gating occurs when the auditory 
evoked potentials amplitude elicited by the second click is suppressed 
when compared to the auditory evoked potentials waveform elicited by the 
first click. The inhibitory process can be detected after just 50 msec, sug­
gesting that gating does not depend on any effortful control. Moreover, it is 
an automatic process, not controlled by sleep or attention.11112 The neural 
circuitry underlying P50 suppression is not precisely understood, but is 
known to involve hippocampal and frontal structures as well as choliner­
gic systems.13114 P50 gating abnormalities have been found in patients with 
schizophrenia and schizotypal personality disorder,15116 but also in psychotic 
patients with bipolar disorder and posttraumatic stress disorder.12;17;18 Re­
cently, decreased sensory gating in the mid-latency auditory evoked poten­
tials N100 and P200 has also been found in patients with schizophrenia.19
In the p p i  paradigm, a motor startle reflex elicited by a loud noise is re­
duced when it is preceded by a weaker nonstartling stimulus, the prepulse. 
Animal and human studies suggest that the startle response is mediated by 
a neuronal circuit in the lower brainstem and that the startle response can 
be attenuated by several structures such as the prefrontal cortex.20;21 A re­
duction of p p i , similar to P50 gating, has been demonstrated in patients 
with schizophrenia -  and their siblings -  and patients with schizotypal per­
sonality disorder.9;22 In addition, effects of second generation antipsy­
chotics on the p p i  deficit have been found.23;24
Although P50 gating, N100 gating, and p p i  are conceptually linked, pre­
vious research suggests different underlying neural circuitries: concurrent 
assessment revealed no strong correlations in either humans or rats and 
there are important methodological differences.14;25-27 Therefore, a com-
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2. Methods
bined use of the paradigms allows a broader range of inhibitory informa­
tion processes to be investigated.
There are three reasons to examine sensory gating in borderline per­
sonality disorder. First, both borderline and schizophrenia spectrum pa­
tients share the vulnerability to develop psychotic symptoms, although 
these symptoms are transient, stress-related, and much less prominent in 
borderline personality disorder. In addition, clinical response on antipsy­
chotics in borderline patients supports a relationship with psychotic dis- 
orders.28 Second, animal research has revealed that early-life social events 
in rats, such as early handling, social isolation, and maternal deprivation, 
have important effects on p p i  and P50 gating in adult life.25 Since dama­
ging early-life events are particularly common in borderline patients,29 
deficit inhibitory mechanisms could be a chain link in pathophysiology. 
Third, previous research using event-related potentials showed similar 
aberrations in schizophrenia and borderline personality disorder,30 al­
though the literature is limited. Event-related potentials research in bor­
derline personality disorder particularly revealed lower amplitudes and 
longer latencies of the P300.31;32 Drake et al. found prolonged latencies and 
decreased amplitudes in mid-latency and long-latency auditory evoked po­
tentials.33 Recently, diminished action monitoring investigated by measuring 
the error-related negativity was found by two different groups.34;35
To date, only one study, by Herpertz and Koetting,36 has addressed sen­
sory motor gating in borderline personality disorder and did not find any 
differences in prepulse inhibition between borderline patients and com­
parison subjects. However, sensory (P50) gating in borderline personality 
disorder has not been investigated yet. We hypothesized that sensory gat­
ing and p p i  would be reduced in borderline patients.
2 .1 Participants
Patients with the primary ( d s m - i v )  diagnosis borderline personality dis­
order were recruited from two Dutch psychiatry departments (inpatient 
clinic for personality disorders and outpatient clinic for dialectical beha­
vior therapy). A trained physician or psychiatrist confirmed the diagnostic 
criteria for borderline personality disorder using s c i d - i i .37 A s c i d - i  screen­
ing was performed to exclude current comorbid alcohol or substance de­
pendence, axis I psychotic and mood disorders (except for dysthymic 
disorder), and neurological, ophthalmologic, and vestibular disorders.38 
We recruited age-matched healthy comparison subjects who had no prior 
history of any major psychiatric or neurological disorders and who did not 
have first- or second-degree family members with psychotic disorders.
All subjects were instructed to abstain from coffee and nicotine 12  
hours prior to testing to prevent confounding by the acute effects of these 
compounds.39;40 In the week prior to testing, the use of cannabis or any 
other illicit drug or alcohol consumption exceeding more than three units 
per day was reason for exclusion as well. Further, on the morning of the 
experiment, no subjects had used any psychotropic drug.
The demographic data of the patients with borderline personality dis­
order and matched comparison subjects are shown in Table 1 . We per­
formed two separate experiments, one on sensory gating and one on p p i , 
and applied the same inclusion and exclusion criteria to the participants. 
The participants gave written informed consent after complete descrip­
tion of the study and received financial compensation for their participa­
tion. The study was approved by the local ethics committee.
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N Sex (M /f) Age (mean, SD, 
median)
Medication use a
Healthy controls 25 14/11 25. 7 (5 .5 /24 .0) None (n= 25)
Schizophreniab 21 17/4 27.0 (9.1/25.0) None (n= 4), AAP (n= 3), CAP 
(n=14)
BPD Patients 
BPD patients w ith psychotic- 
like symptoms
32
20
3/29
1/19
29.4 (5.9/28.0) 
29.5(6.3/30 .5) None (n=11), SSRI (n=6), AAP (n=2), 
TCA (n=2), CAP (n=2)
BPD patients without 
psychotic- like symptoms
12 2/10 27.6 (6.1/27.0) None (n=7), SSRI (n=4), SNRI (n=1)
BPD = Borderline personality disorder, N = number of patients. SSRI = selective seretonin inhibitor. 
TCA= tricyclic antidepressant. AAP = atypical antipsychotic. CAP = classical antipsychotic.
SNRI = seretonin/norepinephrine reuptake inhibitor.
a Medication use was not allowed 12h before measurements.
b 8 patients with schizophreniform disorder, 13 patients with schizophrenia.
Table 1 Participant Characteristics
2.2. Experiment 1: Sensory Gating
2.2.1.Recording Procedures
e e g  recordings were made with Ag/AgCl electrodes mounted in an elastic 
electrode cap at the frontal region (Fz) and central region (Cz) (Rembrandt
5.2 acquisition software). For the detection of eye blinks and eye move­
ment artifacts, horizontal electro-oculogram ( e o g )  recordings were placed 
at the outer canthus of each eye and vertical e o g  recordings infraorbital 
and supraorbital to the left eye. All electrodes were referenced to the left 
mastoid electrode. A ground electrode was attached to the left temporal­
parietal scalp. The impedance for the e e g  electrodes was kept below 3.5 k, 
while the impedance for the e o g  and mastoid electrodes was kept below
5 k. The electrical signals were recorded with band pass filters set at 0-70 
Hz and digitized with a 204.8 Hz sample rate.
We seated each subject in a comfortable armchair and instructed him 
or her to stare at a fixed point. Auditory stimuli were presented through 
headphones and consisted of repeated presentation of two identical clicks: 
a conditioning stimulus (Si) and a test stimulus (S2) with a fixed inter­
stimulus interval of 500 msec. The interval between the pairs of clicks va­
ried randomly between 8 and 12  seconds. Each subject received 60 trials.
2.2.2. Auditory Evoked Potentials Analysis
The e e g  and e o g  signals were analyzed with Brain Vision Analyzer soft­
ware. First, the raw signals were offline-referenced to linked ears. Artifact 
rejection was done by both visual inspection and semiautomatic rejection 
(amplitudes >100 |iV; alpha theta activity). The data were baseline-cor­
rected. To decrease the noise-to-signal ratio, the e e g  signals were band­
pass filtered between 10  and 50 Hz for examination of the P50 and between 
1  and 40 for examination of the N100 and the P200.19 The auditory evoked 
potentials waveforms had to meet the following criteria: the P50 was iden­
tified as the second major positive component between 30 and 80 msec 
poststimulation and is preceded by the photoacoustic wave in the 15  to 40 
msec range. The N100 is the largest negative deflection between 80 and 
150  msec, while the largest positive deflection between 150  and 250 msec 
is identified as the P200. Amplitudes of a waveform were measured from its 
peak to the preceding peak of opposite deflection (“peak-to-peak”).
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Waveform measurements were made from both Cz and Fz, the chan­
nels where gating is known to be most pronounced.41
2.2.3. Statistical Analysis 
For each waveform (P50, N100, P200), analyses of variance (a n o v a s )  were 
performed with the amplitudes of the P50, N100, and P200 as dependent 
variables, patient group as the between-subjects factor (borderline per­
sonality disorder, comparison subjects), and stimulus (S1, S2) and elec­
trode position (Fz, Cz) as within-subjects factors.
In the literature, both difference scores (S1-S2) and suppression ratio 
scores (S2/S1) are used to measure sensory gating.42;43 As previous research 
has shown that the difference score may be more reliable in repeated tes­
ting42 and possibly more sensitive in detecting abnorm alities,19 we de­
cided to report both scores but primarily discuss the difference scores. The 
difference score (S1-S2) of the amplitudes was analyzed with a paired t test. 
Differences in gating between borderline patients and comparison sub­
jects were tested with a n o v a s , with the gating scores of the P50, N100, and 
P200 as dependent variables and electrode position as the within-subjects 
factor (Fz, Cz). The significance level was set at p<0.05 (two-tailed).
2.3 Experiment 2: Prepulse Inhibition of the Startle Response
2.3.1. Recording Procedures
Electrodes were placed beneath and at the site of the right eye, as well as a 
ground electrode on the forehead (impedance <5 k). Subjects were seated 
in a comfortable armchair and instructed to stare at a fixed point while the 
auditory stimuli were presented through a headphone ( m o n a c o r  2000). 
Electromyogram ( e m g )  activity was band-pass filtered (100-500 Hz) and 
recorded with sam pling rate 2000 per second (Windaq Aquisiation Soft­
ware, 50 Hz notch filter). After a 30 second acclimatization period that con­
sisted of 50 dB continuous white noise, the session began with habituation 
trials of 15  (pulse alone) 40 msec pulses (106 dB) with random inter-stim­
ulus intervals between 8 and 1 1  seconds.
Subsequently, the p p i  part of the session consisted of 36 trials including 
six conditions in a pseudorandom order: 106 dB pulse alone, 90 dB pulse 
alone, 65 dB/90 dB prepulse-pulse trial, 75 dB/90 dB prepulse-pulse trial, 
65 dB/106 dB prepulse-pulse trial, and 75 dB/106 dB prepulse-pulse trial 
(all with 100 msec prepulse-pulse interval).
All recordings were visually screened and onset time, peak latency, and peak 
amplitude were measured. Trials were rejected when the startle was a non- 
polyphasic signal, had a peak amplitude <0.1875 microvolt, or had a peak onset 
latency time >9 5 msec. The filter window for response onset was 2 1-14 0  msec.
2.3.2. Statistical Analysis
An a n o v a  was performed with amplitude of the startle reflex as the de­
pendent variable and with prepulse levels (no prepulse, 65 dB, 75 dB) and 
pulse levels (90 dB, 106 dB) as within-subject factors. p p i  was calculated 
with the formula: % p p i  = 100x[1- (amplitude on prepulse-pulse trials/am­
plitude on pulse-alone)]. Group differences (a between-subjects factor) for 
p p i  were tested in a multivariate analysis of variance (m a n o v a )  with pre­
pulse levels (65dB, 75 dB) and pulse levels (90 dB, 106 dB) as within-subject 
factors and percentage p p i  as the dependent variable. The significance 
level was set at p<0.05 (two-tailed).
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3. Results 3 .1  Sensory Gating 
The grand averages of the auditory event-related potentials are presented in 
Figure 1. The a n o v a  with P50 amplitude as the dependent variable revealed 
significant main effects for electrode position (F(30,1) = 17 .1 , p < 0.001) and 
stimulus (F(30,1) = 38.6, p < 0.001). There was no main group effect (F = 0.51, 
d f= 30 ,1, p = 0.48), but the significant groupxstimulus interaction (F(30,1) 
=4.60, p < 0.05) indicated different gating patterns between the groups. The 
groupxelectrode position was not significant (F(30,1) = 3.25, p = 0.08). As 
shown in Table 2, further analysis for electrode position and amplitude in­
dicated that the amplitudes of borderline patients were higher compared to 
healthy comparison subjects on S1, whereas there were no differences on S2.
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Figure 1. Grand Average (Fz) Auditory Evoked Potentials in Borderline Personality Disorder Patients 
and Comparison Subjects. The borderline patients have significantly higher amplitudes on Si.
S1-S2 pV 
(gating)
sta tistic Ratioscore** Statistic S1 pV sta tistic S2 pV sta tistic
P50 (Fz) BPD patients 
Controls
2.97 (2.50) 
1.20 (1.26)
p= .01*
52 %
21%
p= .04*
5.78 (2.80) 
4.10 (2.29)
p= .07
2.80 (2.06) 
2.90 (1.41)
p=  .89
N100 (Fz) BPD patients 
Controls
-12.75 (5.34) 
-8 .9 2  (5.51)
p= .06
75 %
70%
p= .53
-16.70 (5.05) 
-12.42 (4.57)
p= .02*
- 3.95 (3.11)
- 3.50 (3.56)
p=.71
P200 (Fz) BPD patients 
Controls
18.73(7.78)
11.61(9.30)
p= .03*
75 %
6 6 %
p= .43
24.70 (8.80) 
16.33(7.90)
p< .01*
5 .97 (3 .5 4) 
4.73 (5.27)
p=  .43
P50 (Cz) BPD patients 
Controls
2.11 (2.10) 
1.28(1.17)
p= .16
51%
36%
p= .27
4.39 (2.56) 
3.76 (2.10)
p= .45
2.27 (2.14) 
2.48 (1.79) p=  .77
N100 (Cz) BPD patients 
Controls
-11.17 (4.55) 
- 7.86 (3.01)
p= .02*
79 %
77%
p= .86
-14.13 (4.39) 
-10.57 (3.53)
p= .02*
- 2.96 (2.48)
- 2.71 (3.28)
p=  .81
P200 (Cz) BPD patients 
Controls
15.74 (7.56) 
10.33 (6.25)
p= .04* 70 %  
68 %
p= .89 21.84 (7.83) 
15.26 (5.57)
p< .01* 6.10 (2.48) 
4.92 (5.72)
p=  .43
Mean (SD) AEP amplitudes (pV ) o f P50, N100 and P200 as recorded at Fz and Cz 
of BPD patients and controls.
* =  p< 0.05 * *  (1- S2/S1) x 100
Table 2 . Sensory Gating Results
The a n o v a  for N100 and P200 revealed similar results. In both a n o v a s  
there were significant main effects for group (N100: F(30,1) = 4.84, p< 0.05; 
P200: F(30,1) = 6.86, p < 0 .0 1) and stimulus (N100: F(30,1) = 163, p < 0.001; 
P200: F(30,1) = 1 1 1 ,  p < 0.001). The main effect for electrode position was 
only significant for N 100 (F (30,1) = 10 .1 ,  p < 0 .0 1; P200: F(30,1) = 2.34, 
p = 0.14). Further analyses revealed the same pattern with higher ampli­
tudes on S 1 and equal amplitudes on S2. The data are presented in Table 2.
The paired t tests revealed that gating occurred in both groups on all 
three waveforms in both Fz and Cz (borderline patients all waveforms: p <
0.001; comparison subjects p< 0.01 for P50, p< 0.001 forN 100 andP200).
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Additional tests revealed no statistical differences in latencies between the 
two groups (Table 3).
S 1 Latency statistic S 2 Latency statistic
P50 (Fz) BPD patients 
Controls
57.82 (4 .68) 
57.84 (3 .91)
p= .99 57.93 (4 .5 6 ) 
57.02  (3 .71)
p= .54
N100 (Fz) BPD patients 
Controls
108.45 (10.2 4 ) 
113.81 (16.2 4 )
p= .31 104.95 (12.28) 
112.23 (17.21)
p= .21
P200  (Fz) BPD patients 
Controls
2 0 8 .6 8 (19.59 ) 
200.95  (24 .81)
p= .36 208.01 (31.64) 
199.74 (2 2 .32)
p= .39
P50 (Cz) BPD patients 
Controls
56.28  (4 .9 8 ) 
58.59  (5 .27) p= .22
56.38 (4 .4 5 )
57.39  (7 .9 4 )
p 11 6 CJl
N100 (Cz) BPD patients 
Controls
107.42 (11.16) 
111.93 (17.8 8 )
3.4p
103.16 (12.33) 
111.10 (15.8 0 )
p = .12
P200  (Cz) BPD patients 
Controls
202.77  (2 6 .56) 
197.57 (24 .5 5 )
p 5 03 205.18 (29 .67) 
194.11 (2 0 .41)
p = .25
Mean (SD) AEP latencies (msec) as recorded at Fz and Cz of BPD patients and 
controls. Group differences were not statistically significant
Table 3 . Sensory Gating on Three Waveforms in the Frontal (Fz) and Central (Cz) Regions
The results of our primary outcome measures, the P50, N100, and P200 
gating scores, are shown in Table 2. The a n o v a  with P50 gating as de­
pendent variable and electrode position as the within-subject factor re­
vealed a significant group effect ( F ( 3 0 , i )  = 4.60, p < 0.05) indicating that 
borderline patients had higher P50 gating than comparison subjects. The 
effect of electrode position was not significant ( F ( 3 0 , i )  = 1.27, p = 0.27).
The separate a n o v a s  with N100 gating and P200 gating as the depen­
dent variables and electrode position as the within-subject factor revealed 
similar effects: there was a significant group effect (N100: F ( 3 0 , i )  = 5.03, p 
<0.03; P200: F(30,1)= 6.86, p< 0.01) indicating that borderline patients also 
had higher mid-latency gating. The effect of electrode position was also 
significant (N100: F(30,1) = 4.35, p< 0.05; P200: F(30,1) = 110 .6 , p< 0.001).
We obtained essentially the same results while restricting the analyses 
to female patients and to patients without antipsychotic treatment. In ad­
dition, we performed additional analyses with ratio scores as dependent 
variables (Table 2). Only the P50 ratio score on Fz was significantly diffe­
rent, with borderline patients showing more sensory gating.
3.2. Prepulse Inhibition of the Startle Response 
The percentages p p i  of the startle responses are displayed in Table 4. A sig­
nificant effect of the intensity of the pulse (F(1,60) = 7 1.32 , p < 0.001) and in­
tensity of the prepulse (F(2,59) = 51.82, p <  0.001) was found for the 
amplitude of the startle reflex, indicating that the intensity of both the pre­
pulse and the pulse determined the amplitude of the startle response. 
There were no group differences in amplitudes (F(1,60)= 2.38, p=0.13; Figure 2).
BPD  p atien ts C o n tro ls S t a t is t ic
65-dB/9 0 -dB 61.72 (4 8 .41) 62.06 (41.0 4 ) F(61,1) = 0.001 p= .98
75-dB/9 0 -dB 88.91 (28 .15) 88.37 (2 8 .94 ) 61 = 0. 0 CJl p = .94
65-dB/106-dB 40.16 (41.18) 55.84 (3 2 .97) F(61,1) = 2.71 p = .11
75-dB/106-dB 74.84 (2 6 .74) 65.83 (3 0 .36 ) F(61,1)= 1.57 p = .22
Group differences were not statistically significant; PPI=prepulse inhibition
Table 4. Mean and Standard Deviation of the Percentage ppi o f the Startle Response in 
Borderline Personality Disorder Patients (n=34) and Comparison Subjects (n=28)
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Figure 2 . Mean and Standard Deviation o f Peak Amplitudes in Borderline Personality Disorder 
Patients and Comparison Subjects in Pulse-Alone Conditions (9odB and io 6dB) and with 
Prepulses o f 65dB and 75 dB. Group differences were not statistically significant.
On the ANOVA with p p i as dependent variable, significant effects were 
found for the intensity of the prepulse (F(i ,59) = 74.2, p < 0.001) and inten­
sity of the pulse (F(i ,59) = 9.54, p < 0.01). There was no group difference in 
p p i (F(i ,59) = 0.69, p=0.79). The results are presented in Table 3.
The proportion of men to women differed significantly between borderline pa­
tients and comparison subjects (Table 1) and since p p i  exhibits gender differ­
ences,44 additional tests were performed by excluding all male participants or 
setting sex as an extra between-subject factor. This additional analysis, how­
ever, revealed similar results for p p i  to the whole sample. A rerun of these analy­
ses that excluded all patients using antipsychotics also yielded similar results.
4. Discussion We conducted two experiments to investigate sensory (motor) gating in pa­
tients with borderline personality disorder and comparison subjects.
In the auditory evoked potentials experiment we expected to find a gating 
deficit such as described in schizophrenia. In contrast to our hypothesis, we 
found more gating of the P50, N100, and P200. The difference is caused by 
significantly higher S i amplitudes in the borderline personality disorder group 
compared to the comparison group, rather than differences in S2 amplitudes.
The N100 and P200 waves are thought to reflect the allocation of early at­
tention to a stimulus, whereas the P50 is thought to be “pre-attentive’’ .11;14 
In addition, gating of P50, N100, and P200 reflect different mechanisms 
and are only partially correlated.45 The data suggest that borderline pa­
tients differ from comparison subjects in both early attentive as well as 
preattentive information processing and do not exhibit the same deficits 
as patients with schizophrenia.
The increased amplitudes in the early auditory evoked potentials waves 
on S 1 may indicate that borderline patients have a higher response tendency 
to new auditory stimuli than comparison subjects.46 It is generally accepted 
that the amount of synchronization of firing pyramidal cells is the main con­
tributor to the amplitude of a cortical recorded evoked potential. The num­
ber of cells that fire depends on the firing mode of cortical pyramidal 
neurons. These cells fire either in the tonic or bursting mode. Generally, tonic 
firing is typical for alert wakefulness; burst firing is characteristic of drowsi­
ness. It is easier to recruit a larger number of cells when cells are in the burst­
ing mode than in the tonic firing mode.47 Therefore, the larger amplitude 
may be due to more bursting cells, and perhaps to a reduced arousal level.
Elevated mid-latency event-related potentials have also been found in sub­
jects with sensation-seeking and thrill-seeking behavior, characteristics
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that are common in borderline patients.48;49 Our data may therefore support 
the current hypotheses on impulsivity in borderline personality disorder.50 In 
line with this, we also found impulsive response style in a Flankers task and 
saccadic eye movements in a similar patient sample.34;51 The present data 
suggest that borderline patients have an increased physiological predispo­
sition to respond to new stimuli. However, the “compensatory” gating mech­
anism, which prevents the individual from being flooded by sensory input, 
is intact in borderline patients. In fact, the present data suggest that it might 
be even more efficient than in comparison subjects.
There are two possible methodological limitations to the auditory evoked 
potentials experiment. First, there may be a type II error due to the small 
sample size, which in some cases prevented us from demonstrating genuine 
significance effects instead of tendencies (e.g., the N100 at Fz). In addition, 
the number of trials was relatively small. Second, the paradigm we used was 
specifically designed for early preattentive sensory gating and not the “odd­
ball” paradigm, in which subjects need to respond to target stimuli that 
occur infrequently and irregularly within a series of standard stimuli.52 
Therefore, a relation between the present increased neuronal reaction to 
new sensory stimuli and attention deficits should be drawn with caution.
The second experiment replicated previous work by Herpertz and Koet- 
ting and showed that there is no evidence for abnormalities in p p i  of the 
startle response in patients with borderline personality disorder.36 Their 
patient sample did not have similar inclusion criteria to ours; our patients 
had no comorbid m ajor depression and had abstained from nicotine, 
whereas their patients were unmedicated.
Taking both experiments together, it is important to address two 
methodological issues. First, we included patients without comorbid psy­
chotic or depressive disorder and the data were not corrupted by the acute 
effects of medication, illicit drugs, or nicotine. However, some of the pa­
tients used psychotropic medication, but not on the day of the study. In 
post hoc analyses we found no differences between medicated and non­
medicated patients. Second, one should take into account that our parti­
cipants were predominantly female. Since women are known to exhibit less 
p p i  and P50 gating than men, it needs to be established whether increased 
P50 gating and amplitudes of P50, N100, and P200 might be present in 
male borderline personality disorder patients as well.53;54
In conclusion, patients with borderline personality disorder do not 
show sensory (motor) gating deficits such as those described in other 
major psychiatric disorders such as schizophrenia and schizotypal per­
sonality disorder. In contrast, our data showed borderline patients to have 
even higher amplitudes on S i than comparison subjects, which may sug­
gest differences in early preattentive information processes. The latter 
finding merits further exploration in larger patient samples in order to 
demonstrate if this is specific for borderline personality disorder pathology.
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Abstract
introduction
Methods
Results
Discussion
Patients with borderline personality disorder (BPD) are characterized by 
marked impulsive behaviour. The impulsive response style of patients with 
BPD may be associated with diminished action monitoring, which can be 
investigated by measuring the error-related negativity (ERN). The ERN is an 
ERP component generated in the anterior cingulate cortex (ACC) following 
erroneous responses.
Behavioural and ERP measurements were obtained during performance on a 
speeded two-choice reaction task in a group of patients with BPD (N = 12) 
and in a group of age-matched controls (N = 12). The ERP results showed 
that ERN amplitudes were reduced for patients with BPD, as were the P300 
amplitudes after late feedback.
The behavioural results confirmed a more impulsive response style for the 
BPD group, reflected in larger RT differences between correct and incorrect 
responses and in an increase in erroneous responses to the easy congruent 
stimuli. Additionally, analyses on post-error congruency effects 
demonstrated that controls adjusted their behaviour following errors, but 
patients with BPD did not.
The attenuated ERNs indicate reduced action monitoring in patients with 
BPD. This suggests that the ACC, or the action-monitoring network it is part 
of, is not functioning optimally. Due to this reduced action monitoring, 
patients with BPD do not learn from their errors as well as controls. 
Consequently, they do not adjust their behaviour when necessary and thus 
maintain their impulsive response style.
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1. Introduction Marked impulsivity is seen as one of the main characteristics of borderline 
personality disorder ( b p d ) , together with rapidly changing mood states, ag­
gressive behaviour, instability of interpersonal relationships, self-image, 
and affects. Impulsive behaviour may express itself in promiscuity, sub­
stance abuse, adverse financial behaviour, reckless driving, and binge ea­
ting. Suicidal behaviour and self-mutilation are also frequently related to.1
Although impulsiveness is an important clinical feature, the number of 
studies investigating its neural correlates is still relatively small. This may 
be explained by the lack of a unified definition, which is due to the wide 
range of behaviours in which the trait is present.2 Moeller et al., in their re­
view of the psychiatric aspects of impulsivity, concluded that a reliable defi­
nition should at least include the elements of the various behavioural 
models that have been developed based on findings from targeted labora­
tory tasks.3 These elements are: (1) rapid, unplanned reactions to stimuli 
before complete processing of information, (2) decreased sensitivity to 
negative consequences of behaviour, and (3) lack of regard for long-term 
consequences. With the current study we aimed at investigating the neu­
ral correlates of the first two elements in patients with b p d .
Rapid, unplanned reactions and diminished sensitivity to resulting er­
roneous responses can be studied by means of electrophysiological meas­
urements during a speeded forced-choice task. Especially the discovery of 
an event-related potential ( e r p )  component associated with error or con­
flict detection has given this type of action monitoring research an impor­
tant impetus. This so-called error negativity4 or error-related negativity 
( e r n )5 is characterized by a sharp negative deflection over frontocentrally 
located electrodes appearing within 100 ms after an error has been made.
Source localization and fMRi studies have found the anterior cingulate 
cortex ( a c c )  as the most likely generator of the e r n ,6-8 a finding that is in 
line with earlier studies demonstrating error-related activity in unit record­
ings from the a c c  in monkeys.9 The a c c  is a mediofrontal brain structure 
known for its rich innervation from and to other regions of the brain and 
its rich concentration of different types of neurotransmitters like 
dopamine. The area is highly interconnected to the motor system, the lim­
bic system, and to prefrontal regions. Because of these characteristics, the 
a c c  has been described as the interface between cognition, motor control, 
and the drive of the organism.10
Originally, the e r n  was taken to be elicited by a mismatch, i.e., after the 
error detection system has failed to match a representation of the actual be­
haviour with a representation of the desired behaviour.415 More recently, Hol- 
royd and Coles extended this original interpretation in their so-called 
reinforcement-learning theory of the e r n .11 According to the theory, predic­
tive error signals indicating whether events turn out to be worse than ex­
pected are carried to various brain areas by the dopamine system. These 
error signals are used to improve performance in order to prevent future er­
rors. When a predictive error signal arrives at the a c c ,  the e r n  is elicited. 
Alternative accounts refer to the e r n  as the reflection of conflict that arises 
when two incompatible response tendencies are simultaneously activated.12- 
14 For the current study it is relevant that all three accounts agree that the 
e r n  is generated in the a c c ,  that it reflects the outcome of an action-moni­
toring process, and that is used to optimize performance in the future.
Differences in e r n  amplitude have been observed in a variety of per­
sonality traits. Individuals low on socialization tend to exhibit smaller e r n  
amplitudes,15 whereas individuals with greater negative affect16 or those
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with obsessive-compulsive personality traits show larger e r n  amplitudes.17 
Pailing et al. specifically investigated the relation between the e r n  and im- 
pulsivity.18 In their study, subjects with large reaction-time differences be­
tween correct and incorrect responses had sm aller e r n  amplitudes. 
Because (overly) fast reaction times generally lead to more erroneous re­
sponses, these larger reaction-time differences were taken to reflect a more 
impulsive response style. This motivated us to investigate whether this line 
of reasoning could also be applied to patients with b p d .
p e t  and fMRi studies investigating neuropsychiatric disorders have 
demonstrated increased a c c  activity in individuals with obsessive-com­
pulsive disorder ( o c d ) 19;20 and decreased a c c  activity in patients with 
schizophrenia.21122 These differences in a c c  activity were also reflected in 
action monitoring: enhanced e r n  amplitudes were found in individuals 
with o c d ,23 whereas decreased e r n  amplitudes were observed in patients 
with schizophrenia.24-27
With regard to b p d , a number of brain imaging studies examining pa­
tients have shown hypometabolism in prefrontal cortical areas.28-30 Re­
cently, Tebartz van Elst et al. demonstrated volume loss of the right a c c  in 
their b p d  sam ple.31 The authors suggested that specifically this volume 
loss might differentiate b p d  from other neuropsychiatric disorders.
In the present and to our knowledge the first such study in patients with 
b p d , we employed a speeded two-choice task while measuring e r n  am­
plitudes. We predicted that patients with b p d  would show increased im- 
pulsivity in different behavioural measures and reduced action monitoring 
as evidenced by smaller e r n  amplitudes.
In order to examine the entire process o f action monitoring from sti­
mulus onset to feedback processing, we also examined two other e r p  com­
ponents known to be involved in action monitoring, namely the 
stimulus-locked N2 and the feedback-locked P300. The amplitude of the 
N2 is thought to reflect the monitoring of response conflict that arises from 
simultaneously active response tendencies as it is enlarged after incon­
gruent stimuli compared to congruent ones.14 Consequently, the N2 is a 
reflection of a relatively early process. As we specifically anticipated group 
differences for the later processes directly related to erroneous responses, 
we did not expect to find any differences with regard to N2 amplitudes. Pre­
viously, using the same task, we demonstrated that P300 amplitudes 
elicited by less predicted negative feedback were larger for subjects who 
attributed more m eaning to the feedback information.32 When patients 
with b p d  indeed display decreased sensitivity to negative consequences of 
behaviour, sm aller P300 amplitudes to negative feedback are expected 
compared to controls.
2 .1. Participants
Twelve female patients (mean age = 29.3, s d  = 4.5 years) with primary di­
agnosis b p d  (according to d s m - i v )  were recruited from two Dutch (inpa­
tient and outpatient) psychiatry departments. An independent and trained 
physician confirmed the diagnostic criteria for b p d  by use of the structural 
clinical interview for d s m - i v  Axis II Personality Disorders (sciD -ii33). An 
extra clinical screeningwas performed to exclude current (comorbid) axis-
I mood and psychotic disorders (except for dysthymic disorder).
Other exclusion criteria were neurological, ophthalmologic and vestibu­
lar disorders, as well as comorbidity with alcohol or substance depen­
dence. Six patients used a selective serotonin reuptake inhibitor ( s s r i ) , of
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whom one in combination with clozapine and one with cisordinol, and 
one patient used quetiapine only. The remaining five patients did not take 
any psychopharmaca. In the week prior to testing, the use of cannabis or 
any other illicit drug, or alcohol consumption exceeding more than 3 units 
per day, were further reasons for exclusion. In addition, all subjects were 
instructed to abstain from coffee and nicotine 24 hours prior to testing. 
Note that on the day of the experiment, none of the subjects had used any 
psychotropic drug.
Twelve age-matched, healthy female controls (mean age = 26.0, s d  = 6.8 
years) were recruited by means of advertisements in a local paper. They 
had no prior history of psychiatric or neurological illness. In addition, they 
did not take any medication and adhered to the criteria set for alcohol and 
drug intake.
All participants gave written and informed consent and received finan­
cial compensation for their participation. The study was carried out in ac­
cordance with the latest version of the Declaration of Helsinki and was 
approved by the University Medical Centre’s ethical committee.
2.2. Task and procedure
Participants performed a speeded two-choice reaction task, the so- 
called ‘flankers’ task. Visual stimuli in this task are letter strings of five let­
ters. The goal for participants is to respond as fast as possible to the central 
letter of the target string by pushing a button with their left or right index 
finger while ignoring the surrounding or flanking letters. The stim ulus- 
response mappings are known to the subjects beforehand. Instructions 
may, for example, state that a left-hand response is required when the H is 
the central letter and a right-hand response when the central letter of the 
target string is an S. Four strings of letters are presented, two with five iden­
tical letters ( h h h h h  and sssss) and two including deviating flanking let­
ters ( s s h s s  and h h s h h ) . When congruent stimuli are presented, i.e. where 
the flankers are identical to the central target letter, responding is rela­
tively easy, as all visual information primes the correct response. In the 
case of different flankers surrounding the central target, the incongruent 
stimuli, responding is more difficult, as the visual information strongly in­
duces the wrong response. Stim ulus-response mappings were counter­
balanced in both groups and equal emphasis was placed on speed and 
accuracy in the written and verbal task instructions.
Because previous e r n  studies had demonstrated that accuracy could 
affect e r n  amplitude,5 we first calculated individual reaction-time ( r t ) 
deadlines. This procedure, which had already been employed successfully 
in previous studies,34 ensures sim ilar performance levels for the two 
groups. The personal maximum r t  sets the time-frame within which a 
subject should respond to avoid visual feedback indicating that the re­
sponse was late. To this end, the subjects first performed a practice block 
of 60 trials. During the practice block, the initial r t  deadline was set to a 
relatively liberal limit of 800 ms. After completion of the 60 practice trials, 
the participant’s average r t s  and standard deviations ( s d s )  of the correct 
responses were computed. Subsequently, the r t  deadline for each indi­
vidual participant was determined by adding 0.5 s d  to this mean r t .
The experimental phase consisted of five blocks of 100 trials each, i.e. 50 
congruent and 50 incongruent stimuli, with a self-paced pause halfway 
each block. Subjects were first presented with a fixation point (lasting 100 
msec). After 300 ms the stimulus (also lasting 100 msec) would appear. The
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next 900 ms the screen remained blank, after which the visual feedback 
stimulus (1000 msec) appeared. The visual feedback consisted of a yellow, 
a blue, or a red rectangle indicating whether the response had been cor­
rect, incorrect, or late, respectively. Responses were considered late when 
r t s  exceeded the assigned deadline. The next trial was presented after an 
inter-trial interval of 100 msec. The total duration of the experimental 
phase was 35 min including breaks.
2.3. e e g  recording
The electroencephalogram was recorded from four midline electrodes (Fz, 
Fcz, Cz, Pz) mounted in an elastic electrode cap (Electrocap international). 
Electrodes were placed at locations in accordance with the international 
10-20  system. All electrodes were referenced to the left mastoid, but were 
later off-line re-referenced to the average of the left and right mastoid. The 
vertical electro-oculogram ( e o g )  was recorded bipolarly from electrodes 
placed above and below the right eye. The horizontal e o g  was also 
recorded bipolarly from electrodes lateral to both eyes. Electrode impe­
dances were kept below 10  kfi. The e e g  and e o g  signals were amplified 
using a time-constant of 8 s and were filtered off-line low-pass at 15  Hz. All 
signals were digitized with a sampling rate of 200 Hz.
2.4. Analyses
e o g  artifact correction was carried out using the procedure proposed by 
Gratton et al. For both behavioural and e r p  analyses all responses with re­
action times faster than 150  msec (1.1% ) were removed from the data sets. 
e r p s  for correct and incorrect responses to incongruent stimuli were a­
veraged separately off-line time-locked to response onset, starting 200 
msec before and ending 500 msec after response onset relative to a 200 
msec pre-response baseline. Incorrect responses to congruent stimuli 
were not analyzed as the number of trials was too small to obtain reliable 
e r p s . In addition, correct responses were averaged separately for congruent 
and incongruent stimuli time-locked to stimulus onset relative to a 200 
msec pre-stimulus baseline. Finally, e r p s  time-locked to feedback onset 
were averaged separately for feedback type time-locked to feedback onset, 
starting 200 msec before and ending 800 msec after feedback onset, also 
relative to a 200 msec pre-stimulus baseline.
e r n  amplitude was determined on incorrect trials by subtracting the 
most negative peak in the 0-200 ms time-window after response onset 
from the most positive peak in the time-window starting 80 msec before 
and ending 80 msec after response onset at electrodes Fcz and Cz, where 
maximal e r n  amplitudes were expected.
N2 amplitude was determined on correct stimulus-locked e r p s  as the 
difference between the most negative peak in the 200-350 msec time-win- 
dow and its preceding positive peak at electrode Fcz. P300 amplitude was 
defined as the most positive peak in the 300-800 msec time-window after 
feedback onset at electrode Pz.
Individual averages for r t s , amplitudes, and number of responses were 
entered in a repeated measures General Linear Model ( g l m )  with group (2 
levels: b p d  vs. control) as between-subject factor. Possible within-subject 
factors of the different g l m s  were congruency (2 levels: congruent vs. in­
congruent), correctness (2 levels: correct vs. incorrect), feedback type (3 
levels: correct feedback vs. incorrect feedback vs. late feedback), and post­
correctness (2 levels: post-correctvs. post-error). The analyses on e r n  am­
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3 . Results
plitude also included the within-subject factor electrode (2 levels: Fcz vs. 
Cz). Greenhouse-Geisser corrections were applied when appropriate, but 
uncorrected degrees of freedom values are given for ease of interpretation. 
Note that significant e r p  outcomes were additionally analyzed for the 
medication-free subset of patients (N = 5) only, in order to exclude any pos­
sible effects that medication might have on the e r p  measurements.
3 .1 . Behavioural analyses 
Figure 1  shows the mean r t s  of both groups. With regard to correct re­
sponses, the group r t s  differed, with the b p d  group overall responding 
more slowly (382 msec) than the control group (347 msec; F(1,22) = 5.97, p 
= 0.023). Usually, responses to congruent stimuli are given faster than re­
sponses to incongruent stimuli. This congruency effect was also present in 
the current data, as the r t s  for correct responses were shorter following 
congruent (349 msec) than following incongruent stimuli (380 msec; 
F(1,22) = 130.29, p < 0.001). The interaction between congruency and group 
was not significant (F < 1).
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Figure 1. Mean reaction times for correct and incorrect responses to  congruent and incongruent trials for 
the control and the bpd group. Error bars represent standard deviations.
As in similar studies, incorrect responses were faster (322 msec) than correct 
responses [365 msec; F(i,22) = 96.26, p < 0.001]. However, the interaction 
with group revealed that this response effect was larger for the b p d  group 
(56 msec) than for the control group [28 msec; F(i,22) = 10.78, p = 0.003].
Table 1  comprises the percentages of correct, incorrect, and late re­
sponses. Overall, error rate did not differ between the two groups (F< 1). 
More errors were made to incongruent trials (7.0%) than to congruent ones 
[2.0%; F(1,22) = 164.9 1, p < 0.001]. A significant interaction between group 
and congruency revealed that this effect differed between the two groups: 
the b p d  group made more errors in response to congruent trials (2.6%) 
than the control group (1.5%; F(1,22) = 8.02, p = 0.01). The proportion of 
late responses did not differ between the groups (F(1,22) = 2.99, p = 0.098]. 
Incongruent trials induced a larger number of late responses (9.0%) than 
the congruent ones [3.8%; F(1,22) = 83.56, p < 0.001). The interaction be­
tween group and congruency showed that this effect was similar for both 
groups (F<1).
500
400
300
200 Jam
Congruent Incongruent Congruent Incongruent 
Control group BPD group
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Control group BPD group
Congruent Incongruent Congruent Incongruent
Correct 45.3 (1.7) 34.2 (3.6) 43.0 (3.1) 33.9 (3.3)
Incorrect 1.5 (0.5) 7.5 (1.9) 2.6 (1.5) 6.5 (2.1)
Too late 3.2(1.8) 8.3 (2.9) 4.4 (1.4) 9.6 (2.5)
Standard deviations are given in parentheses.
Table 1. Mean percentages of correct, incorrect and too late responses to congruent and incongruent 
trials for the control and the bpd group.
3.2. e r p  analyses
3.2 .1. Response-related e r n
As Figure 2 shows, e r n  amplitude was sm aller for the b p d  group (-6.18 
(iV) than for the control group (-10 .30  |iV; F ( i , 2 2 )  =  4 .9 1 , p = 0.037). There 
was no main effect of electrode site, indicating that the e r n  was equally 
large at both electrodes (F < 1). The interaction between electrode site and 
group was not significant either (F< 1). In addition, no differences were 
found for the peak latency of the e r n  (F< 1). For both groups, the e r n  
peaked around 74 msec after response onset. Importantly, e r n  amplitude 
was also reduced in the b p d  group (-4.65 (iV) when patients who used me­
dication were excluded from the analysis (F(1,15) = 6.42, p = 0.023).
3.2.2. Stimulus-related N2
Although Figure 3 may suggest an overall difference in N2 amplitudes be­
tween the two groups, analyses demonstrated that the main effect of group 
was not significant (F< 1). As expected from previous studies, N2 ampli­
tude was more negative for incongruent stimuli (-5.65 (iV) than for con­
gruent ones (-4.67 iV ; F(1 22) = 4.83, p = 0.039). More importantly, the 
interaction between congruency and group showed that this N2 congru­
ency effect did not differ between the two groups (F < 1).
Figure 2 . Grand average response-locked waveforms fo r correct and incorrect responses for 
the control and the bpd group. Electrodes FCz and Cz are depicted. Responses are given at 
t  = 0 ms.
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3.2.3. Feedback-related P300 
Figure 4 shows the feedback-locked e r p  waveforms. A main effect of feed­
back type was present, indicating that P300 amplitude was affected by 
feedback (F(2,44) = 4 1 .3 1 , p< 0.001). Simple contrasts referenced to ‘cor­
rect’ feedback (5.14  (iV) showed that P300 amplitude was larger after ‘late’ 
feedback (13.79 iV ; F(1,22) = 54.82, p < 0.001), but not different after ‘in­
correct’ feedback (4.84 (iV; F< 1). Although there was no main effect for 
group (F < 1), the interaction between type of feedback and group was sig­
nificant (F(2,44) = 10.04, p = 0.002). Here, simple contrasts referenced to 
correct feedback revealed that this was caused by smaller P300 amplitudes 
after late feedback for the b p d  group (10.69 iV) compared to the control 
group (16.88 (iV; F(1,22) = 10 .73, p = 0.003). These effects on P300 ampli­
tude were also present when patients who used medication were excluded 
from the analysis. Importantly, in these restricted analyses P300 ampli­
tude after late feedback was also found to be sm aller for the b p d  group 
(9.44 (iV; F (1,15) = 6.65, p = 0.021).
Figure 3 . Grand average stimulus-locked waveforms for correct congruent and correct 
incongruent stimuli fo r the control and the bpd group. Electrodes Fz and FCz are depicted. 
Stimuli are presented a t t  = o ms.
3.3. Performance adjustments 
As important as the ability to detect an error is the ability to adjust per­
formance following an incorrect response to prevent similar errors in the 
future. One way to accomplish a successful performance adjustment in 
the Flankers task is to reduce the interference effect of the flanking letters 
by focusing on the central target in the letter string. This type of perfor­
mance adjustment can be investigated in more detail by examining behav­
ioural congruency effects following incorrect and correct responses.34;35 
Typically, standard congruency effects caused by slower responses to in­
congruent stimuli than to congruent ones are reduced following errors. 
This reduction reflects a change in response strategy after an incorrect re­
sponse. The congruency effect is computed by subtracting r t s  on congru­
ent stimuli from r t s  on incongruent stimuli following correct and
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incorrect responses. Note that only correct responses that were preceded 
by incongruent trials were included in the analyses. As can be seen in 
Figure 5, the analyses only revealed a significant interaction between post­
correctness and group (F (1,11) = 9.64, p = 0.005). This interaction indicated 
that a reduction of the congruency effect following errors was present for 
the control group (18 msec), but not for the b p d  group ( - 12  msec).
Figure 4. Grand average feedback-locked waveforms fo r correct, incorrect, and too late 
feedback stimuli fo r the control and the bpd group. Electrodes Cz and Pz are depicted. 
Feedback stimuli are presented at t  = o ms.
Figure 5 . Performance adjustments following erroneous responses. Reaction-time differences 
between correct congruent and correct incongruent trials (congruency e ffec t) are smaller 
following erroneous (dark) responses than when following correct (ligh t) responses fo r the 
control group, but not fo r the bpd group. Error bars represent standard errors.
113
4. Discussion In the current study, action-monitoring processes were investigated in a 
group of patients with b p d  and in a matched control group. The results 
demonstrated that patients with b p d  show reduced action monitoring, re­
flected in attenuated e r n  amplitudes.
The present finding is in line with the impulsive response style charac­
teristically associated with patients suffering from b p d . This marked im- 
pulsivity was also evident in different behavioural measures. The b p d  
patients showed (1) increased reaction-time differences between correct 
and incorrect responses, and (2) an increased number of erroneous re­
sponses to congruent stimuli. As a minimum stimulus-processing time is 
required to give the correct response in a flankers task, a larger reaction­
time difference between correct and incorrect responses indicates that the 
incorrect response is given relatively too fast. This larger reaction-time dif­
ference for patients with b p d  thus reflects an impulsive response style. The 
increased number of incorrect responses to congruent stimuli is of par­
ticular interest, because congruent trials require relatively little attention 
to be processed correctly. When subjects produce errors due to diminished 
attention processes, slower r t s  are expected. However, our results showed 
that the incorrect responses to congruent trials were the fastest of all re­
sponses in both groups. Therefore, our r t  findings suggest that such er­
roneous responses are not simply caused by a loss of concentration, but 
that specifically these errors are related to an impulsive response style.
Group differences were also observed for the feedback-related e r p s .  
Compared to the controls, the b p d  patients showed decreased P300 am­
plitudes for late feedback. P300 amplitude following feedback in a sim i­
lar flankers task was previously shown to be larger when subjects 
attributed more meaning to the stimulus.32 Consequently, the current re­
ductions in P300 amplitudes corroborate the view that the b p d  patients 
attribute less meaning to this type of negative feedback compared to the 
control subjects. This implies that patients with b p d  indeed show de­
creased sensitivity to the negative consequences of their behaviour.3 Note 
that the e r p s  following correct and incorrect feedback were sim ilar for 
both groups. Although incorrect feedback can also be regarded as a nega­
tive consequence of behaviour, differences in e r p  amplitude between cor­
rect and incorrect feedback are not expected, since the error is already 
detected earlier, viz. at the moment of response onset.11 Reductions in P300 
amplitudes have previously been found in patients with b p d ,36 but also in 
patients with schizophrenia,37 and in criminal psychopaths.38 However, 
the present data suggest that the currently found reduction in P300 is not 
just a reflection of a general impairment in cognitive processing. The P300 
was only reduced in the b p d  group following late feedback, indicating that 
this reduction is specifically related to action monitoring.
Although patients were free from medication on the day of testing, it 
needs to be mentioned that the influence of medication cannot be ruled 
out entirely. More specifically, it is known that e r p  components related to 
action monitoring may be affected by psychopharmacological com- 
pounds.34;39 Yet, we feel that any such effects are likely to be limited or non­
existent as additional analyses showed that the effects demonstrating 
reduced action-monitoring processes remained present when patients 
who did use medication were excluded.
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4 .1. Learning from errors 
The theories that attempt to explain the complex interplay between pre- 
frontal, mediofrontal, and limbic areas all seem to agree that the a c c  is 
specifically involved in monitoring and/or selection processes. Prefrontal 
areas are assumed to play an important role in controlling actions and in 
keeping task demands up to date. According to the reinforcement learning 
theory of the e r n , predictive error signals indicate whether ongoing events 
are worse or better than expected and are used to improve performance.11 
In this interpretation, the core function of the e r n  is to learn from errors 
to optimize response behaviour. In the theory, the a c c  plays the role of a 
control filter that is trained through the predictive error signals to select 
appropriate motor controllers.
The current data suggest that patients with b p d  are specifically im­
paired in this learning process. A forced two-choice task like the one we 
employed does not require much learning. After a short practice block, the 
stimulus-response mappings are clear to all subjects. The only aspect of 
the task that does involve learning through feedback is the exact timing of 
the response. Participants need to respond within a certain time window: 
when they respond faster, they tend to respond erroneously and when they 
respond slower, the visual feedback will signal that they responded late. 
Problems with this process of fine-tuning responses in the b p d  group are 
supported by the increased r t  differences between correct and incorrect 
responses and by the absence of performance adjustments. These findings 
suggest that patients with b p d  have more difficulty determining the optimal 
moment to initiate their response. In the current task, this optimal moment 
can be derived from two different types of feedback.
First, there is the external feedback, in the form of visual stimuli indi­
cating that the current response was given late. Although the b p d  patients 
showed decreased sensitivity to this type of feedback in the e r p  results, 
the proportion of late responses did not differ between the two groups. 
The absence of such behavioural effects with regard to late feedback was 
likely caused by the instructions that explicitly emphasized speed and ac­
curacy. However, a post-hoc analysis did confirm some decreased sensi­
tivity at the behavioural level by demonstrating that controls gave 
significantly more correct responses following late feedback (79%) than 
patients with b p d  (72%; p = 0.036).
The second type of feedback is more important. This feedback is inter­
nal and is reflected by the e r n . The e r n  is generated after errors due to 
premature responding. Thus, the internal feedback can be used to boost 
alertness for the subsequent trials or to delay the next response until all 
stimulus features have been processed. The absence of performance ad­
justments following errors in the b p d  group suggests that, unlike control 
participants, patients do not use this internal feedback to optimize the mo­
ment of response initiation.
Taken together, the increased impulsive response style employed by pa­
tients with b p d  results in premature responding, i.e. before all the stimu­
lus information has been adequately processed and evaluated. This 
impulsive response style is reflected in the b p d  group in the increased r t  
differences between correct and incorrect responses and in the higher 
error rate on congruent trials. When patients with b p d  make an error, their 
e r n  amplitudes are reduced compared to the control group. As the e r n  is 
the result of action-monitoring processes, the reduced e r n  amplitudes 
are an indication that the a c c  or the action-monitoring network it is part
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of is not functioning optimally in patients with b p d . Normally, error sig­
nals enable learning reflected in adaptations in behaviour necessary to pre­
vent future errors. Diminished error signals will thus lead to the absence 
of such adaptations. In the current data, this is evident in the lack of per­
formance adjustments in the b p d  group. Finally, when responses are given 
before the stimulus is sufficiently processed, evaluation of a feedback sti­
mulus that is presented even later in time is expected to be minimal. This is 
reflected in the reduced P300 amplitudes following late feedback in the 
b p d  group. Late feedback provides valuable information on the timing of 
the response and is apparently not processed adequately. As a result, the 
entire action-monitoring process, i.e. from stimulus processing until ad­
justing performance, is affected in the b p d  group. Consequently, patients 
with b p d  do not learn from their errors as well as controls, thus maintai­
ning their impulsive response style.
4.2. Affective evaluation of errors
A complementary explanation for the reduced e r n  amplitudes is related 
to an assumed functional subdivision of the a c c .  The caudal part of the 
a c c  has strong connections to the dorsolateral prefrontal cortex and is in­
volved in executive functions and motor control and is therefore termed 
the cognitive a c c .  The rostral part of the a c c  mainly projects to the limbic 
system and is thought to be involved in the emotional regulation of exe­
cutive control, hence it is termed the affective a c c .40
The affective role of the rostral a c c  in action monitoring has been em­
phasized in an fMRi study in which error processing was investigated in 
schizophrenia.22 Laurens and colleagues demonstrated that patients with 
schizophrenia are specifically characterized by decreased rostral a c c  ac­
tivity during the commission of errors. As disturbances in affect and mo­
tivation are common and persistent symptoms of schizophrenia, the 
authors concluded that this reduced a c c  activity leads to disturbances in 
a subjective affective error assessment process.
With regard to b p d , affective instability is, along with marked impul- 
sivity, a main characteristic of the disorder. This is also evident in the pro­
blems patients with b p d  have to contend with on a daily basis, which are 
mostly affective in nature rather than cognitive. Therefore it may be pos­
sible that, similar to patients with schizophrenia, the reduced action mo­
nitoring in our b p d  group is mainly caused by a disturbance in the activity 
of the rostral part of the a c c , leading to a relative diminution of the affec­
tive response associated with the committed error. Future investigations 
using neuroimaging techniques with a higher spatial resolution like fMRi 
could explore whether a specific part of the a c c  is responsible for reduced 
action monitoring in patients with b p d .
4.3. Conclusions
The current study demonstrated impulsivity-related reductions in action 
monitoring in a group of patients with b p d . The results indicate that pa­
tients with b p d  do not learn from their errors as well as controls. Conse­
quently, the patients do not adjust their behaviour following errors 
optimally, thus maintaining their impulsive response style. Although the 
present results warrant replication, in the near future this new insight may 
be applied to help explain the etiology and pathophysiology of b p d  and 
foster the prognosis of treatments.
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Abstract
introduction
Methods
Results
Conclusion
The availability of new atypical antipsychotics provides new opportunities for 
the treatment of borderline personality disorder (BPD).
Original papers on this topic were sought. Our study reviewed and discussed 
14 papers.
2 RCTs, 4 non-controlled open-label studies and 8 case reports. The patient 
populations studied were highly diverse and the dropout rate after a long 
follow-up period was high. All of the articles reported positive effects of 
olanzapine, clozapine, quetiapine and risperidone.
BPD patients with psychotic-like, impulsive or suicidal symptoms might 
benefit from atypical antipsychotics. Since the methodological quality of the 
reviewed articles is poor, further randomised placebo-controlled studies with 
longer follow-ups are needed before any firm conclusions can be drawn.
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1. Introduction
2. Methods
The treatment of borderline personality disorder ( b p d )  usually involves 
a combination of psychotherapy and pharmacotherapy. Previous re­
search indicates that both dialectical behavioural therapy and psycho­
dynamic approaches can be highly effective.112 Psychopharmacological 
agents, such as ssRis, antipsychotics and benzodiazepines, are increa­
singly being prescribed to decrease specific complaints or to increase the 
benefit from psychotherapy (see elsewhere for comprehensive reviews).314 
The ssRis have been found to be particularly valuable and are considered 
the first choice for patients with affective dysregulation and impulsive 
symptom clusters.5
The tendency to develop transient moments of psychotic or dissocia­
tive symptoms in reaction to stressful events has been regarded as a key 
element of b p d . An increased dopaminergic activity might be involved 
in the pathophysiology, in view of the observation that b p d  patients are 
prone to psychosis following the administration of a dopamine agonist.6
The interest in antipsychotic treatment for b p d  patients with cognitive 
perceptual symptoms is increasing. Several placebo-controlled trials 
have shown that b p d  patients can benefit from classical antipsychotics. 
Antipsychotic treatment seemed to be most effective in patients with se­
vere broad-spectrum symptomatology, such as psychotic symptoms and 
impulsiveness,718 whereas less symptomatic subjects demonstrated only 
a limited improvement.9 Continuation therapy significantly decreased 
suicidal behaviour in parasuicidal patients with b p d  and histrionic per­
sonality disorder.10
Since the introduction of second-generation ‘atypical’ antipsychotics 
that combine dopamine and serotonin antagonism, new treatment pos­
sibilities have emerged. Many clinicians tend to use low-dose antipsy­
chotic treatment for cognitive-perceptual distortions, hostility and 
impulsiveness.4 The purpose of this paper is to review the current litera­
ture on atypical antipsychotic agents and b p d .
A systematic search was performed in Medline/ Current Contents/ Psych- 
Info for papers in English on atypical antipsychotics and b p d . We sought 
articles that included the key terms ‘Borderline Personality’ , ‘Antipsy­
chotic’ and the names of the atypical agents. We analysed a list of 16 1  ab­
stracts and selected, after a thorough examination of review papers, 14  
original reports. The articles were not subjected to any quality require­
ments for inclusion in this review.
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3. Results Table 1  gives an overview of published reports about treatment with atyp­
ical antipsychotics in b p d .
A uthor
A n tipsychotic
Agent,
Mean Dose 
(Range)
Design, Duration Num ber and T ype o f Patients
E ffect (Q uantita tive  E ffec t of 
Main O utcom e in Brackets)
Frankenburg e t al. 
(1993)
Clozapine, 253
m g/day
(75 -550 )
Open-label s tudy 
mean
fo llow  u p 4 .2  months
n = 15
BPD and psychotic disorder 
NOS (SCID I, DIB-R, DIPD-R)
Improvem ent in BPRS, CGI, GAS. (Mean 
BPRS-reduction 33 %
( t  = 7 .0 3 , p = 0.001))
Chengappa e t al. 
(1995)
Clozapine, 300 
m g/day Case rep o rt
n = 1
BPS w ith  psychotic com plaints 
(DSM -IIIR )
C linical im provem ent
Benedetti e t al. 
(1998)
Clozapine 43,8
m g/day
(25-100)
Open-label study; 4 
months
n = 12
BPD, psychotic -like  complaints 
(DSM -IV , SCID II)
Improvem ent in BPRS, HAM-D, 
CGI and GAF
Chengappa e t al. 
(1999)
Clozapine 421
m g/day
(30 0 -55 0 )
Case rep o rt
n = 7
BPD and axis I com orbidity 
(DSM  IV)
C linical and GAF im provem ent 
(79 %, p <0.02)
Sw inton
(2000)
Clozapine 4 0 0 ­
500 m g/day
R etrospective self 
rep o rt
n = 5, BPDconsensus 
diagnosis)
Less observed self-m utila tion  
and Hostile incidents
Schulz e t al. 
(1999)
Olanzapine 7.7 
± 2.6 m g/day
Open-label study, 8 
weeks
n = 11
BPS and dysthym ia 
(SCID P en II)
Improvem ent in BPRS, SCL-90, GAF, BIS-11, 
BDHI. (Mean 
BPRS-reduction 29 %
( t = 5.79, p < 0 .005)
Zanarini &
Frankenburg
(2001)
Olanzapine 5.3 
± 3.4 m g/day
Placebo contro lled 
double
blinded tr ia l; 6 
months
n = 28
BPS (19 olanzapine, 9 placebo) 
(DSM -IV , DIPD-R)
Improvem ent on several SC L-90 scales 
(e. g. ‘Anx iety ': z = 3.165, p = 0.002)
Hough
(2001)
Olanzapine 5 
m g/day Case rep o rt
n = 2
BPD, self m utila tion (1 w ith  
dysthym ic d isorder)
C linical im provem ent 
(no quan tita tive  data)
Szigethy & Schulz 
(1997)
Risperidone 2 
m g / day
Case rep o rt n = 1
BPD and dysthym ia
C linical and BPRS im provem ent (21%)
Bogenschutz &
Nurnberg
(2004)
Olanzapine 6.9 
± 3.2 m g / day
Placebo contro lled 
double
blinded tr ia l; 12 
weeks
n = 40
BPD (SCID-II)
Improvem ent on CGI-BPD
(p = 0 .03 ) (in  particu lar inappropriate anger)
Khouzam &
Donnelly
(1997)
Risperidone 4 
m g/day Case rep o rt
n = 1
BPD, self-m utila tion
C linical im provem ent 
(no quan tita tive  data)
Lai
(2001)
Risperidone 1,2 
m g/day 
(0 .8 -2 )
Case rep o rt n = 4BPD and depression
C linical im provem ent 
(no quan tita tive  data)
Rocca e t al. 
(2002 )
Risperidone 3.3 
± 0.5 m g/day
Open-label study, 8 
weeks
n = 15
BPD, aggression (SCID I en II)
Improvem ent in BPRS, HAM -D 
and GAF, AQ.
(Mean BPRS-reduction 21%
( t  = 4.19, p = 0.0003)).
H ilger e t al. 
(2003 )
Quetiapine 700 
m g/day
Case report n = 2
BPD, self-m utila tion
C linical im provem ent 
(no quan tita tive  data)
Abbreviations:
AQ = Aggression Questionnaire 
BDHI = Buss-Durkee H ostility  In terview 
BIS-11 = Ba rre tt Im pulsivity Inventory 
BPD = Borderline Personality Disorder 
BPRS = B rief Psych iatric Rating Scale 
CGI = Clinical Global impression Scale
CGI-BPD = Clinical Global Impression Scale m od ified fo r  Borderline Personality Disorder
DIPD-R; Revised Diagnostic In terview  fo r  Personality disorders
DSM -IV = Diagnostical and sta tistica l manual o f m ental disorders
GAF = Global Assessment o f Functioning
HAM -D  = Ham ilton ra ting  Scale fo r  Depression
SCID-1 = S tructura l In terview  fo r  th e  Diagnosis o f Axis I disorders
Table 1. Atypical antipsychotics in borderline personality disorder
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Clozapine
To date, two open population studies and three case reports have been 
published on clozapine treatment.11-15 Almost all of the patients had severe 
complaints such as aggression, self-mutilation and psychotic symptoms 
and had not responded to previous antipsychotic treatment.
Benedetti et al. described the decrease of severe psychotic-like com­
plaints in 12  b p d  inpatients after one month. A broad-symptom amelio­
ration, including mood and impulsive behaviours, was observed in 7 
patients after 16  weeks.11 The improvement of overall symptomatology was 
also found in a group of 15  neuroleptic-resistant psychotic b p d  patients.14 
Chengappa et al. reported a reduction in self-mutilation and aggressive 
behaviour in 7 b p d  patients with axis I co-morbidity.13 The decrease of hos­
tile incidents in a forensic centre agrees with these findings.15 Further­
more, a letter by Parker et al. retrospectively reports a decline in 
re-admissions in 8 b p d  patients (not included in Tablei).16
Risperidone
One open-label study described 15  outpatients with b p d  combined with ag­
gressive behaviour who were treated with risperidone for 8 weeks without 
a further psychotherapeutic approach. A decrease in depressive sympto­
matology and a broad general improvement was established. Two patients 
dropped out because of non-compliance, and mild side effects were noted 
such as insomnia, somnolence, anxiety, headache and nausea.17
Three case reports described a total of 6 patients with long histories of 
self-mutilation and depressive complaints, which improved in all cases.18-20
Preliminary data from a double-blind trial of risperidone were pre­
sented at the 1999 a p a  congress by Schulz et al., but so far no report on this 
study has been published.
Olanzapine
One case report, one open-label study and two double-blind placebo-con­
trolled trials have been published on olanzapine treatment.21-24
Hough et al. described the decrease of self-mutilation in two b p d  pa­
tients.22 In 1 1  patients with b p d  and dysthymia, a reduction of psychoti- 
cism, depression and anger was described after 8 weeks of olanzapine 
treatment.23
The first placebo-controlled study showed that olanzapine was associ­
ated with a statistically significant improvement on self-reported scales 
such as ‘anxiety’, ‘paranoia’ and ‘anger’ but not for ‘depression’.24 Results 
on other symptom scales were not mentioned. The (female) study popula­
tion was recruited through advertisements, which possibly implies a lower 
severity of the pathology in this study. The only reported side effects were 
minor sedation, constipation and a modest weight gain; no extrapyramidal 
side effects were observed.
Important discussion points of this r c t  are the small population and 
high dropout rate. After 4 weeks, the dropout rate for 19  patients on olan­
zapine and 9 patients on placebo was 11%  in both groups. After 6 months 
the dropout rates had increased to 58% and 90%, respectively.
Recently, a second r c t  was published which showed improvement on 
a modified Clinical Global Impression Scale, in particular on the d s m - i v  
criterion ‘Inappropriate Anger’.21 Secondary measures addressing depres­
sion, anxiety and aggression showed no difference between placebo and 
olanzapine. Twenty-three out of the 40 patients, all without co-medication,
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completed the full 12  weeks of the trial without serious side effects or ex­
trapyramidal symptoms. Again, there was a higher mean weight gain in 
patients treated with olanzapine (3.7 ± 3.4 kg).
Quetiapine
Hilger et al. described the successful impact of quetiapine treatment on 
severe self-mutilation in two b p d  patients.25 It is interesting to note that 
both patients received quetiapine for a longer period of time (6 and 8 
months) without side effects.
4. Discussion To date, 14  papers have been published on atypical antipsychotic treat­
ment in b p d . These include four open-label studies and just one ran­
domised placebo-controlled trial. No studies that compared classical and 
atypical antipsychotics could be found.
The heterogeneity of the study populations was considerable: in some 
case reports patients were severely ill; in one placebo-controlled study pa­
tients were recruited from the community by means of advertisements.24 
This makes it difficult to compare the results of the different studies and 
it underlines the wide differences between patients with b p d  in the clini­
cal practice.
Most studies have a relatively short follow-up. The dropout rates, 19  %23, 
13  %17 and 0 %11 are low in the open studies after 8 weeks. In the placebo­
controlled trial the dropout had increased after half a year. High dropout 
rates can influence the validity of the research findings, and can be in­
dicative of the difficulties of long-term pharmacological treatment in prac­
tice. An important question is whether long-term continuation therapy is 
appropriate, as this particular group of patients most frequently suffers 
from brief crises. The benefits of prophylactic treatment need be weighed 
against the risks of side effects due to chronic use.
A further problem is that most of the studies did not clearly indicate 
which treatment was given (pharmacological or psychotherapeutic) in ad­
dition to the study medication. This is a general discussion point in open­
label studies: in order to prove the effect of the study treatment, 
placebo-controlled studies are necessary. In open-label studies, the possi­
bility of information bias cannot be excluded, and positive effects can be 
caused by the statistical phenomenon of ‘regression to the m ean’. Fur­
thermore, positive findings from initial case reports should be interpreted 
with caution due to the possibility of publication bias.
Yet in spite o f these problem s, all o f the papers reported positive fin­
dings: impulsiveness, self-mutilation and psychotic complaints decreased. 
The effect of other psychotherapeutic and pharmacological treatments 
might have contributed to this result. Furthermore, it has been demon­
strated that hospitalisation is also an important factor.26 
The improvement in a broad-spectrum psychopathology, which is not re­
stricted to psychotic phenomena, is striking. This finding is consistent 
with previous placebo-controlled studies with classical antipsychotics. Of 
great interest is a recently postulated hypothesis suggesting the involve­
ment of dopamine dysfunction in impulsivity, emotional dysregulation 
and cognitive-perceptual impairment.27 This ‘dopamine dysfunction hy­
pothesis’ provides a framework for understanding the broad-spectrum ef­
ficacy of antipsychotics.
To date, only two placebo-controlled studies on atypical antipsychotics 
in b p d  have been published.21124 Care must be exercised when making
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5. Conclusion
statements about the effectiveness. The clinician’s choice between classi­
cal and atypical agents cannot be made on the basis of literature, due to a 
lack of comparative studies. An advantage of classical agents is the possi­
bility for depot treatment. The risks of extrapyramidal side effects need to 
be borne in mind, especially if maintenance treatment is considered. In 
the two r c t  with relatively low doses of olanzapine, no movement disor­
ders were reported.
A subgroup of borderline personality disordered patients with psychotic, 
impulsive and suicidal complaints might benefit from atypical antipsy­
chotics. Since the methodological quality of most of the articles reviewed 
is poor and the dropout rates were high, the positive findings should be 
viewed with caution. Comparative studies between atypical and classical 
antipsychotics are lacking. More randomised placebo-controlled follow- 
up studies in clearly defined (uniform) patient groups are necessary.
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Parti:
Schizophrenia
Comprising various studies investigating cognitive dysfunction in recent- 
onset schizophrenia and borderline personality disorder ( b p d ) ,  this the­
sis also details the effects various antipsychotics exert on the clinical 
phenotypes and cognitive deficits. In this chapter, the results o f the stu­
dies are summarized and put into a larger perspective, while suggestions 
for future research are given and implications for clinical practice dis­
cussed.
In Chapter 1  the main topics of the thesis are introduced and it is ex­
plained that psychiatry has evolved to a science that seeks to integrate neu­
roscience and medicine. Cognitive neuropsychiatry, the most influential of 
the present paradigms, seeks to find explanations for disordered beha­
viour in the context of impaired cognitive functions and hence looks for 
biological underpinnings for these phenomena. The studies on cognitive 
dysfunction included in this thesis have been conducted with a view to ad­
vancing this search for endophenotypes, the ‘building blocks’ of mental 
disorders.
Although cognitive neuropsychiatry has increased our understanding 
of the nature of psychiatric disorders, it has, as yet, not yielded any addi­
tional tests for use in clinical practice. Clinicians still diagnose and treat 
their patients on the basis of clinical signs and symptoms only. Chapter 1  
provides a bird’s eye view of the currently available treatment options for 
schizophrenia and b p d . Antipsychotics remain the cornerstone of the 
treatment of schizophrenia, although there is an ongoing debate about 
which antipsychotic to prescribe. In the treatment of b p d , psychotherapy 
is considered the treatment of choice, but supplementary symptom-tar­
geted pharmacotherapy is thought to provide adjunctive benefit. Next, the 
studies reported in Part I of the thesis that focus on recent-onset schizo­
phrenia are summarized and put into context.
In Part I of the thesis, the studies into cognitive deficits in recent-onset 
schizophrenia are described. The questions guiding the research were: Do 
recent-onset schizophrenia patients show psychomotor dysfunction? Do 
the second-generation antipsychotics olanzapine and ziprasidone improve 
their clinical symptoms as well as the cognitive deficit observed and do 
they do so differently?
Chapter 2 featured the results of our explorations into the motor be­
haviour of patients with early-stage schizophrenia. Using dedicated com­
puter software we were able to record the patients’ drawing movements 
and compare the kinematic data with a matched group of healthy volun­
teers. Previous studies had found psychomotor slowing in samples con­
sisting predominantly of patients with chronic schizophrenia.1 Since 
medication can have serious adverse effects on motor behaviour, we 
deemed our sample of patients with a lifetime exposure to antipsychotics 
of less than 16  weeks specifically suited for the exploration of motor be­
haviour. The movement data showed that our recent-onset patients 
needed more time to initiate the more complex, unfamiliar movements, 
but that they seemed to compensate this initial slowing by adopting a 
movement strategy that was characterized by an even higher velocity than 
employed by their healthy peers.
Together, the results indicate that in recent-onset schizophrenia psy­
chomotor slowing is not caused by a slowing of motor activity perse, which 
conclusion is in line with previous findings suggesting a pattern of poor 
allocation of attention to planning and a strong allocation of attention to
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motor execution.2 Accordingly, it is plausible to assume that psychomotor 
slowing results from deficient planning and lack of attention and appears 
to be related to the core cognitive deficit observed in schizophrenia.
Chapters j ,  4 and 5 describe the results of a double-blind, randomized 
clinical trial ( r c t )  comparing two second-generation (‘atypical’) antipsy­
chotics. In this multicentre research project, patients with recent-onset 
schizophrenia and schizoaffective disorder were either treated with olan­
zapine or with ziprasidone. The main goal of the combined studies was to 
explore the effects of the two agents on the patients’ clinical response and 
cognitive functioning. Many of the larger open studies were (potentially) bi­
ased owing to design- and chronicity-related factors.3 In our r c t , we tried 
to diminish the risk of bias by adopting a double-blind design and by in­
cluding patients in whom the onset of symptoms and associated pharma­
cotherapy were both recent.
In Chapter j  the clinical efficacy of an 8-week regimen of olanzapine and 
ziprasidone is discussed. Study dropout was sim ilar for the two antipsy­
chotics, as were their effects on the clinical symptom scales (e.g. the Posi­
tive and Negative Syndrome Scale ( p a n n s ) ,  the Calgary Depression Scale 
for Schizophrenia, and the Heinrich Quality of Life Scale). About two-thirds 
of the patients in both groups met the response criteria, defined as >20% 
improvement on the p a n s s , and one-third fulfilled the remission criteria 
as defined by Andreasen and colleagues.4 However, the drugs’ side-effect 
profiles did show considerable differences. The patients on ziprasidone 
more often used biperiden to ameliorate extrapyramidal side effects, 
whereas the patients on olanzapine manifested symptoms of the meta­
bolic syndrome and more often an increase of liver transaminases. Most 
prominently, the mean weight gain in the olanzapine group was 6.8 kg 
after 8 weeks of treatment, while this was only 0 .1 kg in the patients treated 
with ziprasidone.
Supported by their suggested positive effects on negative and cognitive 
symptoms, soon after their introduction at the end of the 20th century the 
second-generation antipsychotics were adopted in the clinical practice 
guidelines for schizophrenia. The prevalence of the debilitating ex­
trapyramidal side effects o f ‘classical antipsychotics’ had substantially de­
creased, but the novel antipsychotics generated a different type of adverse 
effect profile: the metabolic syndrome. The metabolic syndrome is a con­
stellation of cardiovascular risk factors linked by insulin resistance, which 
include obesity, dyslipidemia, glucose tolerance and hypertension.5 As the 
cardiovascular risk is already higher in this population due to heavy smo­
king, low treatment adherence for somatic medication, reduced access to 
medical care, and a higher prevalence of diabetes, it is estimated that the 
life expectancy of chronic patients is 20% lower than that for the general 
population, with two-thirds of schizophrenia patients dying of cardiovas­
cular incidents.6 Charting the impact of any additional metabolic risk with 
olanzapine treatment is, therefore, highly relevant.
Chapters 4 and 5 report on the 8-week effects of olanzapine and ziprasi­
done on the cognitive performance of our recent-onset schizophrenia pa­
tients. For this purpose a cognitive assessment battery of validated tests 
was composed to gauge a variety of cognitive domains. Both agents showed 
a similar improvement on the cognitive outcomes, with moderate effect 
sizes. The cognitive enhancement we recorded was unrelated to the im­
provement in clinical symptoms and comparable with the improvement 
rates reported in other recent studies.7-9 Our findings were also consistent
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with two studies of chronic patients that also failed to find a differential 
effect for the two antipsychotics.10;11
Our study protocol gave us the opportunity to switch patients blindly to 
the other antipsychotic after eight weeks in case of insufficient clinical re­
sponse or too many adverse events. Our 8-week follow-up assessment com­
prising the same test battery demonstrated that the drug crossover had not 
led to any further improvement in cognitive performance. The patients 
that responded well to the initial drug and continued their treatment also 
did not improve further on the cognitive tasks, which pattern was consis­
tent with the literature on patients with chronic schizophrenia. Together, 
these results suggest that any cognitive improvement takes place in the 
first eight weeks of antipsychotic treatment and thereafter remains con­
stant irrespective of the choice of drug.
For a correct interpretation of the results, it is important to once more 
stress the strengths andweaknesses ofthe study protocol we adhered to in 
the trials reported in Chapters 3, 4 and 5. We adopted rather strict inclu­
sion criteria for duration of illness and previous medication use to thus 
avoid potential bias resulting from effects of long-term medication or over­
representation of therapy-resistant patients, for instance. Although this is 
a methodological strongpoint of our study design, one should take into ac­
count that our patients are hence not representative of the entire popula­
tion of schizophrenia patients. Further, due to our stringent criteria the 
total number of patients we were able to include in our study was inevitably 
quite low in comparison to other recent larger-scale studies into first- 
episode12 and chronic patients.3;12 The risk of a type-II error in our studies 
therefore is real.
Taken together, the results from the studies described in Chapters 4 
and 5 contribute to the emerging body of literature demonstrating there 
are no differences between the second-generation antipsychotics in their 
beneficial effects on cognition in recent-onset schizophrenia.7;9;13
Suggestions fo r  future research 
The nature of the core cognitive deficit in schizophrenia merits closer 
scrutiny, because in this syndrome the cognitive symptoms are mostly as­
sociated with functional outcome. However, a major problem in this area 
of research is that the findings tend to lack specificity: many patients with 
other disorders, but healthy controls as well, show the same cognitive 
deficits. One should bear in mind that most of the traditional, widely used 
neuropsychological tests were specifically developed for patients with se­
vere brain lesions and not the more subtle deficits in psychiatric disorders. 
The cognitive tests like the ones described in Chapters 4 and 5 do not ne­
cessarily provide a deeper understanding of the pathophysiology of schiz­
ophrenia, but do afford a practical and accurate evaluation of the effects of 
particular treatments on cognition.
Certain tasks that assess specific cognitive functions while the brain is 
‘in action’ may give us more fundamental insight, such as the psychomotor 
tasks described in Chapter 2 and the e e g  paradigms used in Chapters 7 and 
8. The deficit we found in the patients’ writing movements warrants further 
research that can link our kinematic data to neuroimaging results (e.g. e e g  
or fMRi). Hopefully, advances in neuroimaging techniques will allow us to 
target cognitive functions more accurately and discretely by tests gauging 
more domain-specific activities that are less sensitive to practice effects,14 
or by providing other ways to assess the functionality of the brain.
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Part II: 
Borderline 
Personality 
Disorder
Apart from our ongoing search for underlying causes in and more ef­
fective treatments for patients, future research should also take high-risk 
groups (e.g. siblings) into account. For a better understanding of the ge­
netic factors involved in cognitive dysfunctioning it is important to test as 
yet healthy siblings as well, while possibilities to prevent the onset of schiz­
ophrenia in this group also need exploration.
Antipsychotics are effective in the treatment of psychotic episodes, but 
they do not sufficiently improve cognitive dysfunction.15 New classes of 
drugs that combat these latter symptoms are therefore indispensable and 
there are some hopeful new targets, such as g a b a  interneuron function, 
dopamine D i receptor stimulation, and glutamate system potentiation.16
Clinical recommendations 
Antipsychotics are effective in the treatment of psychotic episodes of pa­
tients with schizophrenia. Nevertheless, for many patients treatment ad­
herence remains a major problem due to the drugs’ side effects, among 
which are unpleasant subjective feelings. Community care models with an 
assertive treatment approach can improve medication adherence 
(amongst other effects).17 Together, clinicians and patients can decide on 
the best choice of treatment based on the drugs’ side-effect profiles and 
the patient’s medical history. The possible metabolic complications of an­
tipsychotics, such as described in Chapter 3 of this thesis, should be com­
municated carefully and monitored regularly.
The studies on olanzapine and ziprasidone presented in this part of the 
thesis do not allow clinical recommendations on the basis of their an­
tipsychotic efficacy, which was comparable. However, since they have very 
different clinical side-effect profiles, the various adverse effects should be 
carefully considered before prescribing either. Because of its metabolic 
profile, olanzapine should not be the drug of choice for patients with a 
first-episode psychosis.
At present, few clinicians see improving the patient’s cognitive deficit is 
as a primary treatment target, despite its correlation with functional out­
come. Given the evidence of their efficacy,18 cognitive remediation pro­
grammes should, however, also be considered as a complementary 
treatment option.
Finally, as schizophrenia has a very high genetic load, clinicians should 
pay more attention to potential clinical and cognitive symptoms in first- 
degree relatives. Unfortunately, the (cost) effectiveness of preventing psy­
choses and hospitalization with programmes designed to identify 
individuals at high risk of developing psychiatric problems is not well es­
tablished,19-21 even though they are likely to yield benefits through family 
education and monitoring and treatment of pre-psychotic symptoms such 
as social phobia.
In Part II of the thesis the studies we conducted into the cognitive deficits 
and effects of antipsychotics in patients with borderline personality dis­
order ( b p d )  are presented. Our investigations focused on two topics: Does 
the cognitive performance of patients with b p d  resemble that of schizo­
phrenia patients and are patients with psychotic-like symptoms more 
prone to cognitive deficits? The research questions we posed were: Do pa­
tients with b p d  show aberrant cognitive performance in antisaccades, sen­
sorimotor gating and in action monitoring? And what is the efficacy of 
various second-generation antipsychotics for this patient group?
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In Chapters 6, y and 8 the exploratory studies of the biological correlates in 
b p d  are discussed. The aim of the study described in Chapter 6 was to exa­
mine whether patients with b p d  have deficits in cognitive inhibition as 
measured with an antisaccade eye task sim ilar to those observed in pa­
tients with schizophrenia. We found that our schizophrenia patients pro­
duced more inhibition errors than the b p d  patients and the matched 
healthy controls, with the scores of the b p d  group lying in between those 
of the two comparison groups. Interestingly, the data suggested that inhi­
bition deficits may be characteristic of b p d  patients with psychotic-like 
symptoms.
There is ample literature describing the cognitive processes involved in 
the generation of antisaccadic eye movements.22 Both the dorsolateral pre- 
frontal cortex ( p f c )  and the (posterior) anterior cingulate cortex (a c c )  play 
an important role in the decision processes guiding the control of ocular 
motor behaviour. Results from both imaging and selective lesion studies 
confirm that the two regions can independently induce inhibition er­
rors.22-24 The inhibition deficit we found was distinct from a general pre­
disposition to respond impulsively, as was reflected in the patients’ fast, 
anticipatory errors; this applied to all b p d  patients we examined.
In Chapter y  we explored whether sensory-gating deficits (P50 gating 
and prepulse inhibition of the startle response) would be present in b p d  
patients to a sim ilar extent as it is in schizophrenia. Sensory gating is a 
preattentive inhibitory (‘filter’) mechanism that prevents the brain from 
being overtaxed by sensory input.25 Our data showed that in our b p d  sam­
ple sensory motor gating was intact. In contrast to our hypothesis, the pa­
tients did not show lower but even higher gating of the P50, N100, and P200 
amplitudes than their comparison group. We attributed the unexpected 
higher early (preattentive) and mid-latency evoked potentials to the pa­
tients’ higher response tendencies possibly related to the impulsive b p d  
phenotype. Although at this stage we cannot draw any firm conclusions 
since our findings need replication with a control sample of schizophrenia 
patients, it seems unlikely that b p d  patients have deficits in sensory gating.
In Chapter 8 we investigated whether the impulsive response style of our 
b p d  patients was associated with diminished action monitoring. To this 
end, we measured the error-related negativity ( e r n ) ,  an event-related po­
tential ( e r p )  component generated in the a c c  following erroneous re­
sponses.26 We compared the patients’ behavioural outcomes and e r p  
readings during their performance on a speeded two-choice reaction task 
to the data recorded for a group of matched controls. The e r p  results 
showed that e r n  amplitudes were reduced in the patients, as were the 
P300 amplitudes after late feedback. Additionally, our analyses on post­
error congruency effects demonstrated that the healthy controls had ad­
justed their behaviour following errors, whereas the patients had not. The 
patients’ attenuated e r n s  may indicate that the a c c , or the network it is 
part of, is not functioning optimally. We venture that, due to this reduced 
action monitoring, patients with b p d  do not learn as well from their errors 
as their healthy peers. They, consequently, do not adjust their behaviour 
when necessary and hence persist in their impulsive response style. Our 
findings of an attenuated e r n  in b p d  has been replicated by others.27
The results of Chapters 6 and 8 fit in well with recent hypotheses on the 
neurobiological basis of borderline personality. There is considerable e­
vidence to suggest that a dysfunctional frontolimbic network is the key fea­
ture in b p d .28-31 The a c c  is thought to play a role in the regulation of
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emotions and to have a modulating effect on the amygdala.32 The pre- 
frontal cortex and particularly the a c c  have been associated with b p d  pre­
viously: structural m r i  showed reduced total volume of the frontal lobe33 
and of the a c c  in particular,34 while numerous studies evidenced that me­
tabolism  in the p f c  and the a c c  was reduced relative to the values ob­
tained in healthy controls.34-36
Several studies reported structural as well as functional abnormalities 
in the amygdala in b p d . Although some failed to find significant diffe­
rences,37-39 the majority of structural studies recorded significant amygdala 
volume reductions in patients.34;40-42 Using fMRi, Herpertz and colleagues 
found increased blood-oxygen level-dependent responses in the bilateral 
amygdala in response to negative affective stimuli in their b p d  sample,43 
while Donegan and colleagues recorded enhanced left-sided amygdala re­
activity in response to emotional faces, regardless of their specific valence.44
Moreover, several recent imaging studies designed to manipulate emo­
tional content successfully showed simultaneously elevated right amyg­
dala and attenuated rostral a c c  activation during b p d  patients’ responses 
to fearful faces relative to the values recorded following neutral faces.45 At­
tenuated activations in the ventral mPFc, medial orbitofrontal cortex, and 
the subgenual a c c  were also found during the response inhibition to 
words of negative valence.30 Patients with a borderline personality accord­
ingly show a combination of an exaggerated response in the amygdala and 
an impaired modulating effect of the a c c .
In Chapter g the literature on the effects of antipsychotics in the treat­
ment of b p d  is reviewed with a focus on the efficacy of second-generation 
agents. Although still in its infancy, the available literature does suggest 
that b p d  patients with psychotic-like, impulsive or suicidal symptoms 
might benefit from the second-generation drugs.
Our conclusions underscore the experiences of clinicians working in 
this field, many of whom find that subgroups of b p d  patients benefit from 
treatment with the novel antipsychotics. This view is also supported by a re­
cent meta-analysis.46 However, the pharmacological mechanism of action 
for these antipsychotics in b p d  is not well understood. Recent reports 
found novel antipsychotics to not only have antipsychotic but also antide­
pressive properties in patients with bipolar disorder.47 These mood-stabi­
lizing properties of second-generation antipsychotics may possibly 
ameliorate b p d  symptoms as well. In addition, antipsychotics also have 
anxiolytic effects and may therefore attenuate anxiety- and stress-related 
symptoms. However, most treatment studies so far looked into the shorter- 
term effects of the various antipsychotics. Further randomized placebo­
controlled studies with longer follow-ups are hence needed before any firm 
conclusions can be drawn. Clinicians know that many patients have great 
difficulty adhering long-term to antipsychotic therapy because of the va­
rious serious side effects or a subjective discomfort with or resistance to 
medication.
The clinical practice has also seen advances in the psychotherapeutic 
treatment of b p d  in the last two decades. There are several evidence-based 
psychotherapeutic treatment programmes thatwere successful in managing 
the key symptoms of the disorder.48-50 At present, pharmacological treatment 
seems to be mainly adjunctive to psychotherapeutic interventions. In fact, 
in their recent study, Linehan and colleagues showed superior efficacy 
of olanzapine over placebo when the drug was combined with dialectical 
behaviour therapy.51
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Suggestions fo r  future research 
To date, most studies into borderline personality d isorder-such  as the 
ones reported in this thesis -  have been exploratory. However tentative, the 
findings are certainly interesting and merit further research in larger, bet­
ter-defined patient samples. Today, b p d  is subject to a paradigm shift: 
whatwas once seen as a psychoanalytic concept for untreatable patients is 
now increasingly regarded as a ‘potentially treatable brain disease’.52 Still, 
the literature on b p d  is an amalgam of psychotherapeutic concepts, treat­
ment options, and possible endophenotypes, all of which will hopefully 
be integrated in the near future. Undoubtedly, much of the confusion is 
related to the very heterogeneous phenotype of the syndrome in the cur­
rent d s m - i v  classification. It is therefore crucial for researchers to target 
relevant trait dimensions such as emotional instability, impulsivity and 
psychotic-like symptoms.29 The next d s m  b p d  classification should do jus­
tice to the multidimensional nature of the symptom complex. A narrower 
definition of the syndrome and an accurate delineation of patient samples 
would also help neurobiological research and psycho- and pharm a­
cotherapy studies to gauge effects on specific symptoms. When b p d  sub­
populations were to be better defined (e.g. if patients were to be 
characterized as ‘unstable affect’, ‘high impulsivity’, or ‘severe identity dis­
turbance’), research and treatment options could possibly benefit from re­
search developments in disorders such as schizophrenia, bipolar disorder, 
attention deficit hyperactivity disorder, or post-traumatic stress disorder.
If we are to unravel the complex pathophysiology of b p d , research 
groups from various disciplines should clearly combine their efforts. 
Larger-scale ‘imaging genetics’ studies, combining genetics, endopheno­
types and clinical characteristics, will substantially improve our under­
standing of the syndrome, as has happened in other disorders, among 
which schizophrenia. As remarked in relation to genetics research in schi­
zophrenia in Part I of the thesis, such projects should not only include re­
cently diagnosed or confirmed chronic b p d  patients, but also high-risk 
populations, such as their first-degree relatives or people with early-life 
traumas. The antisaccade and error-monitoring paradigms as used in se­
veral of the studies compiled in this thesis are good candidates for en- 
dophenotyping.
Clinical recommendations 
The combined results of our studies on borderline personality disorder in­
dicate that, like in schizophrenia, cognitive deficits are also manifest in 
this syndrome. We cautiously conclude that a reduced inhibition and an 
impaired ability to learn form errors may underlie some of the key symp­
toms as well as the poor treatment response in b p d  patients. If patients, 
their family, and both formal and informal caregivers are adequately in­
formed about the nature of the disorder, this may help to avoid the nega­
tive (countertransference) reactions sometimes seen in professional or lay 
caregivers.
Finally, there are indications that patients with b p d  may benefit from 
second-generation antipsychotics. However preliminary these results are, 
the current guidelines do need updating since they still recommend first­
generation antipsychotics only53 or even reject the use of antipsychotics 
for medium or long-term use all together.54
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What do 
schizophrenia 
and borderline 
personality 
disorder have 
in common?
Although our studies of schizophrenia and b p d  presented in this thesis 
were not designed for direct comparison, it is still interesting to look at the 
similarities and dissimilarities in the two syndromes both from a clinical 
and from a neurobiological perspective.
The stereotypic signs and symptoms of schizophrenia and b p d  are dis­
tinct from each other, although a subgroup of b p d  patients, i.e. those dis­
playing a cognitive deficit, does resemble the schizophrenia phenotype. 
Moreover, for both patient groups the efficacy of antipsychotics has been 
established in clinical trials and the clinical practice. Perhaps the diffe­
rentiation of Axis-I and Axis-II disorders in the present d s m - i v  classifica­
tion needlessly widens the gap between the two diagnoses.
From a neurobiological point of view, the two disorders also possibly 
share certain commonalities. Friedel postulated a dopamine hypothesis 
to explain emotional dysregulation, impulsivity, and cognitive-perceptual 
impairments in b p d . The hypothesis is supported by the disturbed reac­
tions of patients in dopaminergic challenge studies.55 Although the results 
detailed in this thesis do indicate that both b p d  and recent-onset schizo­
phrenia patients show deficits in the antisaccade and e r n  paradigms,56157 
this type of evidence is only circumstantial. Similarities in cognitive out­
comes do not necessarily mean that the patient groups share a common 
pathophysiology. In our study presented in Chapter 7, for instance, we 
failed to find any evidence of b p d  patients having the fundamental preat- 
tentive sensory-gating deficits in common with schizophrenia patients and 
their relatives, in whom the deficiency is well established.
Head-to-head comparisons of the cognitive performance of patients 
from different diagnostic categories are likely to provide more insight into 
the underlying pathology of the disorders, possibly more so than compa­
risons with healthy controls. Such comparative studies and trials using 
state-of-the-art genetic and imaging techniques are indispensable to help 
us gain a better understanding of the neurobiological underpinnings of 
complex psychiatric disorders and thus improve psychiatric care.
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Cognitief 
disfunctioneren 
en effecten van 
antipsychotica 
bij schizofrenie 
en borderline 
persoonlijk­
heidsstoornis
Deel I: 
schizofrenie
In dit proefschrift worden verschillende studies beschreven naar het cog­
n itief functioneren van patiënten m et schizofrenie en borderline per­
soonlijkheidsstoornis ( b p s ) .  Daarbij kom en de effecten aan bod van 
antipsychotica op zowel klinische als cognitieve sym ptom en. Dit hoofd­
stuk is een sam envatting van de resultaten, waarbij wij deze ook in een bre­
der perspectief bekijken. Verder volgen er suggesties voor nader onderzoek 
en een bespreking van klinische im plicaties .
Hoofdstuk i  is een beschrijving van de hoofdth em a’s van dit proef­
schrift. De psychiatrie heeft zich ontwikkeld tot een discipline die neuro­
w etenschappen en geneeskunde integreert. Cognitieve neuropsychiatrie, 
het op dit m om ent m eest invloedrijke hedendaagse paradigm a, probeert 
verklaringen voor afwijkend gedrag te vinden vanuit verstoorde cognitieve 
functies en de onderliggende biologische fundam enten. De in dit proef­
schrift beschreven studies zijn uitgevoerd m et het oog op deze zoektocht 
naar de ‘bouw stenen van psychiatrische stoornissen’: endophenotypes.
Hoewel de cognitieve neuropsychiatrie ons begrip van de aard van psy­
chiatrische stoornissen heeft verbeterd, heeft het vooralsnog niet geleid 
tot testen voor de klinische praktijk. Clinici diagnosticeren en behande­
len nog steeds op basis van klinische symptomen.
Hoofdstuk 1 geeft in vogelvlucht een overzicht over de bestaande ken­
nis van de pathofysiologie, de sym ptom en en behandelopties van 
schizofrenie en borderline persoonlijkheidsstoornis.
Deel I van dit proefschrift beschrijft studies naar cogn itief disfunctione­
ren van beginnende schizofrenie. Dit zijn de onderzoeksvragen: vertonen 
patiënten m et beginnende schizofrenie afw ijkingen in de psychom oto- 
riek? Kunnen de tweede-generatie-antipsychotica olanzapine en ziprasi- 
done de klinische sym ptom en en het cognitieve functioneren verbeteren, 
en is er verschil tussen beide geneesm iddelen?
In hoofdstuk 2 kom en de resultaten aan bod van onze exploratie van het 
m otorisch gedrag van patiënten m et beginnende schizofrenie. M et behulp 
van specifieke com putersoftware konden we schrijf- en tekenbewegingen 
van patiënten opnem en en vergelijken m et een gem atchte groep gezonde 
leeftijdgenoten.
Het onderzoek naar psychom otore vertraging is gedaan in een patiën­
tengroep waarin de blootstelling aan m edicatie nog van korte duur was. 
Bij eerdere studies werd psychom otore vertraging gevonden in groepen 
m et hoofdzakelijk schizofreniepatiënten in een vergevorderd stadium .1 
M edicatie kan forse (extrapiram idale) invloed hebben op m otorisch 
gedrag. Om  die reden leek onze patiëntenpopulatie m et een zeer korte 
blootstelling aan antipsychotica (levenslang m inder dan 16 weken) uiter­
mate geschikt om m otorisch gedrag te bestuderen. De bewegingsgegevens 
lieten zien dat in tegenstelling tot chronische patiënten onze patiënten 
m eer tijd nodig hadden om complexe, voor hen nieuwe bew egingen uit te 
voeren. Maar zij com penseerden de initiële vertraging m et een juist hogere 
snelheid dan hun gezonde leeftijdgenoten.
Samengevat geven deze resultaten aan dat de psychom otore vertraging 
niet wordt veroorzaakt door motorische vertraging per se, m aar eerder een 
patroon suggereren van verm inderde toekenn in g van aandacht aan de 
planning en m eer aan de m otorische uitvoering.2
In de Hoofdstukken 3 ,4  en 5 beschrijven we de resultaten van een dub­
belblind, gerandom iseerd, klinisch onderzoek waarbij twee verschillende 
tweede-generatie-antipsychotica m et elkaar vergeleken worden. In dit on-
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derzoeksproject werden patiënten m et beginnende schizofrenie en schizo- 
affectieve stoornis behandeld m et olanzapine ofwel ziprasidone. Hoofd­
doel van de studies was het effect te beoordelen van de twee 
geneesm iddelen op de psychiatrische sym ptom en en het cognitief functi­
oneren. Veel grote open studies zijn (potentieel) verstoord door factoren 
gerelateerd aan het onderzoeksdesign en de ziekteduur van de deelne­
m ende patiënten.3 In ons onderzoek verm inderen we het risico hierop 
door een dubbelblinde onderzoeksopzet te kiezen en enkel patiënten met 
beginnende schizofrenie te includeren. Het zijn patiënten die nog geen of 
pas sinds kort m edicijnen gebruikten.
Hoofdstuk 3 is een beschrijving van de klinische effecten van een acht- 
weekse behandeling m et olanzapine en ziprasidone. De studie-uitval was 
gelijk voor beide onderzoeksgroepen, evenals de effecten op klinische 
sym ptoom schalen (zoals de Positive and Negative Syndrome Scale 
(PANNS), de Calgary Depression Scale for Schizophrenia, en de Heinrich 
Quality o f Life Scale). Ongeveer tweederde van de patiënten in beide groe­
pen voldeden aan de vooraf opgestelde criteria voor klinische respons, ge­
definieerd als >20% verbetering op de p a n s s , en eenderde voldeed aan de 
rem issiecriteria opgesteld door Andreasen en collega’s.4 Als het gaat om 
bijwerkingen zijn daarentegen aanm erkelijke verschillen te zien. M et zi- 
prasidone behandelde patiënten gebruikten vaker biperideen ter verbete­
ring van de extrapiramidale bijwerkingen. Patiënten m et olanzapine lieten 
kenm erken van het m etabool syndroom zien en hadden vaker stijging van 
de levertransam inasen. M eest opvallend was de gem iddelde gewichtstoe- 
nam e van 6,8 kg na 8 w eken behandeling m et olanzapine, terwijl dit 
slechts 0,1 kg was bij patiënten behandeld m et ziprasidone.
Tweede-generatie-antipsychotica w erden kort na hun introductie aan 
het eind van de twintigste eeuw opgenom en in de klinische richtlijnen, 
m ede door het gesuggereerde positieve effect op negatieve en cognitieve 
symptomen. Extrapiramidale bijwerkingen kwam en bij tweede-generatie- 
antipsychotica substantieel m inder vaak voor dan bij de ‘k lassieke’ an- 
tipsychotica, m aar een andere type bijw erkingenprofiel dook op: het 
m etabool syndroom. Dit is een constellatie van cardiovasculaire risicofac­
toren gelieerd aan insulineresistentie, onder meer obesitas, dyslipedemie, 
hyperglycaem ie en hypertensie.5 De levensverw achting van schizofre- 
niepatiënten is bij chronische patiënten al 20% lager dan voor de algemene 
populatie. M aarliefst tweederde van de schziofreniepatiënten sterft aan 
hart- en vaatziekten, door risicofactoren zoals roken, verminderde toegang 
tot gezondheidsdiensten en verhoogde kans op suikerziekte.6 De im pact 
van elk extra m etabool risico door behandeling m et olanzapine is daarom 
zeer relevant.
Hoofdstukken 4 en 5 beschrijven de effecten op het cognitief functione­
ren na 8 weken behandeling m et olanzapine en ziprasidone bij patiënten 
m et beginnende schizofrenie. Voor dit doel werd een cognitieve testbatte­
rij m et gevalideerde taken sam engesteld om zo een variëteit aan cognitieve 
dom einen te kunnen beoordelen. Beide geneesm iddelen lieten een soort­
gelijke verbetering van de cognitieve uitkom stm aten zien m et een rede­
lijke effectgrootte. De w aargenom en cognitieve verbetering was niet 
gerelateerd aan de klinische sym ptom en en was vergelijkbaar m et resul- 
tatenvan recente onderzoeken.7-9 Onze bevindingen waren ook consistent 
m et resultaten van twee eerdere studies bij chronische patiënten waarin 
ook geen verschillen werden vonden tussen deze twee antipsychotica.10;11
Het onderzoeksprotocol gaf ons de unieke m ogelijkheid om  patiënten
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dubbelblin d over te zetten op het andere antipsychoticum  als er na 8 
w eken een onvoldoende klinische respons was o f als er te veel bijwerkin­
gen waren. De herbeoordeling m et dezelfde testbatterij na w eer 8 weken 
lietgeen  enkele verdere verbetering zien op de cognitieve functietaken. De 
patiënten die direct goed reageerden op antipsychotica en hierm ee 
doorgingen lieten ook geen additionele verbetering zien na 8 weken, het­
geen consistent is m et de literatuur. Deze resultaten suggereren dat cog­
nitieve verbetering plaatsvindt in de eerste 8 w eken van de behandeling 
m et een antipsychoticum  en hierna constant blijft onafhankelijk van de 
keuze van het geneesm iddel.
Om  de resultaten op waarde te kunnen schatten is het goed om  de 
sterke en zwakke kanten van ons onderzoeksprotocol uit hoofdstukken 
3,4, en 5 op een rij te zetten. Om  vertekening van de resultaten te 
voorkom en hanteerden wij strikte voorwaarden voor deelname van patiën­
ten. Daarbij w aren ziekteduur en voorheen voorgeschreven m edicatie 
belangrijke criteria. Op die m anier is ‘b ias’ voorkom en van langeterm ijn­
effecten van m edicatie en overrepresentatie van bijvoorbeeld chronische, 
therapieresistente patiënten. Hoewel dit een m ethodologische kracht is 
van ons onderzoeksdesign, is hierdoor onze onderzoekspopulatie m inder 
representatief voor de totale populatie schizofreniepatiënten. Het totaal 
aantal patiënten dat we hierdoor konden includeren was lager dan in 
enkele recente, groot opgezette studies.
Samengevat, de resultaten van hoofdstukken 4 en 5 dragen bij aan een 
beginnende literatuur die laat zien dat er w einig verschillen zijn tussen an- 
tipsychotica onderling in de mate van positieve effecten op cognitie.7;9;12
Suggesties voor nader onderzoek 
Verder onderzoek kan m eer duidelijkheid scheppen over de aard en oor­
zaak van het cogn itief disfunctioneren bij schizofrenie. Het zijn ju ist de 
cognitieve sym ptom en, zoals geheugen- of concentratieproblem en, die 
im pact hebben op bijvoorbeeld werk of relaties van patiënten. Een groot 
probleem  in dit onderzoeksgebied is het gebrek aan specificiteit: veel pa­
tiënten m et andere stoornissen m aar ook gezonde vrijwilligers laten de­
zelfde cognitieve beperkingen zien. We m oeten beseffen dat de m eeste 
traditionele neuropsychologische taken zijn  ontw ikkeld voor het testen 
van patiënten m et hersenlaesies en niet de som s subtielere afwijkingen 
bij psychiatrische stoornissen. De cognitieve tests zoals in hoofdstuk 4 en
5 werden beschreven, geven niet zozeer een beter begrip van de pathofysi- 
ologie van schizofrenie. Het zijn wel praktische en accurate instrum enten 
om de effecten van m edicatie op cognitie te meten.
Taken die zeer specifiek cognitieve functies beoordelen terwijl het brein 
‘in actie’ is, zoals de psychomotore taken in hoofdstuk 3 en de EEG-taken in 
hoofdstukken 7 en 8, geven ons w ellicht een fundam enteler inzicht. De 
afwijkingen die we vonden in de schrijfbewegingen, vragen om nader on­
derzoek. Daarbij is het interessant om kinem atische data te koppelen aan 
beeldvorm ende onderzoek (bijvoorbeeld e e g  o f fMRi). H opelijk gaan de 
technische vorderingen in neuroimaging ons specifiekere en gerichtere cog­
nitieve functietests opleveren die m inder gevoelig zijn voor oefeneffecten.13
Naast het voortgaande onderzoek naar onderliggende oorzaken en ef­
fectieve behandelingen bij patiënten m oet toekom stig onderzoek ook 
groepen m eenem en m et een verhoogd risico op schizofrenie, zoals bloed­
verwanten. Voor een beter begrip van de genetische invloed op het cogni­
tief functioneren is het zaak om gezonde bloedverwanten te testen. Daarbij
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is h etvan  belang om  m ogelijkheden te onderzoeken om  het ontstaan van 
schizofrenie voor te zijn.
Antipsychotica zijn effectief in de behandelingvan psychotische episo­
des, m aar zijn niet voldoende in staat om het cognitief disfunctioneren te 
verbeteren.14 Nieuwe soorten m edicijnen die deze sym ptom en behande­
len zijn onontbeerlijk. Er zijn een aantal veelbelovende farm acologische 
ontw ikkelingen gaande gericht op GABA-interneuronfunctie, dopamine- 
Di-receptorstim ulatie en glutam aat-systeem -potentiering.18
Klinische aanbevelingen 
Antipsychotica zijn effectief in de behandelingvan psychotische episoden 
van schizofrenie. Een groot probleem  is echter de therapietrouw door bij­
werkingen zoals gewichtstoenam e, m otorische bijwerkingen en een sub­
je ctie f gevoel van onbehagen.14 M et behulp van zorgm odellen m et een 
actieve rol van hulpverleners zoals assertive community treatment kan 
(onder meer) therapietrouw verbeteren.15
Patiënten en psychiaters zouden in gezam enlijkheid moeten besluiten 
welk antipsychoticum de beste keuze is, op basis van een bijwerkingenprofiel 
en de medische voorgeschiedenis van de patiënt. De mogelijke metabole com­
plicaties zoals beschreven in hoofdstuk 3 moeten patiënten duidelijk zijn en 
geregeld worden gecontroleerd tijdens een lopende behandeling.
De studies die olanzapine en ziprasidone vergelijken in dit proefschrift 
leiden niet tot aanbevelingen voor één van beide geneesm iddelen op basis 
van klinische effectiviteit, die gelijk was voor beide m iddelen. Echter, het 
zeer verschillende bijw erkingenprofiel m oet in overwegingen w orden 
genom en bij het voorschrijven. Vanwege het riskante m etabole profiel lijkt 
olanzapine niet het voorkeurspreparaat voor patiënten m et een eerste psy­
chotische episode.
W einig clinici zien het cognitieve defect als de primaire behandeldoel- 
stelling, ondanks het feit dat dit sterk gecorreleerd is m et de functionele 
uitkomst. Gezien het aangetoonde effect zouden cognitieve revalidatie-pro- 
gram m a’s overwogen moeten worden als complementaire behandelopties.
Ten slotte, schizofrenie heeft een grote genetische com ponent.16 In de 
zorg zou m eer aandacht besteed kunnen worden aan m ogelijke cognitieve 
en klinische sym ptom en bij fam ilieleden van patiënten. Helaas is de kos­
teneffectiviteit van program m a’s om  m ensen m et een verhoogd risico op 
te sporen niet vastgesteld, bezien vanuit het voorkóm en van psychosen en 
verm inderen van opnam edagen in het ziekenhuis.17-19 De voordelen van 
zulke program m a’s zijn echter ook op andere vlakken duidelijk, zoals tij­
dige en adequate fam ilie-educatie en beh an d elin gvan  prepsychotische 
symptomen, zoals sociale fobie.
Deel II:
Borderline 
persoonlijk­
heidsstoornis
In deel II van dit proefschrift staan de onderzoeken centraal die gericht 
zijn op het cognitieve functioneren en de effecten van antipsychotica bij 
patiënten m etborderline persoonlijkheidsstoornis ( b p s ) . De vraagstellin­
gen waren op een aantal them a’s gericht: Laten patiënten afwijkingen zien 
in het cognitief functioneren bij de verschillende paradigm a’s antisacca­
des, sensorimotorgatingen action monitoring? Zijn er overeenkom sten tus­
sen patiënten m et b p s  en schizofrenie? Zo ja , zijn  er m eer cognitieve 
afw ijkingen te vinden in de subgroep van patiënten m et zogenaam de 
pseudo-psychotische sym ptom en, zoals dissociatie en aan stress gebon­
den gestoorde realiteitstoeting en hallucinaties? W at is het effect van de 
verschillende tweede-generatie-antipsychotica bij b p s ?
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Hoofdstukken 6 ,y  en 8 beschrijven verschillende exploratieve studies naar 
biologische correlaten bij b p s . In hoofdstuk 6 komt de vraag aan de orde of b p s  
patiënten evenals schizofreniepatiënten een verminderde cognitieve inhibi­
tie vertonen. Dit valt te meten met behulp van een visuele test, de zogenaamde 
anti-saccadetaak. We vonden dat schizofreniepatiënten meer fouten maakten 
dan personen in de controlegroep en BPS-patiënten, waarbij de BPS-groep tus­
sen beide controlegroepen inzat. De inhibitiedefecten bleken karakteristiek 
voor de borderlinepatiënten m et (pseudo-)psychotische symptomen.
Er is een grote hoeveelheid literatuur die beschrijft w elke cognitieve 
processen betrokken zijn bij het m aken van antisaccade-oogbewegingen.20 
Zowel de dorsolaterale prefrontale cortex ( p f c )  als de (posterieure) anteri- 
eure cingulate cortex (a c c )  spelen een belangrijke rol in het beslissings­
proces in de aansturing van de oogmotoriek. Resultaten van beeldvormend 
onderzoek en selectieve laesiestudies bevestigen dat deze twee regio’s on­
afhankelijk van elkaar inhibitiefouten kunnen veroorzaken.20-22 Het inhi- 
b itiedefect dat wij vonden was niet gerelateerd aan de predispositie om 
im pulsief te reageren. Dit is te zien aan de snelle anticiperende fouten die 
bij de patiënten m et b p s  werden waargenom en.
In hoofdstuk y  is bekeken of afwijkingen in sensorimotorgating aanwe­
zig zouden zijn bij BPS-patiënten zoals bij schizofreniepatiënten het geval 
is. Sensorimotor gating is een onbewust inhibitie-(‘filter’) m echanism e dat 
voorkom t dat het brein wordt overspoeld door sensorische input.23 Op de 
eerste plaats kan de schrikreflex op een hard geluid w orden verlaagd als 
vlak vooraf hier aan een zacht geluid wordt gehoord(‘prepulse inhibitie van 
de schrikreactie’). Een tweede paradigm a laat zien dat ook in de hersen- 
activiteit een sensorisch filter bestaat als twee identieke klikgeluiden m et 
een kort interval worden aangeboden. De reactie na 50 m illiseconden op 
het tweede geluid  is dan aanm erkelijk lager dan op het eerste (‘p50-ga- 
ting’). De gegevens lieten zien dat in onze borderlinepatiënten sensory ga­
ting intact was. Echter, in tegenstellin g tot onze hypothese lieten de 
patiënten niet een lagere m aar zelfs een hogere gating zien van de P50-, 
N100- en P200-amplitudes dan de controlegroep, hetgeen m ogelijk gere­
lateerd is aan het BPS-fenotype. Hoewel we op dit m om ent geen ferm e con­
clusies kunnen trekken (om dat een positieve controlegroep ontbreekt) 
lijkt het uitgesloten dat borderlinepatiënten gestoorde sensory gating ver­
tonen zoals gezien wordt bij schizofreniepatiënten.
In hoofdstuk 8 is onderzocht of de im pulsieve responsstijl van border- 
linepatiënten gerelateerd is aan verm inderde action-m onitoring, het 
hersenproces dat betrokken is bij foutendetectie. Hiervoor maten wij met 
behulp van elektrodes op het hoofd de error-related negativity ( e r n ) , een 
negatieve hersenpotentiaal die gegenereerd wordt in de A c c  na foutieve 
responsen.24 We vergeleken de gedragsm atige uitkom sten en e e g - 
gegevens tijdens een keuze-reactietijd taak m et een groep gem atchte con­
troles. De resultaten lieten zien dat de ERN-amplitudes verm inderd waren 
bij de patiënten, evenals de P300-amplitudes na feedback als de respons te 
laat was. Bovendien bleek uit de analyse van congruentie-effecten dat de 
controlegroep hun gedrag aanpaste na het m aken van fouten, terwijl de 
patiëntengroep dit niet deed. De verlaagde e r n  bij patiënten kan beteke­
nen dat de A cc , o f het netwerk waarvan het deel uitm aakt, niet optim aal 
functioneert bij b p s . Het is een interessante hypothese dat patiënten met 
b p s  door deze verm inderde action m onitoring m inder van fouten leren en 
daardoor een impulsieve responsstijl blijven volhouden. Resultaten in een 
andere onderzoeksgroep bevestigen inm iddels onze bevindingen.25
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De resultaten van hoofdstuk 6 en 8 passen goed in recente hypotheses over 
een neurobiologische basis voor b p s .26-29 Er is aanzienlijk bewijs voor een 
disfunctioneel frontolim bisch netwerk als basis voor b p s . De A c c  wordt 
geacht een belangrijke rol te spelen in het reguleren van em oties en speelt 
een rol in het m oduleren van de amygdala. De prefrontale cortex en met 
nam e de A c c  werden eerder gekoppeld aan b p s : structurele m r i  liet een 
verm inderd totaal volum e zien van de frontale hersenkw ab en die van 
de A c c  in het bijzonder.30;31;31-33 Een aantal studies liet een verm inderd m e­
tabolisme zien in de p f c  en A cc, in vergelijking m et gezonde controles.31-33 
Een aantal, hoewel niet alle, onderzoeken rapporteert zowel structurele 
als functionele afwijkingen van de amygdala bij b p s .31;34-39 Samengevat lijkt 
er bij borderline persoonlijkheidsstoornis sprake van een com binatie van 
toegenom en responsiviteit in de amygdala en een verm inderde m odule­
rende werking van de A cc.
Hoofdstuk g  is een overzicht van de literatuur die de effecten van tweede- 
generatie-antipsychotica bij b p s  beschrijft. Hoewel onderzoek hiernaar 
nog in de kinderschoenen staat, lijkt het aannem elijk dat patiënten m et 
(pseudo-)psychotische, im pulsieve of suïcidale sym ptom en baat kunnen 
hebben bij de tweede-generatie-antipsychotica. Onze conclusies onder­
schrijven de ervaringen van m enig clinicus op de werkvloer die w eet dat 
bepaalde borderlinepatiënten hier baat bij kunnen hebben. Een recente 
meta-analyse ondersteunt dit bovendien.40 De verklaring hiervoor is far­
m acologisch gezien niet precies begrepen. In recente artikelen staat dat 
de nieuwere antipsychotica naast het bekende antipsychotische effect ook 
antidepressieve eigenschappen hebben bij patiënten m et een bipolaire 
stoornis.41 Deze stem m ingstabiliserende eigenschappen van tweede-ge- 
neratie-antipsychotica kunnen de Bps-symptomen m ogelijk ook verbete­
ren. Bovendien hebben antipsychotica ook anxiolytische effecten en 
kunnen dus angst- en stressgerelateerde sym ptom en verlagen. De meeste 
behandelstudies hebben m et name de korte termij n-effecten bestudeerd. 
Meer gerandom iseerde, gecontroleerde studies m et langere follow-up zijn 
nodigvoordat een duidelijke conclusie te trekken is. Clinici weten immers 
dat veel patiënten m oeite hebben m et het trouw blijven aan de lange ter- 
m ijnbehandeling m et antipsychotica door bijwerkingen of een weerstand 
tegen medicatie.
De laatste twee decennia is er grote vooruitgang geboekt in de psy­
chotherapeutische behandeling van b p s .42-44 Er is een aantal psychothe­
rapeutisch behandelm ethoden die effectief blijken. M om enteel wordt de 
farm acotherapie voornam elijk als toevoeging op de psychotherapie 
gezien. Linehan en collega’s vonden in een recent onderzoek inderdaad 
dat dialectische gedragstherapie gecom bineerd m et olanzapine effectiever 
was dan m et placebo.45
Suggesties voor verder onderzoek 
Tot dusver zijn de m eeste neurobiologische onderzoeken naar borderline 
persoon lijkh eid sstoorn is-zoals ook die in dit proefschrift- verkennend 
van aard. De hier beschreven resultaten verdienen verder onderzoek in gro­
tere, beter gedefinieerde steekproeven. Er is m om enteel een paradigm a­
wisseling gaande over b p s : borderline begon ooit als een psychoanalytische 
concept voor onbehandelbare patiënten, m aar wordt nu steeds m eer als 
een potentieel behandelbare hersenziekte gezien.46 De literatuur over b p s  
laat een m engeling van psychotherapeutische concepten, behandelopties
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Wat hebben 
beginnende 
schizofrenie 
en borderline 
persoonlijk­
heidsstoornis 
gemeen?
e n  m o g e li jk e  e n d o p h e n o t y p e s  z ie n , d ie  a l le n  h o p e l i jk  g e ïn te g r e e r d  
k u n n e n  w o r d e n  in  d e  to e k o m s t. H e t e rg  h e te r o g e n e  fe n o ty p e  v a n  h e t  s y n ­
d r o o m  in  de h u id ig e  D S M -iv -c la ssifica tie  m a a k t  d e  z a a k  n ie t  e e n v o u d ig e r . 
H e t is d a a r o m  c ru c ia a l d a t o n d e r z o e k e r s  z ic h  o o k  s p e c if ie k e r  g a a n  r ic h te n  
o p  re le v a n te  d im e n s ie s ,  z o a ls  e m o t io n e le  in s t a b il i te it ,  im p u ls iv it e it  e n  
p s y c h o tis c h e  s y m p t o m e n .27 D e  v o lg e n d e  D S M -c la s s ific a tie  v a n  b p s  z o u  
h ie r m e e  m e e r  r e c h t  m o e te n  d o e n  a a n  d e  m u lt id im e n s io n e le  a a rd  v a n  h e t  
s y m p to m e n c o m p le x . E e n  n a u w e r e  d e fin it ie  v a n  h e t  s y n d r o o m  e n  e e n  
a c c u ra te  a fb a k e n in g v a n  v e r s c h ille n d e  p a t ië n te n g r o e p e n  is e e n  s t im u la n s  
v o o r  o n d e r z o e k  n a a r  n e u r o b io lo g is c h e  a c h te r g r o n d e n  e n  th e ra p ie  g e r ic h t  
o p  s p e c if ie k e  d o m e in e n . A ls  b p s  s u b p o p u la t ie s  b e te r  g e d e fin ie e r d  w o r ­
d e n  (b ijv o o r b e e ld  g e k a r a k te r is e e r d  a ls  ‘ im p u ls ie f ’ , ‘ in s ta b ie l  a f fe c t ’ , ‘g e ­
s to o r d e  r e a li t e i ts t o e t is in g ’), z o u d e n  o o k  o n d e r z o e k  e n  b e h a n d e lin g e n  
p r o fijt  k u n n e n  h e b b e n  v a n  o n tw ik k e lin g e n  in  ‘a a n g r e n z e n d e ’ s to o r n is ­
s e n  z o a ls  s c h iz o fr e n ie ,  b ip o la ir e  s to o r n is , a d h d  e n  p o s t t r a u m a t is c h e  
s tre s s s to o rn is .
Onderzoeksgroepen van verschillende disciplines zouden hun krachten 
m oeten bundelen om  com plexe pathofysiologie van b p s  te ontrafelen. 
G rootschalig onderzoek dat genetica, endophenotypering en klinische 
sym ptom en com bineert (‘im aging g en etics’) zal ons begrip van het syn­
droom  aanm erkelijk vergroten, zoals m om enteel al plaatsvindt in andere 
psychiatrische stoornissen zoals schizofrenie. In lijn m et de opm erkingen 
over deel I van dit proefschrift zou dit soort projecten niet alleen gediag­
nosticeerde b p s  patiënten m oeten includeren, m aar ook risicogroepen 
zoals eerstegraads fam ilieleden ofvroeg-getraum atiseerde patiënten.
De antisaccade- en EEG-paradigma’s zoals beschreven in dit proefschrift 
zijn kandidaten voor endophenotypering.
Klinische aanbevelingen 
De resultaten van de onderzoeken uit deel II van dit proefschrift w ijzen er 
op dat er ook bij borderline persoonlijkheidsstoornis cognitieve functie­
stoornissen aanw ezigzijn, zoals hetverm inderd verm ogen om responsen 
te inhiberen en gedrag aan te passen na het m aken van fouten. Als pa­
tiënten, hun fam ilie en zorgverleners hierover goed op de hoogte zouden 
zijn, zou dit m ogelijk negatief getinte (‘tegenoverdrachts’-) reacties kun­
nen voorkom en die deze patiënten som s kunnen oproepen.
Ten slotte zijn er indicaties dat patiënten m et b p s  kunnen profiteren 
van tweede-generatie-antipsychotica. Hoewel deze resultaten replicatie be­
hoeven, kunnen som m ige van de huidige richtlijnen een update ge­
bruiken. Zij bevelen nog steeds de eerste generatie antipsychotica a an 47 
of zelfs het gebruik van antipsychotica voor m iddenlange en lange termij n- 
gebruik in het algem een afwijzen.48
Niet al het onderzoek naar schizofrenie en borderline uit dit proefschrift 
was opgezet voor een directe onderlinge vergelijking. Toch is het interes­
sant om verschillen en overeenkom sten van de twee syndrom en te bezien 
vanuit klinisch en neurobiologisch perspectief.
De stereotype sym ptom en van schizofrenie en b p s  verschillen van el­
kaar, hoewel er een overlap zichtbaar is in subgroepen (bijvoorbeeld b p s  
patiënten m et psychotische symptomen). Voor beide stoornissen is de ef­
fectiviteit van antipsychotica vastgesteld. W ellicht heeft het onderscheid 
tussen de zogenaam de as-I en as-II stoornissen in d s m - i v  classificatie de 
afstand tussen beide stoornissen nodeloos vergroot.
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O ok vanuit neurobiologisch persp ectief hebben beide stoornissen b e­
paalde overeenkom sten. Friedel stelde een dopam ine-hypothese op om 
de em otionele disregulatie, im pulsiviteit en cognitef-perceptuele stoor­
nissen in b p s  te verklaren. Deze hypothese w ordt onder andere onder­
steund door de gestoorde reactie op toediening van dopam inerge stoffen 
aan patiënten.49 Hoewel de resultaten uit dit proefschrift laten zien dat 
zowel schizofrenie en b p s  patiënten soortgelijke afwijkingen kunnen ver­
tonen in de antisaccade en ERN-paradigma’s,50;51 is deze vorm  van bew ijs­
last indirect: overeenkomsten in cognitieve uitkom stm aten betekenen nog 
niet dat de patiënten groepen dezelfde pathofysiologie delen. Het onder­
zoek uit hoofdstuk 7 toont overigens geen verm inderde sensory gating bij 
borderline aan, terwijl dit bij schizofreniepatiënten en hun fam ilieleden 
w el is vastgesteld.
Directe vergelijkingen van het cognitief functioneren van patiënten uit 
verschillende diagnostische categorieën geeft m eer inzicht in de onder­
liggende pathofysiologie, m ogelijk m eer dan vergelijkingen m et gezonde 
controles. Dit soort onderzoek m et state o f the art genetica en beeldvor­
m end onderzoek is noodzakelijk. Het kan ons helpen de neurobiologische 
bouwstenen van com plexe psychiatrische stoornissen te begrijpen en de 
psychiatrische zorg te verbeteren.
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En dan nu het best gelezen hoofdstuk van het proefschrift!
Dit proefschrift zou niet tot stand gekom en zij n zonder de hulp van talloze 
m ensen die ik graag zou willen bedanken.
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